U.S. patent application number 13/572488 was filed with the patent office on 2013-02-14 for polymerase compositions, methods of making and using same.
This patent application is currently assigned to LIFE TECHNOLOGIES CORPORATION. The applicant listed for this patent is Mindy LANDES, Tommie LINCECUM, Guobin LUO, Daniel MAZUR, Theo NIKIFOROV, Eileen TOZER, Peter VANDER HORN. Invention is credited to Mindy LANDES, Tommie LINCECUM, Guobin LUO, Daniel MAZUR, Theo NIKIFOROV, Eileen TOZER, Peter VANDER HORN.
Application Number | 20130040365 13/572488 |
Document ID | / |
Family ID | 46755104 |
Filed Date | 2013-02-14 |
United States Patent
Application |
20130040365 |
Kind Code |
A1 |
VANDER HORN; Peter ; et
al. |
February 14, 2013 |
POLYMERASE COMPOSITIONS, METHODS OF MAKING AND USING SAME
Abstract
The present disclosure provides compositions, methods, kits,
systems and apparatus that are useful for nucleic acid
polymerization. In particular, modified polymerases and
biologically active fragment thereof are provided that allow for
nucleic acid amplification. In one aspect, the disclosure relates
to modified polymerases useful for nucleic acid sequencing,
genotyping, copy number variation analysis, paired-end sequencing
and other forms of genetic analysis. In some aspects, the
disclosure relates to modified polymerases useful for the
generation of nucleic acid libraries or nucleic acid templates for
use in various downstream processes. In some aspects, the
disclosure relates to the identification of homologous amino acid
mutations that can be transferred across classes or families of
polymerases to provide novel polymerases with altered catalytic
properties. In some aspects, the disclosure provides modified
polymerases having enhanced catalytic properties as compared to a
reference polymerase.
Inventors: |
VANDER HORN; Peter;
(Encinitas, CA) ; NIKIFOROV; Theo; (Carlsbad,
CA) ; LUO; Guobin; (Oceanside, CA) ; LANDES;
Mindy; (Carlsbad, CA) ; MAZUR; Daniel; (San
Diego, CA) ; TOZER; Eileen; (San Diego, CA) ;
LINCECUM; Tommie; (Houston, TX) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
VANDER HORN; Peter
NIKIFOROV; Theo
LUO; Guobin
LANDES; Mindy
MAZUR; Daniel
TOZER; Eileen
LINCECUM; Tommie |
Encinitas
Carlsbad
Oceanside
Carlsbad
San Diego
San Diego
Houston |
CA
CA
CA
CA
CA
CA
TX |
US
US
US
US
US
US
US |
|
|
Assignee: |
LIFE TECHNOLOGIES
CORPORATION
Carlsbad
CA
|
Family ID: |
46755104 |
Appl. No.: |
13/572488 |
Filed: |
August 10, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61522125 |
Aug 10, 2011 |
|
|
|
61545434 |
Oct 10, 2011 |
|
|
|
61585133 |
Jan 10, 2012 |
|
|
|
61643844 |
May 7, 2012 |
|
|
|
61681593 |
Aug 9, 2012 |
|
|
|
Current U.S.
Class: |
435/194 |
Current CPC
Class: |
C12Q 1/6846 20130101;
C12Q 1/686 20130101; C12N 9/1252 20130101; C12Y 207/07007
20130101 |
Class at
Publication: |
435/194 |
International
Class: |
C12N 9/12 20060101
C12N009/12 |
Claims
1. A composition comprising an isolated polypeptide having at least
90% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID
NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO:
24, or a biologically active fragment thereof.
2. The composition of claim 1, wherein the isolated polypeptide
retains polymerase activity.
3. The composition of claim 2, wherein the polymerase activity is
selected from DNA binding activity, primer extension activity,
strand displacement activity, proofreading activity, nick-initiated
polymerase activity, reverse transcriptase activity or nucleotide
polymerization activity.
4. The composition of claim 1, wherein, the isolated polypeptide
comprises at least 90% identity to SEQ ID NO: 2 and includes one or
more amino acid mutations selected from the group consisting of
N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H, D144M, D144K,
L212A, E220K, N234R, N234K, V241K, V251K, D264Q, D264S, D264K,
Y272R, H273R, L280R, H281A, E294S, E294F, E294G, E294K, V299K,
V299H, V299F, D303R, I331Q, E325R, L335T, E336P, I354W, I354F,
I370A, Q409R, G416K, V418M, V418I, G420K, D423S, D423K, D423N,
D423R, D423T, D423G, D423I, D423K, G425R, Q428W, N429R, N429K,
F448K, N457T, A462T, H473R, Y477F, D480R, D480F, D480H, D480A,
D480S, D480N, D480Q, N485W, N485Y, N487H, N487W, N487F, N487I,
V488R, E493Q, M495Q, V533I, W577Y and D579F.
5. The composition of claim 1, wherein the isolated polypeptide
comprises at least 90% identity to SEQ ID NO: 15 and includes one
or more amino acid mutations selected from the group consisting of
E471K, N485R, R492K, D513K, A675K, D732R, S739W, V740R and
E745Q.
6. The composition of claim 1, wherein the isolated polypeptide
comprises at least 90% identity to SEQ ID NO: 18 and includes one
or more amino acid mutations selected from the group consisting of
E245K, S259R, T266K, E290K, A448K, D505R, A512W, R513R and
E518Q.
7. A composition comprising a recombinant polymerase homologous to
SEQ ID NO: 1 or a biologically active fragment thereof having at
least 90% identity to SEQ ID NO: 1 or a biologically active
fragment thereof and wherein the recombinant polymerase comprises a
mutation or combination of mutations relative to SEQ ID NO: 1
selected from: (a) H46R, wherein the polymerase further includes a
mutation at one or more of: E446Q, H572R, H273R, H281A, H473R,
Y477F, D480R, or H528A; (b) E446Q, wherein the polymerase further
includes a mutation at one or more of: H46R, H572R, H273R, H281A,
H473R, Y477F, D480R, or H528A; (c) H572R, wherein the polymerase
further includes a mutation at one or more of: E446Q, H572R, H273R,
H281A, H473R, Y477F, D480R, or H528A; (d) C93 mutation; (e) Q238
mutation; (f) H273 mutation; (g) H281 mutation; (h) H473 mutation;
and (i) H528 mutation.
8. The composition of claim 7, wherein the recombinant polymerase
homologous to SEQ ID NO: 1 or biologically active fragment thereof
comprises any one or more mutations relative to SEQ ID NO: 1
selected from the group consisting of: N31, D77, D113, D114, D130,
D144, L212, E220, N234, V241, V251, D264, Y272, H273, L280, H281,
E294, V299, D303, I331, E325, L335, E336, I354, I370, Q409, G416,
V418, G420, D423, G425, Q428, N429, E446, F448, N457, A462, H473,
Y477, D480, N485, N487, V488, E493, M495, H528, V533, H572, W577
and D579.
9. The composition of claim 8, wherein the recombinant polymerase
homologous to SEQ ID NO: 1 or biologically active fragment thereof
comprises any one or more mutations relative to SEQ ID NO: 1
selected from the group consisting of: N31R, N31K, D77K, D77H,
D113N, D114R, D130A, D130H, D144M, D144K, L212A, E220K, N234R,
N234K, V241K, V251K, D264Q, D264S, D264K, Y272R, H273R, L280R,
H281A, H281M, E294S, E294F, E294G, E294K, V299K, V299H, V299F,
D303R, I331Q, E325R, L335T, E336P, I354W, I354F, I370A, Q409R,
G416K, V418M, V418I, G420K, D423S, D423K, D423N, D423R, D423T,
D423G, D423I, D423K, G425R, Q428W, N429R, N429K, E446Q, F448K,
N457T, A462T, H473R, Y477F, D480R, D480F, D480H, D480A, D480S,
D480N, D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R,
E493Q, M495Q, H528A, H528R, H528K, V533I, H572R, W577Y and
D579F.
10. The composition of claim 9, wherein the recombinant polymerase
homologous to SEQ ID NO: 1 is any biologically active fragment of
the recombinant polymerase that retains polymerase activity.
11. The composition of claim 10, wherein the recombinant polymerase
homologous to SEQ ID NO: 1 comprises a mutation that increases
dissociation time constant, increases processivity, increases
accuracy, increases average read length, increases minimum read
length, increases AQ20 or increase 200Q17 value as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to the recombinant polymerase homologous to SEQ ID NO:
1.
12. A composition comprising a recombinant polymerase homologous to
SEQ ID NO: 15 or a biologically active fragment thereof having at
least 90% identity to SEQ ID NO: 15 or a biologically active
fragment thereof and wherein the recombinant polymerase comprises a
mutation or combination of mutations relative to SEQ ID NO: 15
selected from: (a) E471K, wherein the polymerase further includes a
mutation at one or more of: N485R, R492K, D513K, A675K, D732R,
S739W, V740R and E745Q; (b) V740R, wherein the polymerase further
includes a mutation at one or more of: E471K, N485R, D513K and
E745Q; (c) an N485 mutation; (d) an D513 mutation; (e) an D732
mutation; and (f) an E745 mutation.
13. The composition of claim 12, wherein the recombinant polymerase
homologous to SEQ ID NO: 15 or the biologically active fragment
thereof comprises: (a) increased accuracy as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to SEQ ID NO: 15; (b) increased dissociation time constant
as compared to a reference polymerase lacking a mutation or
combination of mutations relative to SEQ ID NO: 15; (c) increased
minimum read length as compared to a reference polymerase lacking a
mutation or combination of mutations relative to SEQ ID NO: 15; (d)
increased sequencing performance in the presence of a high ionic
strength solution as compared to a reference polymerase lacking a
mutation or combination of mutations relative to the recombinant
polymerase homologous to SEQ ID NO: 15; or (e) increased average
read length as compared to a reference polymerase lacking a
mutation or combination of mutations relative to SEQ ID NO: 15.
14. The composition of claim 12, wherein the recombinant polymerase
homologous to SEQ ID NO: 15 or the biologically active fragment
thereof is any biologically active fragment that retains polymerase
activity.
15. The composition of claim 12, wherein the recombinant polymerase
homologous to SEQ ID NO: 15 comprises a mutation that increases
dissociation time constant, increases processivity, increases
accuracy, increases average read length, increases minimum read
length, increases AQ20 or increase 200Q17 value as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to the recombinant polymerase homologous to SEQ ID NO:
15.
16. A composition comprising a recombinant polymerase homologous to
SEQ ID NO: 18 or a biologically active fragment thereof having at
least 90% identity to SEQ ID NO: 18 or a biologically fragment
thereof and wherein the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 18 selected
from: (a) E245K, wherein the polymerase further includes a mutation
at one or more of: S259R, T266K, E290K, A448K, D505R, A512W, R513R
and E518Q; (b) D505R, wherein the polymerase further includes a
mutation at one or more of: E245K, S259R, T266K, E290K, A448K,
A512W, R513R and E518Q; (c) an E290 mutation (d) an 5259 mutation;
(e) an R513 mutation; and (f) an A512 mutation.
17. The composition of claim 16, wherein the recombinant polymerase
homologous to SEQ ID NO: 18 or the biologically active fragment
thereof comprises: (a) increased accuracy as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to SEQ ID NO: 18; (b) increased dissociation time constant
activity as compared to a reference polymerase lacking a mutation
or combination of mutations relative to SEQ ID NO: 18; (c)
increased minimum read length as compared to a reference polymerase
lacking a mutation or combination of mutations relative to SEQ ID
NO: 18; (d) increased sequencing performance in the presence of
high ionic strength as compared to a reference polymerase lacking a
mutation or combination of mutations relative to the recombinant
polymerase homologous to SEQ ID NO: 18; or (e) increased average
read length as compared to a reference polymerase lacking a
mutation or combination of mutations relative to SEQ ID NO: 18.
18. The composition of claim 16, wherein the recombinant polymerase
homologous to SEQ ID NO: 18 or biologically active fragment thereof
is any fragment of the recombinant polymerase that retains
polymerase activity.
19. The composition of claim 16, wherein the recombinant polymerase
homologous to SEQ ID NO: 18 comprises a mutation that increases
dissociation time constant, increases processivity, increases
accuracy, increases average read length, increases minimum read
length, increases AQ20 or increase 200Q17 value as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to the recombinant polymerase homologous to SEQ ID NO: 18.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority under 35 U.S.C.
.sctn.119(e) to U.S. Provisional Application No. 61/522,125, filed
Aug. 10, 2011, U.S. Provisional Application No. 61/545,434, filed
Oct. 10, 2011, U.S. Provisional Application No. 61/585,133, filed
Jan. 10, 2012, U.S. Provisional Application No. 61/643,844, filed
May 7, 2012, and U.S. Provisional Application No. 61/681,593, filed
Aug. 9, 2012 entitled "POLYMERASE COMPOSITIONS, METHODS OF MAKING
AND USING THE SAME", the disclosures of which are incorporated
herein by reference in their entireties.
SEQUENCE LISTING
[0002] This application hereby incorporates by reference the
material of the electronic Sequence Listing filed concurrently
herewith. The material in the electronic Sequence Listing is
submitted as a text (.txt) file entitled
"LT00556_Sequence_Listing_ST25.txt" created on Aug. 9, 2012, which
has a file size of 65 KB, and is herein incorporated by reference
in its entirety.
TECHNICAL FIELD
[0003] In some embodiments, the disclosure relates generally to
polymerase compositions, methods of making and using the same. In
some embodiments, the disclosure relates generally to one or more
modified polymerases, where the one or more modified polymerases
contain at least one amino acid mutation as compared to a reference
polymerase. In some embodiments, the disclosure relates generally
to compositions comprising a modified DNA or RNA polymerase. In
some embodiments, the compositions can include a modified
polymerase from an A family DNA polymerase or a B family DNA
polymerase. In some embodiments, the disclosure relates generally
to the transfer of a homologous amino acid mutation across a class
or family of polymerases. In some embodiments, the disclosure
relates generally to a polymerase composition for nucleic acid
sequencing, including next-generation sequencing. In some
embodiments, the disclosure relates generally to a modified
polymerase composition for the generation of nucleic acid libraries
or nucleic acid templates. In some embodiments, the disclosure
relates to systems, apparatuses and kits that contain one or more
of the modified polymerases. In some embodiments, the compositions,
systems, apparatuses and kits can be used for synthesizing a DNA
strand. In some embodiments, the compositions, systems, apparatuses
and kits can be used for amplifying at least 10, 50, 100, 500,
1000, 2500, 5000, 7500, 10000, 25000, 50000, 100000, or more
nucleic acid templates in a single reaction.
BACKGROUND
[0004] The ability of enzymes to catalyze biological reactions is
fundamental to life. A range of biological applications use enzymes
to synthesize various biomolecules in vitro. One particularly
useful class of enzymes is the polymerases, which can catalyze the
polymerization of biomolecules (e.g., nucleotides or amino acids)
into biopolymers (e.g., nucleic acids or peptides). For example,
polymerases that can polymerize nucleotides into nucleic acids,
particularly in a template-dependent fashion, are useful in
recombinant DNA technology and nucleic acid sequencing
applications. Many nucleic acid sequencing methods monitor
nucleotide incorporations during in vitro template-dependent
nucleic acid synthesis catalyzed by a polymerase. Single Molecule
Sequencing (SMS) and Paired-End Sequencing (PES) typically include
a polymerase for template-dependent nucleic acid synthesis.
Polymerases are also useful for the generation of nucleic acid
libraries, such as libraries created during emulsion PCR or bridge
PCR. Nucleic acid libraries created using such polymerases can be
used in a variety of downstream processes, such as genotyping,
nucleotide polymorphism (SNP) analysis, copy number variation
analysis, epigenetic analysis, gene expression analysis,
hybridization arrays, analysis of gene mutations including but not
limited to detection, prognosis and/or diagnosis of disease states,
detection and analysis of rare or low frequency allele mutations,
and nucleic acid sequencing including but not limited to de novo
sequencing or targeted resequencing.
[0005] When performing polymerase-dependent nucleic acid synthesis
or amplification, it can be useful to modify the polymerase (for
example via mutation or chemical modification) so as to alter its
catalytic properties. In some instances, it can be useful to modify
the polymerase to enhance its catalytic properties. Polymerase
performance in various biological assays involving nucleic acid
synthesis can be limited by the kinetic behavior of the polymerase
towards nucleotide substrates. For example, analysis of polymerase
activity can be complicated by undesirable behavior such as the
tendency of a given polymerase to dissociate from the template; to
bind and/or incorporate the incorrect, e.g., non Watson-Crick
base-paired, nucleotide; or to release the correct, e.g.,
Watson-Crick based paired, nucleotide without incorporation. These
and other desirable properties can be enhanced via suitable
selection, engineering and/or modification of a polymerase of
choice. For example, such modification can be performed to
favorably alter the polymerase's rate of nucleotide incorporation,
affinity of binding to template, processivity or average read
length; such alterations can increase the amount of sequence
information obtained from a single sequencing reaction. There
remains a need in the art for improved polymerase compositions
exhibiting altered, e.g., increased processivity, read length
(including error-free read length) and/or affinity for DNA
template. Such polymerase compositions can be useful in a wide
variety of assays involving polymerase-dependent nucleic acid
synthesis, including nucleic acid sequencing and production of
nucleic acid libraries.
BRIEF DESCRIPTION OF THE DRAWINGS
[0006] The accompanying drawings, which are incorporated into and
form a part of the specification, illustrate one or more exemplary
embodiments and serve to explain the principles of various
exemplary embodiments. The drawings are exemplary and explanatory
only and are not to be construed as limiting or restrictive in any
way.
[0007] FIG. 1 is a schematic outlining an exemplary dissociation
rate curve according to the disclosure.
[0008] FIG. 2 is a schematic outlining an exemplary dissociation
assay performed according to the disclosure.
[0009] FIG. 3 is a table providing exemplary template affinity data
obtained for a modified polymerase obtained according to the
disclosure, as compared to a reference polymerase.
[0010] FIG. 4 is a table providing exemplary nucleic acid
sequencing data obtained using exemplary modified polymerases
according to the disclosure.
[0011] FIG. 5 is a table providing exemplary nucleic acid
sequencing data obtained using exemplary modified polymerases
according to the disclosure.
[0012] FIG. 6 shows a graph providing exemplary error rate data
obtained using exemplary modified polymerases according to the
disclosure.
[0013] FIG. 7 shows a graph providing exemplary error rate data
obtained using exemplary modified polymerases according to the
disclosure.
[0014] FIG. 8 is a schematic outlining an exemplary dissociation
rate curve for exemplary modified polymerases obtained according to
the disclosure.
[0015] FIG. 9 is an exemplary binding affinity assay performed
using exemplary modified polymerases obtained according to the
disclosure.
[0016] FIG. 10 is an exemplary binding affinity assay performed
using exemplary modified polymerases obtained according to the
disclosure.
[0017] FIG. 11 is an exemplary binding affinity assay performed
using exemplary modified polymerases obtained according to the
disclosure.
[0018] FIG. 12 is an exemplary binding affinity assay performed
using exemplary modified polymerases obtained according to the
disclosure.
[0019] FIG. 13 is a table providing exemplary nucleic acid
sequencing data obtained using an exemplary modified polymerase
according to the disclosure.
[0020] FIG. 14 is a table providing exemplary nucleic acid
sequencing data obtained using an exemplary modified polymerase
according to the disclosure.
[0021] FIG. 15 is a table providing exemplary nucleic acid
sequencing data obtained using an exemplary modified polymerase
according to the disclosure.
[0022] FIG. 16 is a table providing exemplary nucleic acid
sequencing data obtained using an exemplary modified polymerase
according to the disclosure.
[0023] FIG. 17 provides exemplary nucleic acid sequencing data
obtained using an exemplary modified polymerase according to the
disclosure.
SUMMARY
[0024] In some embodiments, the disclosure relates generally to a
method for performing a nucleotide polymerization reaction
comprising or consisting of contacting a modified polymerase or a
biologically active fragment thereof with a nucleic acid template
in the presence of one or more nucleotides, where the modified
polymerase or the biologically active fragment thereof includes one
or more amino acid modifications relative to a reference polymerase
and where the modified polymerase or the biologically active
fragment thereof has an increased dissociation time constant
relative to the reference polymerase, and polymerizing at least one
of the one or more nucleotides using the modified polymerase or the
biologically active fragment thereof. In some embodiments, the
method includes polymerizing at least one of the one or more
nucleotides using the modified polymerase or the biologically
active fragment thereof in the presence of a high ionic strength
solution. In some embodiments, the method can further include
polymerizing the at least one nucleotide in a template-dependent
fashion. In some embodiments, the method can further including
hybridizing a primer to the template prior to, during or after the
contacting, and where the polymerizing includes polymerizing the at
least one nucleotide onto an end of the primer using the modified
polymerase or the biologically active fragment thereof. In some
embodiments, the polymerizing is performed in the proximity of a
sensor that is capable of detecting the polymerization of the at
least one nucleotide by the modified polymerase or the biologically
active fragment thereof. In some embodiments, the method can
further include detecting a signal indicating the polymerization of
the at least one of the one or more nucleotides by the modified
polymerase or the biologically active fragment thereof using a
sensor. In some embodiments, the sensor is an ISFET. In some
embodiments, the modified polymerase or the biologically active
fragment thereof comprises or consists of at least 80% identity to
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO:
20 or SEQ ID NO: 24. In some embodiments, the modified polymerase
or the biologically active fragment thereof comprises at least 25
contiguous amino acids from the polymerase catalytic domain. In
some embodiments, the modified polymerase or the biologically
active fragment thereof comprises at least 25 contiguous amino
acids from the polymerase DNA binding domain. In some embodiments,
the modified polymerase or the biologically active fragment thereof
comprises or consists of at least 100 amino acid residues having at
least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ
ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24. In some embodiments, the
modified polymerase or the biologically active fragment thereof
comprises or consists of at least 150 amino acid residues of the
polymerase catalytic domain having at least 90% identity to SEQ ID
NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or
SEQ ID NO: 24.
[0025] In some embodiments, the disclosure generally relates to a
method for performing nucleic acid amplification comprising or
consisting of generating an amplification reaction mixture having a
modified polymerase or a biologically active fragment thereof, a
primer, a nucleic acid template, and one or more nucleotides, where
the modified polymerase or the biologically active fragment thereof
includes one or more amino acid modifications relative to a
reference polymerase and has an increased dissociation time
constant relative to the reference polymerase; and subjecting the
amplification reaction mixture to amplifying conditions, where at
least one of the one or more nucleotides is polymerized onto the
end of the primer using the modified polymerase or the biologically
active fragment thereof. In some embodiments, the modified
polymerase or the biologically active fragment thereof comprises or
consists of at least 80% identity SEQ ID NO: 2, SEQ ID NO: 3, SEQ
ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24. In some
embodiments, the modified polymerase or the biologically active
fragment thereof comprises at least 25 contiguous amino acids of
the polymerase catalytic domain. In some embodiments, the modified
polymerase or the biologically active fragment thereof comprises at
least 25 contiguous amino acid residues of the polymerase DNA
binding domain. In some embodiments, the modified polymerase or the
biologically active fragment thereof comprises or consists of at
least 100 contiguous amino acid residues of the polymerase
catalytic domain having at least 80% identity to SEQ ID NO: 2, SEQ
ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO:
24. In some embodiments, the modified polymerase or the
biologically active fragment thereof comprises or consists of at
least 150 contiguous amino acid residues of the polymerase
catalytic domain having at least 90% identity to SEQ ID NO: 2, SEQ
ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO:
24. In some embodiments, the modified polymerase or the
biologically active fragment thereof comprises or consists of at
least 150 contiguous amino acid residues of the polymerase
catalytic domain having at least 95% identity to SEQ ID NO: 2, SEQ
ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO:
24. In some embodiments, the method includes amplifying conditions
having a high ionic strength solution.
[0026] In some embodiments, the disclosure generally relates to a
method for performing a nucleotide polymerization reaction
comprising or consisting of mixing a modified polymerase or a
biologically active fragment thereof with a nucleic acid template
in the presence of one or more nucleotides, where the modified
polymerase or the biologically active fragment thereof includes one
or more amino acid modifications relative to a reference polymerase
and has increased accuracy relative to a reference polymerase; and
polymerizing at least one of the one or more nucleotides using the
modified polymerase or the biologically active fragment thereof in
the mixture. In some embodiments, the modified polymerase or the
biologically active fragment thereof has an increased accuracy as
determined by measuring increased accuracy in the presence of a
high ionic strength solution. In some embodiments, the modified
polymerase or the biologically active fragment thereof comprises or
consists of at least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3,
SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24. In
some embodiments, the modified polymerase or the biologically
active fragment thereof comprises or consists of at least 150 amino
acid residues of the polymerase catalytic domain having at least
80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID
NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24.
[0027] In some embodiments, the disclosure generally relates to a
method of detecting nucleotide incorporation comprising or
consisting of performing a nucleotide incorporation using a
modified polymerase or a biologically active fragment thereof
having at least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID
NO: 4, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 24, a nucleic
acid template, and one or more nucleotide triphosphates; generating
one or more byproducts of the nucleotide incorporation, detecting
the presence of at least one of the one or more byproducts of the
nucleotide incorporation, and thereby detecting the nucleotide
incorporation.
[0028] In some embodiments, the method includes or consists of a
modified polymerase or the biologically active fragment thereof
that includes at least 25 contiguous amino acid residues of the
polymerase catalytic domain or the polymerase DNA binding domain.
In some embodiments, the method comprises or consists of
determining the identity of the nucleotide incorporation. In some
embodiments, the byproduct of the nucleotide incorporation is a
hydrogen ion.
[0029] In some embodiments, the disclosure generally relates to a
method of detecting a change in ion concentration during a
nucleotide polymerization reaction comprising or consisting of
performing a nucleotide polymerization reaction using a modified
polymerase or a biologically active fragment thereof having at
least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ
ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 24, where the concentration
of at least one type of ion changes during the course of the
nucleotide polymerization reaction and detecting a signal
indicating the change in concentration of the at least one type of
ion. In some embodiments, the ion is a hydrogen ion. In some
embodiments, the modified polymerase or the biologically active
fragment thereof comprises or consists of at least 150 contiguous
amino acid residues of the polymerase catalytic domain having at
least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ
ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24.
[0030] In some embodiments, the disclosure generally relates to a
method for amplifying a nucleic acid comprising or consisting of
contacting a nucleic acid with a polymerase or a biologically
active fragment thereof comprising at least 80% identity to SEQ ID
NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20, or
SEQ ID NO: 24, under suitable conditions for amplification of the
nucleic acid and amplifying the nucleic acid. In some embodiments,
the amplifying is performed by polymerase chain reaction, emulsion
polymerase chain reaction, isothermal amplification, recombinase
polymerase amplification or strand displacement amplification. In
some embodiments, the polymerase or the biologically active
fragment thereof comprises or consists of at least 150 contiguous
amino acid residues having at least 80% identity to SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID
NO: 24. In some embodiments, the polymerase or the biologically
active fragment thereof comprises or consists of at least 150
contiguous amino acid residues having at least 90% identity to SEQ
ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20,
or SEQ ID NO: 24. In some embodiments, the polymerase or the
biologically active fragment thereof comprises or consists of at
least 150 contiguous amino acid residues having at least 95%
identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
19, SEQ ID NO: 20, or SEQ ID NO: 24.
[0031] In some embodiments, the disclosure relates generally to a
composition comprising or consisting of an isolated polymerase or a
biologically active fragment thereof having at least 25 contiguous
amino acid resides of the polymerase catalytic domain having at
least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ
ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24. In some embodiments, the
isolated polymerase or the biologically active fragment thereof has
detectable polymerase activity. In some embodiments, the isolated
polymerase or the biologically active fragment thereof is a DNA
polymerase.
[0032] In some embodiments, disclosure is generally related to an
isolated and purified polypeptide comprising or consisting of at
least 80% identity to SEQ ID NO: 1 and having one or more amino
acid mutations selected from the group consisting of N31R, N31K,
H46R, D77K, D77H, D113N, D114R, D130A, D130H, D144M, D144K, L212A,
E220K, N234R, N234K, V241K, V251K, D264Q, D264S, D264K, Y272R,
H273R, L280R, H281A, E294S, E294F, E294G, E294K, V299K, V299H,
V299F, D303R, I331Q, E325R, L335T, E336P, I354W, I354F, I370A,
Q409R, G416K, V418M, V418I, G420K, D423S, D423K, D423N, D423R,
D423T, D423G, D423I, D423K, G425R, Q428W, N429R, N429K, E446Q,
F448K, N457T, A462T, H473R, Y477F, D480R, D480F, D480H, D480A,
D480S, D480N, D480Q, N485W, N485Y, N487H, N487W, N487F, N487I,
V488R, E493Q, M495Q, H528A, V533I, H572R, W577Y and D579F.
[0033] In some embodiments, disclosure is generally related to an
isolated and purified polypeptide comprising or consisting of at
least 80% identity to SEQ ID NO: 2 and having one or more amino
acid mutations selected from the group consisting of N31R, N31K,
D77K, D77H, D113N, D114R, D130A, D130H, D144M, D144K, L212A, E220K,
N234R, N234K, V241K, V251K, D264Q, D264S, D264K, Y272R, H273R,
L280R, H281A, E294S, E294F, E294G, E294K, V299K, V299H, V299F,
D303R, I331Q, E325R, L335T, E336P, I354W, I354F, I370A, Q409R,
G416K, V418M, V418I, G420K, D423S, D423K, D423N, D423R, D423T,
D423G, D423I, D423K, G425R, Q428W, N429R, N429K, F448K, N457T,
A462T, H473R, Y477F, D480R, D480F, D480H, D480A, D480S, D480N,
D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R, E493Q,
M495Q, H528A, V533I, W577Y and D579F.
[0034] In some embodiments, disclosure is generally related to an
isolated and purified polypeptide comprising or consisting of at
least 80% identity to SEQ ID NO: 15 and having one or more amino
acid mutations selected from the group consisting of E471K, N485R,
R492K, D513K, A675K, D732R, S739W, V740R and E745Q.
[0035] In some embodiments, disclosure is generally related to an
isolated and purified polypeptide comprising or consisting of at
least 80% identity to SEQ ID NO: 18 and having one or more amino
acid mutations selected from the group consisting of E245K, S259R,
T266K, E290K, A448K, D505R, A512W, R513R and E518Q.
[0036] In some embodiments, the disclosure is generally related to
an isolated nucleic acid sequence comprising or consisting of a
nucleic acid sequencing encoding a polypeptide having at least 80%
identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
19, SEQ ID NO: 20 or SEQ ID NO: 24.
[0037] In some embodiments, the disclosure is generally related to
a vector comprising an isolated nucleic sequence encoding a
polypeptide having at least 80% identity to SEQ ID NO: 2, SEQ ID
NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO:
24.
[0038] In some embodiments, the disclosure is generally related to
a kit comprising an isolated polypeptide having at least 80%
identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
19, SEQ ID NO: 20 or SEQ ID NO: 24. In some embodiments, the kit
comprises an isolated polypeptide comprising or consisting of at
least 150 contiguous amino acid residues having at least 80%
identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
19, SEQ ID NO: 20 or SEQ ID NO: 24. In some embodiments, the
isolated polypeptide comprises at least 25 contiguous amino acid
residues from the polypeptide catalytic and/or DNA binding
domain.
[0039] In some embodiments, the disclosure generally relates to a
method for identifying one or more mutations in a gene, comprising
amplifying said gene using a modified polymerase or a biologically
active fragment thereof having at least 80% identity to SEQ ID NO:
2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ
ID NO: 24, under conditions that allow amplification. In some
embodiments, the gene is clinically associated with cancer or an
inherited disease. In some embodiments, the disease is associated
with pathogenicity. In some embodiments, the gene associated with
infectious disease. In some embodiments, the gene is associated
with disease resistance in plants or animals. In some embodiments,
the gene is associated with a pathology associated with a human or
animal disease. In some embodiments, the gene is associated with
bacterial resistance to one or more antibiotics. In some
embodiments, the conditions that allow amplification include
polymerase chain reaction, emulsion polymerase chain reaction,
isothermal amplification, recombinase polymerase amplification or
strand displacement amplification. In some embodiments, the
modified polymerase or the biologically active fragment thereof
comprises or consists of at least 150 contiguous amino acid
residues having at least 80% identity to SEQ ID NO: 2, SEQ ID NO:
3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24. In
some embodiments, the modified polymerase or the biologically
active fragment thereof comprises at least 25 contiguous amino acid
residues from the polymerase catalytic and/or DNA binding
domain.
[0040] In some embodiments, the disclosure generally relates to a
polymerase or a biologically active fragment thereof having DNA
polymerase activity and at least 80% identity to SEQ ID NO: 1, SEQ
ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 18, where the polymerase or
the biologically active fragment thereof includes at least one
amino acid mutation as compared to SEQ ID NO: 1, SEQ ID NO: 15, SEQ
ID NO: 16, or SEQ ID NO: 18. In some embodiments, the polymerase or
biologically active fragment thereof comprises at least one amino
acid mutation located in the polymerase DNA binding or catalytic
domain. In some embodiments, the polymerase or the biologically
active fragment thereof comprises substantial identity over at
least 150 contiguous amino acid residues with respect to any part
of SEQ ID NO: 1, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO. 18. In
some embodiments, the polymerase of the biologically active
fragment thereof comprises or consists of 150 contiguous amino acid
residues of any part of the polymerase DNA binding or catalytic
domain. In some embodiments, the polymerase or the biologically
active fragment thereof comprises at least 90% identity over the
150 contiguous amino acid residues.
[0041] In some embodiments, the disclosure generally relates to a
substantially purified polymerase having an amino acid sequence
comprising or consisting of at least 80% identity to SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID
NO. 24. In some embodiments, the disclosure generally relates to a
substantially purified polymerase having an amino acid sequence
comprising or consisting of a sequence variant having at least 95%
identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
19, SEQ ID NO: 20 or SEQ ID NO. 24. In some embodiments, the
disclosure generally relates to a substantially purified polymerase
having an amino acid sequence comprising or consisting of a
fragment of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
19, SEQ ID NO: 20 or SEQ ID NO. 24 that retain polymerase activity.
In some embodiments, the polymerase activity is selected from DNA
binding activity, primer extension activity, strand displacement
activity, proofreading activity, nick-initiated polymerase
activity, reverse transcriptase activity or nucleotide
polymerization activity. In some embodiments the polymerase
activity is determined in the presence of a high ionic strength
solution.
[0042] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 1 selected from
H46R, and where the polymerase further includes a mutation at one
or more of E446Q, H572R, H273R, H281A, H473R, Y477F, D480R, or
H528A.
[0043] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 1 selected from
E446Q, where the polymerase further includes a mutation at one or
more of H46R, H572R, H273R, H281A, H473R, Y477F, D480R, or
H528A.
[0044] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 1 selected from
H572R, where the polymerase further includes a mutation at one or
more of E446Q, H572R, H273R, H281A, H473R, Y477F, D480R, or
H528A.
[0045] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a C93
mutation.
[0046] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a Q238
mutation.
[0047] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a H273
mutation.
[0048] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a H281
mutation.
[0049] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a H473
mutation.
[0050] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 1 or a biologically active fragment
thereof and where the recombinant polymerase comprises a H528
mutation. In some embodiments, the recombinant polymerase
homologous to SEQ ID NO: 1 comprises a mutation that increases
dissociation time constant, increases processivity, increases
accuracy, increases average read length, increases minimum read
length, increases AQ20 or increase 200Q17 value as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to the recombinant polymerase homologous to SEQ ID NO: 1.
In some embodiments, the recombinant polymerase homologous to SEQ
ID NO: 1 comprises increased accuracy as compared to a reference
polymerase lacking a mutation or combination of mutations relative
to the recombinant polymerase homologous to SEQ ID NO: 1. In some
embodiments, the recombinant polymerase homologous to SEQ ID NO: 1
comprises increased average read length as compared to a reference
polymerase lacking a mutation or combination of mutations relative
to the recombinant polymerase homologous to SEQ ID NO: 1. In some
embodiments, the recombinant polymerase homologous to SEQ ID NO: 1
comprises increased sequencing throughout in the presence of a high
ionic strength solution as compared to a reference polymerase
lacking a mutation or combination of mutations relative to the
recombinant polymerase homologous to SEQ ID NO: 1. In some
embodiments, the recombinant polymerase homologous to SEQ ID NO: 1
comprises increased dissociation time constant as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to the recombinant polymerase homologous to SEQ ID NO: 1.
In some embodiments, the increased dissociation time constant,
increased processivity, increased accuracy, increased average read
length, increased minimum read length, increased AQ20 or increased
200Q17 value is measured using an ISFET. In some embodiments, the
ISFET is coupled to a semiconductor based sequencing platform. In
some embodiments, the semiconductor based sequencing platform is a
Personal Genome Machine or a Proton Sequencer.
[0051] In some embodiments, the disclosure generally relates to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 15 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 15 or a biologically active fragment
thereof and where the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 15 selected from
E471K, wherein the polymerase further includes a mutation at one or
more of: N485R, R492K, D513K, A675K, D732R, S739W, V740R and
E745Q.
[0052] In some embodiments, the disclosure generally relates to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 15 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 15 or a biologically active fragment
thereof and where the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 15 selected from
V740R, wherein the polymerase further includes a mutation at one or
more of: E471K, N485R, D513K and E745Q. In some embodiments, the
disclosure generally relates to a composition comprising a
recombinant polymerase homologous to SEQ ID NO: 15 or a
biologically active fragment thereof having at least 80% identity
to SEQ ID NO: 15 or a biologically active fragment thereof and
where the recombinant polymerase comprises a N485 mutation. In some
embodiments, the disclosure generally relates to a composition
comprising a recombinant polymerase homologous to SEQ ID NO: 15 or
a biologically active fragment thereof having at least 80% identity
to SEQ ID NO: 15 or a biologically active fragment thereof and
where the recombinant polymerase comprises a mutation or
combination of mutations relative to SEQ ID NO: 15 selected from a
D513 mutation.
[0053] In some embodiments, the disclosure generally relates to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 15 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 15 or a biologically active fragment
thereof and where the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 15 selected from
a D732 mutation.
[0054] In some embodiments, the disclosure generally relates to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 15 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 15 or a biologically active fragment
thereof and where the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 15 selected from
an E745 mutation. In some embodiments, the recombinant polymerase
homologous to SEQ ID NO: 15 or the biologically active fragment
thereof comprises increased accuracy as compared to a reference
polymerase lacking a mutation or combination of mutations relative
to SEQ ID NO: 15 or increased dissociation time constant as
compared to a reference polymerase lacking a mutation or
combination of mutations relative to SEQ ID NO: 15 or increased
minimum read length as compared to a reference polymerase lacking a
mutation or combination of mutations relative to SEQ ID NO: 15 or
increased sequencing performance in the presence of a high ionic
strength solution as compared to a reference polymerase lacking a
mutation or combination of mutations relative to the recombinant
polymerase homologous to SEQ ID NO: 15 or increased average read
length as compared to a reference polymerase lacking a mutation or
combination of mutations relative to SEQ ID NO: 15.
[0055] In some embodiments, the disclosure is generally related to
a composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 18 or a biologically fragment thereof
and where the recombinant polymerase comprises a mutation or
combination of mutations relative to SEQ ID NO: 18 selected from
E245K, where the polymerase further includes a mutation at one or
more of: S259R, T266K, E290K, A448K, D505R, A512W, R513R and E518Q.
In some embodiments, the disclosure is generally related to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 18 or a biologically fragment thereof
and where the recombinant polymerase comprises a mutation or
combination of mutations relative to SEQ ID NO: 18 selected from
E245K, where the polymerase further includes a mutation at one or
more of: S259R, T266K, E290K, A448K, D505R, A512W, R513R and
E518Q.
[0056] In some embodiments, the disclosure is generally related to
a composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 18 or a biologically fragment thereof
and where the recombinant polymerase comprises a mutation or
combination of mutations relative to SEQ ID NO: 18 selected from
D505R, where the polymerase further includes a mutation at one or
more of: E245K, S259R, T266K, E290K, A448K, A512W, R513R and E518Q.
In some embodiments, the disclosure is generally related to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 18 or a biologically fragment thereof
and where the recombinant polymerase comprises an E290 mutation. In
some embodiments, the disclosure is generally related to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 18 or a biologically fragment thereof
and where the recombinant polymerase comprises an 5259 mutation. In
some embodiments, the disclosure is generally related to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 18 or a biologically fragment thereof
and where the recombinant polymerase comprises an R513 mutation. In
some embodiments, the disclosure is generally related to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18 or a biologically active fragment thereof having at least
80% identity to SEQ ID NO: 18 or a biologically fragment thereof
and where the recombinant polymerase comprises an A512 mutation. In
some embodiments, the recombinant polymerase homologous to SEQ ID
NO: 18 or the biologically active fragment thereof comprises
increased accuracy as compared to a reference polymerase lacking a
mutation or combination of mutations relative to SEQ ID NO: 18 or
increased dissociation time constant activity as compared to a
reference polymerase lacking a mutation or combination of mutations
relative to SEQ ID NO: 18 or increased minimum read length as
compared to a reference polymerase lacking a mutation or
combination of mutations relative to SEQ ID NO: 18 or increased
sequencing performance in the presence of high ionic strength as
compared to a reference polymerase lacking a mutation or
combination of mutations relative to the recombinant polymerase
homologous to SEQ ID NO: 18 or increased average read length as
compared to a reference polymerase lacking a mutation or
combination of mutations relative to SEQ ID NO: 18.
[0057] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or a biologically active fragment thereof, where the
recombinant polymerase comprises a mutation or combination of
mutations relative to SEQ ID NO: 1 selected from any one or more
of: N31, D77, D113, D114, D130, D144, L212, E220, N234, V241, V251,
D264, Y272, H273, L280, H281, E294, V299, D303, I331, E325, L335,
E336, I354, I370, Q409, G416, V418, G420, D423, G425, Q428, N429,
E446, F448, N457, A462, H473, Y477, D480, N485, N487, V488, E493,
M495, H528, V533, H572, W577 and D579.
[0058] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 1 or biologically active fragment thereof comprises a
mutation or combination of mutations relative to SEQ ID NO: 1
selected from any one or more of: N31R, N31K, D77K, D77H, D113N,
D114R, D130A, D130H, D144M, D144K, L212A, E220K, N234R, N234K,
V241K, V251K, D264Q, D264S, D264K, Y272R, H273R, L280R, H281A,
H281M, E294S, E294F, E294G, E294K, V299K, V299H, V299F, D303R,
I331Q, E325R, L335T, E336P, I354W, I354F, I370A, Q409R, G416K,
V418M, V418I, G420K, D423S, D423K, D423N, D423R, D423T, D423G,
D423I, D423K, G425R, Q428W, N429R, N429K, E446Q, F448K, N457T,
A462T, H473R, Y477F, D480R, D480F, D480H, D480A, D480S, D480N,
D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R, E493Q,
M495Q, H528A, H528R, H528K, V533I, H572R, W577Y and D579F. In some
embodiments, the recombinant polymerase homologous to SEQ ID NO: 1
is any biologically active fragment of the recombinant polymerase
that retains polymerase activity.
[0059] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 16 or a biologically active fragment thereof, where the
recombinant polymerase comprises a mutation or combination of
mutations relative to SEQ ID NO: 16 selected from any one or more
of: H341, C388, Q533, H568, H576, E741, H768, Y772, H823, C845 and
H867. In some embodiments, the recombinant polymerase homologous to
SEQ ID NO: 16, comprises a mutation or combination of mutations
relative to SEQ ID NO: 16 selected from any one or more of: H341R,
C388R, Q533C, H568R, H576A, E741Q, H768R, Y772F, H823A, C845Q and
H867R. In some embodiments, the recombinant polymerase homologous
to SEQ ID NO: 16 is any biological fragment of the recombinant
polymerase that retains polymerase activity.
[0060] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 15, where the recombinant polymerase comprises a mutation or
combination of mutations relative to SEQ ID NO: 15 selected from
any one or more of: E471, N485, R492, D513, A675, D732, 5739, V740
and E745. In some embodiments, the recombinant polymerase
homologous to SEQ ID NO: 15, comprises a mutation or combination of
mutations relative to SEQ ID NO: 15 selected from any one or more
of: E471K, N485R, R492K, D513K, A675K, D732R, S739W, V740R and
E745Q. In some embodiments, the recombinant polymerase homologous
to SEQ ID NO: 15 is any biological fragment of the recombinant
polymerase that retains polymerase activity.
[0061] In some embodiments, the disclosure relates generally to a
composition comprising a recombinant polymerase homologous to SEQ
ID NO: 18, wherein the recombinant polymerase comprises a mutation
or combination of mutations relative to SEQ ID NO: 18 selected from
any one or more of: E245, 5259, T266, E290, A448, D505, A512, and
E518. In some embodiments, the recombinant polymerase homologous to
SEQ ID NO: 18, comprises a mutation or combination of mutations
relative to SEQ ID NO: 18 selected from any one of more of: E245K,
S259R, T266K, E290K, A448K, D505R, A512W, and E518Q. In some
embodiments, the recombinant polymerase homologous to SEQ ID NO: 18
is any biological fragment of the recombinant polymerase that
retains polymerase activity.
[0062] In some embodiments, the disclosure relates generally to a
method for performing nucleic acid sequencing comprising contacting
a modified polymerase or a biologically active fragment thereof
with a nucleic acid template in the presence of one or more
nucleotides, where the modified polymerase or the biologically
active fragment thereof includes one or more amino acid
modifications relative to a reference polymerase, and where the
modified polymerase or the biologically active fragment thereof has
an increased dissociation time constant relative to the reference
polymerase; and polymerizing at least one of the one or more
nucleotides using the modified polymerase or the biologically
active fragment thereof. In some embodiments, the nucleic acid
template is a DNA template. In some embodiments, the one or more
nucleotides do not contain a detectable label. In some embodiments,
the modified polymerase or the biologically active fragment thereof
is a family A or family B DNA polymerase. In some embodiments, the
disclosure relates generally to a modified polymerase comprising at
least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ
ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID
NO 24. In some embodiments, the disclosure relates generally to a
modified polymerase comprising or consisting of a sequence variant
at least 95% identical to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,
SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 or SEQ
ID NO. 24.
[0063] In some embodiments, the disclosure relates generally to a
modified polymerase comprising a fragment of SEQ ID NO: 2, SEQ ID
NO: 3, SEQ ID NO: 4, SEQ ID NO 20, SEQ ID NO: 18, SEQ ID NO: 19,
SEQ ID NO: 20 or SEQ ID NO. 24 that retains polymerase activity. In
some embodiments, the modified polymerase comprises a biologically
active fragment having at least 80% identity to any fragment of SEQ
ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 18,
SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO 24. In some embodiments,
the modified polymerase comprises a biologically active fragment
having at least 25 contiguous amino acids of the polymerase
catalytic domain and at least 80% identity to SEQ ID NO: 2, SEQ ID
NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19,
SEQ ID NO: 20, or SEQ ID NO 24. In some embodiments, the
biologically active fragment includes at least 100 contiguous amino
acid residues having at least 80% identity to SEQ ID NO: 2, SEQ ID
NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19,
SEQ ID NO: 20, or SEQ ID NO 24. In some embodiments, the method
further includes determining the identity of the one or more
nucleotides polymerized by the modified polymerase. In some
embodiments, the method further includes determining the number of
nucleotides polymerized by the modified polymerase. In some
embodiments, at least 50% of the one or more nucleotides
polymerized by the modified polymerase are identified. In some
embodiments, substantially all of the one or more nucleotides
polymerized by the modified polymerase are identified. In some
embodiments, the polymerization occurs in the presence of a high
ionic strength solution. In some embodiments the high ionic
strength solution comprises about 200 mM to about 250 mM salt. In
some embodiments, the high ionic strength solution comprises KCl
and/or NaCl.
[0064] In some embodiments, the disclosure relates generally to a
method for performing a nucleotide polymerization reaction
comprising contacting a modified polymerase or a biologically
active fragment thereof with a nucleic acid template in the
presence of one or more nucleotides, where the modified polymerase
or the biologically active fragment thereof includes one or more
amino acid modifications relative to a reference polymerase and has
an increased accuracy relative to the reference polymerase, and
polymerizing at least one of the one or more nucleotides using the
modified polymerase. In some embodiments, the modified polymerase
or the biologically active fragment thereof comprises or consists
of at least 150 contiguous amino acid residues having at least 80%
identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO 24.
In some embodiments, the modified polymerase or the biologically
active fragment thereof comprises at least 25 contiguous amino acid
residues having at least 80% identity to SEQ ID NO: 2, SEQ ID NO:
3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ
ID NO: 20, or SEQ ID NO 24 from the polymerase catalytic or DNA
binding domain. In some embodiments, the modified polymerase or the
biologically active fragment thereof comprises at least 25
contiguous amino acid residues from the polymerase catalytic or DNA
binding domain of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID
NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO
24. In some embodiments, the polymerizing is performed in the
presence of a high ionic strength solution.
[0065] In some embodiments, the disclosure relates generally to a
method for performing nucleic acid sequencing comprising or
consisting of contacting a modified polymerase with a nucleic acid
template in the presence of one or more nucleotides, where the
modified polymerase includes one or more amino acid modifications
relative to a reference polymerase and has an increased accuracy
relative to the reference polymerase, and polymerizing at least one
of the one or more nucleotides using the modified polymerase. In
some embodiments, the modified polymerase or the biologically
active fragment thereof comprises or consists of at least 150
contiguous amino acid residues having at least 80% identity to SEQ
ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 18,
SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO 24. In some embodiments,
the modified polymerase or the biologically active fragment thereof
comprises at least 25 contiguous amino acid residues having at
least 80% identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ
ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID
NO 24 from the polymerase catalytic or DNA binding domain. In some
embodiments, the modified polymerase or the biologically active
fragment thereof comprises at least 25 contiguous amino acid
residues from the polymerase catalytic or DNA binding domain of SEQ
ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 18,
SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO 24. In some embodiments,
the polymerizing is performed in the presence of a high ionic
strength solution. In some embodiments, the modified polymerase or
the biologically active fragment thereof is a DNA or RNA
polymerase.
DETAILED DESCRIPTION
[0066] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as is commonly understood by one
of ordinary skill in the art to which these inventions belong. All
patents, patent applications, published applications, treatises and
other publications referred to herein, both supra and infra, are
incorporated by reference in their entirety. If a definition and/or
description is explicitly or implicitly set forth herein that is
contrary to or otherwise inconsistent with any definition set forth
in the patents, patent applications, published applications, and
other publications that are herein incorporated by reference, the
definition and/or description set forth herein prevails over the
definition that is incorporated by reference.
[0067] The practice of the disclosure will employ, unless otherwise
indicated, conventional techniques of molecular biology,
microbiology and recombinant DNA techniques, which are within the
skill of the art. Such techniques are explained fully in the
literature. See, for example, Sambrook, J., and Russell, D. W.,
2001, Molecular Cloning: A Laboratory Manual, Third Edition;
Ausubel, F. M., et al., eds., 2002, Short Protocols In Molecular
Biology, Fifth Edition.
[0068] Note that not all of the activities described in the general
description or the examples are required, that a portion of a
specific activity may not be required, and that one or more further
activities may be performed in addition to those described. Still
further, the order in which activities are listed are not
necessarily the order in which they are performed.
[0069] In some instances, some concepts have been described with
reference to specific embodiments. However, one of ordinary skill
in the art appreciates that various modifications and changes can
be made without departing from the scope of the invention as set
forth in the claims below. Accordingly, the specification and
figures are to be regarded in an illustrative rather than a
restrictive sense, and all such modifications are intended to be
included within the scope of invention.
[0070] As used herein, the terms "comprising" (and any form or
variant of comprising, such as "comprise" and "comprises"),
"having" (and any form or variant of having, such as "have" and
"has"), "including" (and any form or variant of including, such as
"includes" and "include"), or "containing" (and any form or variant
of containing, such as "contains" and "contain"), are inclusive or
open-ended and do not exclude additional, unrecited additives,
components, integers, elements or method steps. For example, a
process, method, article, or apparatus that comprises a list of
features is not necessarily limited only to those features but may
include other features not expressly listed or inherent to such
process, method, article, or apparatus.
[0071] Unless expressly stated to the contrary, "or" refers to an
inclusive-or and not to an exclusive-or. For example, a condition A
or B is satisfied by any one of the following: A is true (or
present) and B is false (or not present), A is false (or not
present) and B is true (or present), and both A and B are true (or
present).
[0072] Benefits, other advantages, and solutions to problems have
been described with regard to specific embodiments. However, such
benefits, advantages, solutions to problems, and any feature(s)
that may cause any benefit, advantage, or solution to occur or
become more pronounced are not to be construed as a critical,
required, or essential feature of any or all the claims.
[0073] After reading the specification, skilled artisans will
appreciate that certain features that are, for clarity, described
herein in the context of separate embodiments can also be provided
in combination in a single embodiment. Conversely, various features
that are, for brevity, described in the context of a single
embodiment can also be provided separately or in any
subcombination. Further, references to values stated in ranges
include each and every value within that range.
[0074] Also, the use of articles such as "a", "an" or "the" are
employed to describe elements and components described herein. This
is done merely for convenience and to give a general sense of the
scope of the invention. This description should be read to include
one or at least one and the singular also includes the plural
unless it is obvious that it is meant otherwise. Accordingly, the
terms "a," "an," and "the" and similar referents used herein are to
be construed to cover both the singular and the plural unless their
usage in context indicates otherwise. Accordingly, the use of the
word "a" or "an" or "the" when used in the claims or specification,
including when used in conjunction with the term "comprising", may
mean "one," but it is also consistent with the meaning of "one or
more," "at least one," and "one or more than one."
[0075] As used herein, the term "polymerase" and its variants
comprise any enzyme that can catalyze the polymerization of
nucleotides (including analogs thereof) into a nucleic acid strand.
Typically but not necessarily such nucleotide polymerization can
occur in a template-dependent fashion. Such polymerases can include
without limitation naturally occurring polymerases and any subunits
and truncations thereof, mutant polymerases, variant polymerases,
recombinant, fusion or otherwise engineered polymerases, chemically
modified polymerases, synthetic molecules or assemblies, and any
analogs, homologs, derivatives or fragments thereof that retain the
ability to catalyze such polymerization. Optionally, the polymerase
can be a mutant polymerase comprising one or more mutations
involving the replacement of one or more amino acids with other
amino acids, the insertion or deletion of one or more amino acids
from the polymerase, or the linkage of parts of two or more
polymerases. Typically, the polymerase comprises one or more active
sites at which nucleotide binding and/or catalysis of nucleotide
polymerization can occur. Some exemplary polymerases include
without limitation DNA polymerases (such as for example Phi-29 DNA
polymerase, reverse transcriptases and E. coli DNA polymerase) and
RNA polymerases. The term "polymerase" and its variants, as used
herein, also refers to fusion proteins comprising at least two
portions linked to each other, where the first portion comprises a
peptide that can catalyze the polymerization of nucleotides into a
nucleic acid strand and is linked to a second portion that
comprises a second polypeptide. In some embodiments, the second
polypeptide can include a reporter enzyme or a
processivity-enhancing domain.
[0076] As used herein, the terms "link", "linked", "linkage" and
variants thereof comprise any type of fusion, bond, adherence or
association that is of sufficient stability to withstand use in the
particular biological application of interest. Such linkage can
comprise, for example, covalent, ionic, hydrogen, dipole-dipole,
hydrophilic, hydrophobic, or affinity bonding, bonds or
associations involving van der Waals forces, mechanical bonding,
and the like. Optionally, such linkage can occur between a
combination of different molecules, including but not limited to:
between a nanoparticle and a protein; between a protein and a
label; between a linker and a functionalized nanoparticle; between
a linker and a protein; between a nucleotide and a label; and the
like. Some examples of linkages can be found, for example, in
Hermanson, G., Bioconjugate Techniques, Second Edition (2008);
Aslam, M., Dent, A., Bioconjugation: Protein Coupling Techniques
for the Biomedical Sciences, London: Macmillan (1998); Aslam, M.,
Dent, A., Bioconjugation: Protein Coupling Techniques for the
Biomedical Sciences, London: Macmillan (1998).
[0077] The terms "modification" or "modified" and their variants,
as used herein with reference to polypeptide or protein, for
example a polymerase, comprise any change in the structural,
biological and/or chemical properties of the protein. In some
embodiments, the modification can include a change in the amino
acid sequence of the protein. For example, the modification can
optionally include one or more amino acid mutations, including
without limitation amino acid additions, deletions and
substitutions (including both conservative and non-conservative
substitutions).
[0078] The term "conservative" and its variants, as used herein
with reference to any change in amino acid sequence, refers to an
amino acid mutation wherein one or more amino acids is substituted
by another amino acid having highly similar properties. For
example, one or more amino acids comprising nonpolar or aliphatic
side chains (for example, glycine, alanine, valine, leucine, or
isoleucine) can be substituted for each other. Similarly, one or
more amino acids comprising polar, uncharged side chains (for
example, serine, threonine, cysteine, methionine, asparagine or
glutamine) can be substituted for each other. Similarly, one or
more amino acids comprising aromatic side chains (for example,
phenylalanine, tyrosine or tryptophan) can be substituted for each
other. Similarly, one or more amino acids comprising positively
charged side chains (for example, lysine, arginine or histidine)
can be substituted for each other. Similarly, one or more amino
acids comprising negatively charged side chains (for example,
aspartic acid or glutamic acid) can be substituted for each other.
In some embodiments, the modified polymerase is a variant that
comprises one or more of these conservative amino acid
substitutions, or any combination thereof. In some embodiments,
conservative substitutions for leucine include: alanine,
isoleucine, valine, phenylalanine, tryptophan, methionine, and
cysteine. In other embodiments, conservative substitutions for
asparagine include: arginine, lysine, aspartate, glutamate, and
glutamine.
[0079] Throughout this disclosure, various amino acid mutations,
including, for example, amino acid substitutions are referenced
using the amino acid single letter code, and indicating the
position of the residue within a reference amino acid sequence. In
the case of amino acid substitutions, the identity of the
substituent is also indicated using the amino acid single letter
code. For example, a reference to the hypothetical amino acid
substitution "D166A, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 7" indicates an amino acid substitution
wherein an alanine (A) residue is substituted for the normally
occurring aspartic acid (D) residue at amino acid position 166 of
the amino acid sequence of SEQ ID NO: 7. Many of the amino acid
sequences disclosed herein begin with a methionine residue ("M"),
which is typically introduced at the beginning of nucleic acid
sequences encoding peptides desired to be expressed in bacterial
host cells. However, it is to be understood that the disclosure
also encompasses all such amino acid sequences beginning from the
second amino acid residue onwards, without the inclusion of the
first methionine residue.
[0080] As used herein, the terms "identical" or "percent identity,"
and their variants, when used in the context of two or more nucleic
acid or polypeptide sequences, refer to two or more sequences or
subsequences that are the same or have a specified percentage of
amino acid residues or nucleotides that are the same, when compared
and aligned for maximum correspondence, as measured using any one
or more of the following sequence comparison algorithms:
Needleman-Wunsch (see, e.g., Needleman, Saul B.; and Wunsch,
Christian D. (1970). "A general method applicable to the search for
similarities in the amino acid sequence of two proteins" Journal of
Molecular Biology 48 (3):443-53); Smith-Waterman (see, e.g., Smith,
Temple F.; and Waterman, Michael S., "Identification of Common
Molecular Subsequences" (1981) Journal of Molecular Biology
147:195-197); or BLAST (Basic Local Alignment Search Tool; see,
e.g., Altschul S F, Gish W, Miller W, Myers E W, Lipman D J, "Basic
local alignment search tool" (1990) J Mol Biol 215
(3):403-410).
[0081] As used herein, the terms "substantially identical" or
"substantial identity", and their variants, when used in the
context of two or more nucleic acid or polypeptide sequences, refer
to two or more sequences or subsequences (such as biologically
active fragments) that have at least 60%, at least 70%, at least
75%, at least 80%, at least 85%, at least 90%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% nucleotide
or amino acid residue identity, when compared and aligned for
maximum correspondence, as measured using a sequence comparison
algorithm or by visual inspection. Substantially identical
sequences are typically considered to be homologous without
reference to actual ancestry. In some embodiments, "substantial
identity" exists over a region of the sequences being compared. In
some embodiments, substantial identity exists over a region of at
least 25 residues in length, at least 50 residues in length, at
least 100 residues in length, at least 150 residues in length, at
least 200 residues in length, or greater than 200 residues in
length. In some embodiments, the sequences being compared are
substantially identical over the full length of the sequences being
compared. Typically, substantially identical nucleic acid or
protein sequences include less than 100% nucleotide or amino acid
residue identity as such sequences would generally be considered
"identical".
[0082] Proteins and/or protein subsequences (such as biologically
active fragments) are "homologous" when they are derived, naturally
or artificially, from a common ancestral protein or protein
sequence. Similarly, nucleic acids and/or nucleic acid sequences
are homologous when they are derived, naturally or artificially,
from a common ancestral nucleic acid or nucleic acid sequence.
Homology is generally inferred from sequence similarity between two
or more nucleic acids or proteins (or biologically active fragments
or sequences thereof). The precise percentage of similarity between
sequences that is useful in establishing homology varies with the
nucleic acid and protein at issue, but as little as 25% sequence
similarity over 25, 50, 100, 150, or more nucleic acids or amino
acid residues, is routinely used to establish homology. Higher
levels of sequence similarity, e.g., 30%, 40%, 50%, 60%, 70%, 80%,
85%, 90%, 95%, 98% or 99%, can also be used to establish
homology.
[0083] Methods for determining sequence similarity percentages
(e.g., BLASTP and BLASTN using default parameters) are described
herein and are generally available. For sequence comparison and
homology determination, typically one sequence acts as a reference
sequence to which test sequences are compared. Generally, when
using a sequence comparison algorithm, test and reference sequences
are input into a computer, subsequence coordinates are designated,
if necessary, and sequence algorithm program parameters are
designated. The sequence comparison algorithm then calculates the
percent sequence identity for the test sequence(s) relative to the
reference sequence, based on the designated program parameters.
Optimal alignment of sequences for comparison can be conducted,
e.g., by the local homology algorithm of Smith & Waterman, Adv.
Appl. Math. 2:482 (1981), by the homology alignment algorithm of
Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search
for similarity method of Pearson & Lipman, Proc. Nat'l. Acad.
Sci. USA 85:2444 (1988), by computerized implementations of these
algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin
Genetics Software Package, Genetics Computer Group, 575 Science
Dr., Madison, Wis.), or by visual inspection (see generally Current
Protocols in Molecular Biology, Ausubel et al., eds., Current
Protocols, a joint venture between Greene Publishing Associates,
Inc. and John Wiley & Sons, Inc., supplemented through 2004).
One example of an algorithm that is suitable for determining
percent sequence identity and sequence similarity is the BLAST
algorithm, which is described in Altschul et al., J. Mol. Biol.
215:403-410 (1990). Software for performing BLAST analyses is
publicly available through the National Center for Biotechnology
Information. This algorithm involves first identifying high scoring
sequence pairs (HSPs) by identifying short words of length "W" in
the query sequence, which either match or satisfy some
positive-valued threshold score "T" when aligned with a word of the
same length in a database sequence. "T" is referred to as the
neighborhood word score threshold (Altschul et al., supra). These
initial neighborhood word hits act as seeds for initiating searches
to find longer HSPs containing them. The word hits are then
extended in both directions along each sequence for as far as the
cumulative alignment score can be increased. Cumulative scores are
calculated using, for nucleotide sequences, the parameters "M"
(reward score for a pair of matching residues; always >0) and
"N" (penalty score for mismatching residues; always <0). For
amino acid sequences, a scoring matrix is used to calculate the
cumulative score. Extension of the word hits in each direction are
halted when: the cumulative alignment score falls off by the
quantity X from its maximum achieved value; the cumulative score
goes to zero or below, due to the accumulation of one or more
negative-scoring residue alignments; or the end of either sequence
is reached. The BLAST algorithm parameters "W", "T", and "X"
determine the sensitivity and speed of the alignment. The BLASTN
program (for nucleotide sequences) uses as defaults a wordlength
(W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4,
and a comparison of both strands. For amino acid sequences, the
BLASTP program uses as defaults a wordlength (W) of 3, an
expectation (E) of 10, and the BLOSUM62 scoring matrix (see
Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA
89:10915).
[0084] In addition to calculating percent sequence identity, the
BLAST algorithm also performs a statistical analysis of the
similarity between two sequences (see, e.g., Karlin & Altschul,
Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of
similarity provided by the BLAST algorithm is the smallest sum
probability (P(N)), which provides an indication of the probability
by which a match between two nucleotide or amino acid sequences
would occur by chance. For example, a nucleic acid is considered
similar to a reference sequence if the smallest sum probability in
a comparison of the test nucleic acid to the reference nucleic acid
is less than about 0.1, less than about 0.01, or less than about
0.001. The term "primer extension activity" and its variants, as
used herein, when used in reference to a given polymerase, comprise
any in vivo or in vitro enzymatic activity characteristic of a
given polymerase that relates to catalyzing nucleotide
incorporation onto the terminal 3'OH end of an extending nucleic
acid molecule. Typically but not necessarily such nucleotide
incorporation occurs in a template-dependent fashion. In some
embodiments, the primer extension activity of a given polymerase
can be quantified as the total number of nucleotides incorporated
(as measured by, e.g., radiometric or other suitable assay) by a
unit amount of polymerase (in moles) per unit time (seconds) under
a particular set of reaction conditions.
[0085] The term "DNA binding activity" and its variants, as used
herein, when used in reference to a given polymerase, comprise any
in vivo or in vitro enzymatic activity characteristic of a given
polymerase that relates to interaction of the polymerase with a DNA
sequence in a recognition-based manner. Typically but not
necessarily such interaction includes binding of the polymerase,
and more specifically binding of the DNA-binding domain of the
polymerase, to the recognized DNA sequence. In some embodiments,
recognition includes binding of the polymerase to a
sequence-specific or non-sequence specific DNA sequence. In some
embodiments, the DNA binding activity of a given polymerase can be
quantified as the affinity of the polymerase to recognize and bind
to the recognized DNA sequence. For example, DNA binding activity
can be monitored and determined using an anistrophy signal change
(or other suitable assay) as a protein-DNA complex is formed under
a particular set of reaction conditions.
[0086] As used herein, the term "biologically active fragment" and
its variants, when used in reference to a given biomolecule, refers
to any fragment, derivative, homolog or analog of the biomolecule
that possesses an in vivo or in vitro activity that is
characteristic of the biomolecule itself. For example, a polymerase
can be characterized by various biological activities, for example
DNA binding activity, nucleotide polymerization activity, primer
extension activity, strand displacement activity, reverse
transcriptase activity, nick-initiated polymerase activity, 3'-5'
exonuclease (proofreading) activity, and the like. In some
embodiments, a "biologically active fragment" of a polymerase is
any fragment, derivative, homolog or analog of the polymerase that
can catalyze the polymerization of nucleotides (including homologs
and analogs thereof) into a nucleic acid strand. In some
embodiments, the biologically active fragment, derivative, homolog
or analog of the polymerase possesses 10%, 20%, 30%, 40%, 50%, 60%,
70%, 75%, 80%, 85%, or 90% or greater of the biological activity of
the polymerase in any in vivo or in vitro assay of interest such
as, for example, DNA binding assays, nucleotide polymerization
assays (which may be template-dependent or template-independent),
primer extension assays, strand displacement assays, reverse
transcriptase assays, proofreading assays, and the like. In some
embodiments, the biological activity of a polymerase fragment is
assayed by measuring the primer extension activity in vitro of the
fragment under defined reaction conditions. In some embodiments,
the biological activity of a polymerase fragment is assayed by
measuring the polymerization activity in vitro of the fragment
under defined reaction conditions. In some embodiments, the
biological activity of a polymerase fragment is assayed by
measuring the DNA binding activity in vitro of the fragment under
defined reaction conditions. In some embodiments, the biological
activity of a polymerase fragment is assayed by measuring the
strand displacement activity in vitro of the fragment under defined
reaction conditions. In some embodiments, the biological activity
of a polymerase fragment is assayed by measuring the reverse
transcriptase activity in vitro of the fragment under defined
reaction conditions. In some embodiments, the biological activity
of a polymerase fragment is assayed by measuring the nick-initiated
polymerase activity in vitro of the fragment under defined reaction
conditions. In some embodiments, the biological activity of a
polymerase fragment is assayed by measuring the proofreading
activity in vitro of the fragment under defined reaction
conditions. In some embodiments, the biologically active fragment
of a polymerase can include measuring the biological activity of
any one or more of the polymerase biological activities outlined
herein.
[0087] In some embodiments, a biologically active fragment can
include any part of the DNA binding domain or any part of the
catalytic domain of the modified polymerase. In some embodiments,
the biologically active fragment can optionally include any 25, 50,
75, 100, 150 or more contiguous amino acid residues of the DNA
binding or catalytic domain. In some embodiments, a biologically
active fragment of the modified polymerase can include at least 25
contiguous amino acid residues of the catalytic domain or the DNA
binding domain having at least 80%, 85%, 90%, 95%, 98%, or 99%
identity to any one or more of the polymerases encompassed by the
disclosure. In some embodiments, a biologically active fragment of
a modified polymerase can include at least 25 contiguous amino acid
residues of the catalytic domain or the DNA binding domain having
at least 80%, 85%, 90%, 95%, 98%, or 99% identity to any one or
more of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0088] Biologically active fragments can optionally exist in vivo,
such as, for example, fragments which arise from post
transcriptional processing or which arise from translation of
alternatively spliced RNAs, or alternatively can be created through
engineering, bulk synthesis, or other suitable manipulation.
Biologically active fragments include fragments expressed in native
or endogenous cells as well as those made in expression systems
such as, for example, in bacterial, yeast, insect or mammalian
cells.
[0089] In some embodiments, the disclosure relates generally to not
only the specific polymerases disclosed herein, but also to any
biologically active fragment of such polymerases, which are
encompassed within the scope of the present disclosure. In some
embodiments, a biologically active fragment of any polymerase of
the disclosure includes any fragment that exhibits primer extension
activity in vitro.
[0090] In some embodiments, the disclosure relates generally to not
only the specific polymerases disclosed herein, but also to any
biologically active fragment of such polymerases, which are
encompassed within the scope of the present disclosure. In some
embodiments, a biologically active fragment of any polymerase of
the disclosure includes any fragment that exhibits DNA binding
activity in vitro.
[0091] In some embodiments, the disclosure relates generally to not
only the specific polymerases disclosed herein, but also to any
biologically active fragment of such polymerases, which are
encompassed within the scope of the present disclosure. In some
embodiments, a biologically active fragment of any polymerase of
the disclosure includes any fragment that retains polymerase
activity in vitro. Polymerase activity can be determined by any
method known in art. For example, determination of polymerase
activity can be based on the activity of extending a primer on a
template.
[0092] In some embodiments, the disclosure generally relates to a
modified polymerase having one or more amino acid mutations (such
as a deletion, substitution or addition) relative to a reference
polymerase lacking the one or more amino acid mutations, and
wherein the modified polymerase retains polymerase activity in
vitro, exhibits DNA binding activity in vitro or exhibits primer
extension activity in vitro. In some embodiments, the modified
polymerase includes any biologically active fragment of such
polymerase that retains polymerase activity in vitro, exhibits DNA
binding activity in vitro or exhibits primer extension activity in
vitro.
[0093] In some embodiments, the disclosure generally relates to a
modified polymerase having one or more amino acid mutations (such
as a deletion, substitution or addition) relative to a reference
polymerase lacking the one or more amino acid mutations, and
wherein the modified polymerase retains proofreading activity in
vitro, exhibits nick-initiated polymerase activity in vitro or
reverse transcriptase activity in vitro. In some embodiments, the
modified polymerase includes any biologically active fragment of
such polymerase that retains proofreading activity in vitro,
exhibits nick-initiated polymerase activity in vitro or exhibits
reverse transcriptase activity in vitro. Determination of whether a
polymerase exhibits exonuclease activity or exhibits reduced
exonuclease activity, can be readily determined by standard
methods. For example, polynucleotides can be synthesized such that
a detectable proportion of the nucleotides are radioactively
labeled. These polynucleotides can be incubated in an appropriate
buffer in the presence of the polypeptide to be tested. After
incubation, the polynucleotide is precipitated and exonuclease
activity is detectable as radioactive counts due to free
nucleotides in the supernatant. As will be appreciated by the
skilled artisan, an appropriate polymerase or biologically active
fragment may be selected from those described herein based on any
of the above biological activities, or combinations thereof,
depending on the application of interest.
[0094] As used herein, the term "nucleotide" and its variants
comprise any compound that can bind selectively to, or can be
polymerized by, a polymerase. Typically, but not necessarily,
selective binding of the nucleotide to the polymerase is followed
by polymerization of the nucleotide into a nucleic acid strand by
the polymerase; occasionally however the nucleotide may dissociate
from the polymerase without becoming incorporated into the nucleic
acid strand, an event referred to herein as a "non-productive"
event. Such nucleotides include not only naturally-occurring
nucleotides but also any analogs, regardless of their structure,
that can bind selectively to, or can be polymerized by, a
polymerase. While naturally-occurring nucleotides typically
comprise base, sugar and phosphate moieties, the nucleotides of the
disclosure can include compounds lacking any one, some or all of
such moieties. In some embodiments, the nucleotide can optionally
include a chain of phosphorus atoms comprising three, four, five,
six, seven, eight, nine, ten or more phosphorus atoms. In some
embodiments, the phosphorus chain can be attached to any carbon of
a sugar ring, such as the 5' carbon. The phosphorus chain can be
linked to the sugar with an intervening O or S. In one embodiment,
one or more phosphorus atoms in the chain can be part of a
phosphate group having P and O. In another embodiment, the
phosphorus atoms in the chain can be linked together with
intervening O, NH, S, methylene, substituted methylene, ethylene,
substituted ethylene, CNH.sub.2, C(O), C(CH.sub.2),
CH.sub.2CH.sub.2, or C(OH)CH.sub.2R (where R can be a 4-pyridine or
1-imidazole). In one embodiment, the phosphorus atoms in the chain
can have side groups having O, BH.sub.3, or S. In the phosphorus
chain, a phosphorus atom with a side group other than O can be a
substituted phosphate group. Some examples of nucleotide analogs
are described in Xu, U.S. Pat. No. 7,405,281. In some embodiments,
the nucleotide comprises a label (e.g., reporter moiety) and
referred to herein as a "labeled nucleotide"; the label of the
labeled nucleotide is referred to herein as a "nucleotide label".
In some embodiments, the label can be in the form of a fluorescent
dye attached to the terminal phosphate group, i.e., the phosphate
group or substitute phosphate group most distal from the sugar.
Some examples of nucleotides that can be used in the disclosed
methods and compositions include, but are not limited to,
ribonucleotides, deoxyribonucleotides, modified ribonucleotides,
modified deoxyribonucleotides, ribonucleotide polyphosphates,
deoxyribonucleotide polyphosphates, modified ribonucleotide
polyphosphates, modified deoxyribonucleotide polyphosphates,
peptide nucleotides, metallonucleosides, phosphonate nucleosides,
and modified phosphate-sugar backbone nucleotides, analogs,
derivatives, or variants of the foregoing compounds, and the like.
In some embodiments, the nucleotide can comprise non-oxygen
moieties such as, for example, thio- or borano-moieties, in place
of the oxygen moiety bridging the alpha phosphate and the sugar of
the nucleotide, or the alpha and beta phosphates of the nucleotide,
or the beta and gamma phosphates of the nucleotide, or between any
other two phosphates of the nucleotide, or any combination
thereof.
[0095] As used herein, the term "nucleotide incorporation" and its
variants comprise polymerization of one or more nucleotides to form
a nucleic acid strand including at least two nucleotides linked to
each other, typically but not necessarily via phosphodiester bonds,
although alternative linkages may be possible in the context of
particular nucleotide analogs.
[0096] As used herein, the term "processivity" and its variants
comprise the ability of a polymerase to remain bound to a single
primer/template hybrid. In some embodiments, processivity can be
measured by the number of nucleotides that a polymerase
incorporates into a nucleic acid (such as a sequencing primer)
prior to dissociation of the polymerase from the primer/template
hybrid. In some embodiments, the polymerase has a processivity of
at least 100 nucleotides, although in other embodiments it has a
processivity of at least 200 nucleotides, at least 300 nucleotides,
at least 400 nucleotides, at least 500 nucleotides or greater. It
will be understood by those of ordinary skill in the art that the
higher the processivity of the polymerase, the more nucleotides
that can be incorporated prior to dissociation and therefore the
longer the sequence (read-length) that can be obtained. In other
words, polymerases having low processivity will typically provide
shorter average read-lengths than will polymerases having higher
processivity. In one embodiment, polymerases of the instant
disclosure containing one or more amino acid mutations can possess
enhanced processivity as compared to a parent polymerase lacking
the one or more amino acid mutations.
[0097] In one exemplary assay, the processivity of a given
polymerase can be measured by incubating the polymerase with a
primer:template duplex under nucleotide incorporation conditions,
and resolving the resulting primer extension products using any
suitable method, for example via gel electrophoresis. The primer
can optionally include a label to enhance detectability of the
primer extension products. The nucleotide incorporation reaction
mixture typically includes a vast excess of unlabeled competitor
template, thereby ensuring that virtually all of the extension
products are produced through a single template binding event.
Following such resolution, the average amount of full-length
extension products can be quantified using any suitable means,
including fluorimetric or radiometric detection of full-length
extension products. To compare the processivity of two or more
different enzymes (e.g., reference and modified polymerases), each
enzyme can be employed in a parallel and separate reaction,
following which the resulting full-length primer extension products
can be resolved and measured, and such measurements compared.
[0098] In other exemplary embodiments, the processivity of a given
polymerase can be measured using any suitable assay known in the
art, including but not limited to the assays described in Von
Hippel, P. H., Faireld, F. R. and Dolejsi, M. K., On the
processivity of polymerases, Ann. NY Acad. Sci., 726:118-131
(1994); Bambara, R. A., Uyemura, D. and Choi, T., On the processive
mechanism of Escherichia coli DNA polymerase I. Quantitative
assessment of processivity, J. Biol. Chem., 253:413-423 (1978);
Das, S. K. and Fujimura, R. K., Processiveness of DNA polymerases.
A comparative study using a simple procedure, J. Biol. Chem., 254:
1227-1232 (1979); Nasir, M. S, and Jolley, M. E., Fluorescence
polarization: An Analytical Tool for Immunoassay and Drug
Discovery, Combinational Chemistry and High Throughput Screening,
2:177-190 (1999); Mestas, S. P., Sholders, A. J., and Peersen, O.
B., A Fluorescence Polarization Based Screening Assay for Nucleic
Acid Polymerase Elongation Activity, Anal. Biochem., 365:194-200
(2007); Nikiforov, T. T., Fluorogenic polymerase, endonuclease, and
ligase assays based on DNA substrates labeled with a single
fluorophore, Analytical Biochemistry 412: 229-236; and Yan Wang,
Dennis E. Prosen, Li Mei, John C. Sullivan, Michael Finney and
Peter B. Vander Horn, Nucleic Acids Research, 32(3):1197-1207
(2004).
[0099] The terms "read length" or "read-length" and their variants,
as used herein, refer to the number of nucleotides that are
polymerized (or incorporated into an existing nucleic acid strand)
in a template-dependent manner by a polymerase prior to
dissociation from a template nucleic acid strand. In some
embodiments, a polymerase that dissociates from the template
nucleic acid strand after five incorporations will typically
provide a sequence having a read length of 5 nucleotides, while a
polymerase that dissociates from the template nucleic acid strand
after 500 nucleotide incorporations will typically provide a
sequence having a read length of about 500 nucleotides. While the
actual or absolute processivity of a given polymerase (or the
actual read length of polymerization products produced by the
polymerase) can vary from reaction to reaction (or even within a
single reaction mixture wherein the polymerase produces different
products having different read lengths), the polymerase can be
characterized by the average processivity (or average read length
of polymerization products) observed under a defined set of
reaction conditions. The "error-free read length" comprises the
number of nucleotides that are consecutively and contiguously
incorporated without error (i.e., without mismatch and/or deviation
from an established and predictable set of base pairing rules) into
the newly synthesized nucleic acid strand.
[0100] In some embodiments, the disclosure relates generally to
compositions, methods, systems, apparatuses and kits comprising
modified polymerases that are characterized by increased
processivity, read length (including error-free read length) and/or
accuracy as compared to their unmodified counterparts, as well as
to methods for making and using such modified polymerases in a wide
range of biological and chemical reactions such as nucleotide
polymerization, primer extension, generation of nucleic acid
libraries and nucleic acid sequencing reactions. In some
embodiments, the modified polymerases include one or more amino
acid mutations (e.g., amino acid substitutions, additions or
deletions) relative to their corresponding unmodified counterparts.
In some embodiments, the term accuracy as used herein can be
measured by determining the rate of incorporation of a correct
nucleotide during polymerization as compared to the rate of
incorporation of an incorrect nucleotide during polymerization. In
some embodiments, the rate of incorporation of an incorrect
nucleotide can be greater than 0.3, 0.4, 0.5, 0.6, 0.7 seconds or
more under elevated salt conditions (high ionic strength solution)
as compared to standard (lower) salt conditions. While not wishing
to be bound by any particular theory, it has been found by the
applicants that the presence of elevated salt during polymerization
slows down the rate of incorporation of the incorrect nucleotide,
thereby producing a slower incorporation constant for the incorrect
nucleotide. In some embodiments, a modified polymerase of the
disclosure has enhanced accuracy compared to a relative polymerase,
optionally the modified polymerase or a biological fragment thereof
has enhanced accuracy (as compared to a relative polymerase) in the
presence of a high ionic strength solution.
[0101] In some embodiments, the disclosure relates generally to a
modified polymerase that retains polymerase activity in the
presence of a high ionic strength solution. In some embodiments, a
high ionic strength solution can be about 10, 20, 40, 50, 60, 80,
100, 150, 200, 250, 300, 400, 500, 750 mM or greater salt
concentration. In some embodiments, the high ionic strength
solution can be about 100 mM to about 500 mM salt. In some
embodiments, the high ionic strength solution can be about 125 mM
to about 400 mM salt. In some embodiments, the high ionic strength
solution can be about 200 mM to about 275 mM salt. In some
embodiments, the high ionic strength solution can be about 225 mM
to about 250 mM salt. In some embodiments, the salt can include a
potassium and/or sodium salt, such as KCl and/or NaCl. It will be
apparent to the skilled artisan that various other suitable salts
can be used in place, or in combination with KCl and/or NaCl. In
some embodiments, the ionic strength solution can further include a
sulfate.
[0102] In some embodiments, the modified polymerase can amplify
and/or sequence a nucleic acid molecule in the presence of a high
ionic strength solution. In some embodiments, a modified polymerase
is capable of amplifying (and/or sequencing) a nucleic acid
molecule in the presence of a high ionic strength solution to a
greater extent (for example as measured by accuracy) than a
reference polymerase lacking one or more of the same mutations (or
homologous mutations) under identical conditions. In some
embodiments, a modified polymerase is capable of amplifying (and/or
sequencing) a nucleic acid molecule in the presence of a high ionic
strength solution to a greater capacity (for example as measured by
accuracy) than a reference polymerase lacking one or more of the
mutations (or homologous mutations) under standard ionic strength
conditions (i.e., lower ionic strength as compared to high ionic
strength solution).
[0103] In some embodiments, the disclosure generally relates to a
modified polymerase or a biologically active fragment thereof that
can perform nucleotide polymerization or nucleotide incorporation
in the presence of elevated salt conditions as compared to a
reference polymerase.
[0104] In some embodiments, the disclosure generally relates to a
modified polymerase or a biologically active fragment thereof that
has increased accuracy or increased dissociation time constant in
the presence of elevated salt conditions as compared to a reference
polymerase.
[0105] In some embodiments, the disclosure generally relates to a
modified polymerase or a biologically fragment thereof that can
detect a change in ion concentration during nucleotide
polymerization in the presence of elevated salt conditions as
compared to a reference polymerase.
[0106] In some embodiments, the disclosure generally relates to a
modified polymerase or a biologically active fragment thereof that
can amplify or sequence a nucleic acid molecule in the presence of
elevated salt conditions.
[0107] In some embodiments, the disclosure generally relates to a
modified polymerase or a biologically active fragment thereof that
has increased accuracy as compared to a reference polymerase.
[0108] In some embodiments, the disclosure relates generally to
methods, compositions, systems and kits comprising the use of such
modified polymerases in nucleotide polymerization reactions,
including nucleotide polymerization reactions wherein sequence
information is obtained from a nucleic acid molecule. In some
embodiments, the disclosure relates generally to methods,
compositions, systems and kits comprising the use of such modified
polymerases in clonal amplification reactions, including nucleic
acid library synthesis. In some embodiments, the disclosure relates
to methods for using such modified polymerases in ion-based nucleic
acid sequencing reactions, wherein sequence information is obtained
from a template nucleic acid using an ion-based sequencing system.
In some embodiments, the disclosure relates generally to
compositions, methods, systems, kits and apparatuses for carrying
out a plurality of label-free DNA sequencing reactions (e.g.,
ion-based sequencing reactions) using a large-scale array of
electronic sensors, for example field effect transistors
("FETs").
[0109] In some embodiments, the disclosure relates generally to
compositions (as well as related methods, systems, kits and
apparatuses using such compositions) comprising a modified
polymerase including at least one amino acid modification (e.g.,
amino acid substitution, addition, deletion or chemical
modification) relative to a reference polymerase (where the
reference polymerase does not include the at least one
modification), where the modified polymerase is optionally
characterized by a change (e.g., increase or decrease) in any one
or more of the following properties relative to the reference
polymerase: dissociation time constant, rate of dissociation of
polymerase from a given nucleic acid template (also referred to
herein as "off-rate"), binding affinity of the polymerase for a
given nucleic acid template, average read length, minimum read
length, accuracy, performance in salt (i.e., ionic strength), AQ20,
average error-free read length, 100Q17 value, 200Q17 value and
processivity.
[0110] As used herein, the terms "Q17" or "Q20" and their variants,
when used in reference to a given polymerase, refer to certain
aspects of polymerase performance, particularly accuracy, in a
given polymerase reaction, for example in a polymerase-based
sequencing by synthesis reaction. For example, in a particular
sequencing reaction, accuracy metrics can be calculated either
through prediction algorithms or through actual alignment to a
known reference genome. Predicted quality scores ("Q scores") can
be derived from algorithms that look at the inherent properties of
the input signal and make fairly accurate estimates regarding if a
given single base included in the sequencing "read" will align. In
some embodiments, such predicted quality scores can be useful to
filter and remove lower quality reads prior to downstream
alignment. In some embodiments, the accuracy can be reported in
terms of a Phred-like Q score that measures accuracy on logarithmic
scale such that: Q10=90%, Q17=98%, Q20=99%, Q30=99.9%, Q40=99.99%,
and Q50=99.999%. Phred quality scores ("Q") are defined as a
property which is logarithmically related to the base-calling error
probabilities ("P'"). Often the formula given for calculating "Q"
is Q 10*log.sup.10(1/error rate). In some embodiments, the data
obtained from a given polymerase reaction can be filtered to
measure only polymerase reads measuring "N" nucleotides or longer
and having a Q score that passes a certain threshold, e.g., Q10,
Q17, Q100 (referred to herein as the "NQ17" score). For example,
the 100Q20 score can indicate the number of reads obtained from a
given reaction that are at least 100 nucleotides in length and have
Q scores of Q20 (99%) or greater. Similarly, the 200Q20 score can
indicate the number of reads that are at least 200 nucleotides in
length and have Q scores of Q20 (99%) or greater.
[0111] In some embodiments, the accuracy can also be calculated
based on proper alignment using a reference genomic sequence,
referred to herein as the "raw" accuracy. This is single pass
accuracy, involving measurement of the true per base error
associated with a single read, as opposed to consensus accuracy,
which measures the error rate from the consensus sequence which is
the result of multiple reads. Raw accuracy measurements can be
reported in terms of "AQ" scores (for aligned quality). In some
embodiments, the data obtained from a given polymerase reaction can
be filtered to measure only polymerase reads measuring "N"
nucleotides or longer having a AQ score that passes a certain
threshold, e.g., AQ10, AQ17, AQ100 (referred to herein as the
"NAQ17" score). For example, the 100AQ20 score can indicate the
number of reads obtained from a given polymerase reaction that are
at least 100 nucleotides in length and have AQ scores of AQ20 (99%)
or greater. Similarly, the 200AQ20 score can indicate the number of
reads that are at least 200 nucleotides in length and have AQ
scores of AQ20 (99%) or greater.
[0112] In some embodiments, the accuracy of the polymerase,
(including for example accuracy in a given sequencing reaction) can
be measured in terms of the total number of "perfect" (i.e.,
zero-error) reads obtained from a polymerase reaction that are
greater than 100, 200, 300, 400, 500, 750, 1000, 5000, 10000,
100000 nucleotides in length.
[0113] In some embodiments, the accuracy of the polymerase can be
measured in terms of the longest perfect read (typically measured
in terms of number of nucleotides included in the read) that is
obtained from a polymerase reaction.
[0114] In some embodiments, the accuracy of the polymerase can be
measured in terms of fold-increase in sequencing throughput
obtained in a given sequencing reaction. For example, in some
embodiments an exemplary modified polymerase of the instant
application may have an increased accuracy of 2-fold, 5-fold,
10-fold, 20-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold,
400-fold, 500-fold, or greater, accuracy than a reference
polymerase.
[0115] Some exemplary non-limiting descriptions of accuracy metrics
can be found in: Ewing B, Hillier L, Wendl M C, Green P. (1998):
Base-calling of automated sequencer traces using phred. I. Accuracy
assessment. Genome Res. 8(3):175-185; Ewing B, Green P. (1998):
Base-calling of automated sequencer traces using phred. II. Error
probabilities. Genome Res. 8(3):186-194; Dear S, Staden R (1992): A
standard file format for data from DNA sequencing instruments. DNA
Sequence, 3, 107-110; Bonfield J K, Staden R (1995): The
application of numerical estimates of base calling accuracy to DNA
sequencing projects. Nucleic Acids Res. 1995 Apr. 25;
23(8):1406-10, herein incorporated by reference in their
entireties.
[0116] In some embodiments, the sequencing accuracy of a given set
of polymerases (including any of the reference or modified
polymerases described herein) can be measured in an ion based
sequencing reaction run; such accuracies can optionally be compared
with each other to determine whether a given amino acid mutation
increases or decreases the sequencing accuracy relative to a
reference or unmodified polymerase. In some embodiments, the
sequencing accuracy of one or more polymerases can be measured
using any ion-based sequencing apparatus supplied by Ion Torrent
Technologies (Ion Torrent Systems, Life Technologies, Carlsbad,
Calif.), including for example the Ion Torrent PGM.TM. Sequencer
(Ion Torrent Systems, Life Technologies, Part No. 4462917),
optionally using the sequencing protocols and reagents provided by
Ion Torrent Systems. Some examples of calculation of accuracy
metrics of a given polymerase using such ion-based sequencing
systems is described further in the Ion Torrent Application Note
titled "Ion Torrent: Ion Personal Genome Machine.TM. Performance
Overview, Performance Spring 2011", hereby incorporated by
reference.
[0117] As used herein, the terms "dissociation rate constant" and
"dissociation time constant", when used in reference to a given
polymerase, refer to the time constant for dissociation ("koff") of
a polymerase from a nucleic acid template under a defined set of
reaction conditions. Some exemplary assays for measuring the
dissociation time constant of a polymerase are described further
below. In some embodiments, the dissociation time constant can be
measured in units of inverse time, e.g., sec.sup.-1 or
min.sup.-1.
[0118] In some embodiments, the disclosure relates generally to an
isolated modified polymerase including at least one amino acid
modification relative to a reference polymerase and providing an
increased average read length of primer extension products in a
primer extension reaction using the modified polymerase, relative
to the average read length of primer extension products obtained
using the reference polymerase. In some embodiments, the isolated
modified polymerase provides an increased average error-free read
length of primer extension products in a primer extension reaction
using the modified polymerase, relative to the average error-free
read length of primer extension products obtained using the
corresponding unmodified polymerase. Optionally, the modified
polymerase includes two or more amino acid substitutions relative
to the unmodified polymerase.
[0119] In some embodiments, the primer extension reaction is an
ion-based sequencing reaction.
[0120] In some embodiments, the isolated modified polymerase
provides an increased 100Q17 or 200Q17 value in a nucleic acid
sequencing reaction (for example in an ion-based sequencing
reaction) relative to the 100Q17 or 200Q17 value obtained using the
reference polymerase.
[0121] In some embodiments, the reference polymerase includes a
naturally occurring or wild type polymerase. In other embodiments,
the reference polymerase includes a derivative, truncated, mutant
or variant form of a naturally occurring polymerase.
[0122] In some embodiments, the disclosure relates generally to
methods for performing a nucleotide polymerization reaction,
comprising: contacting a modified polymerase with a nucleic acid
template in the presence of one or more nucleotides; and
polymerizing at least one of the one or more nucleotides using the
modified polymerase. The polymerizing optionally further includes
polymerizing the at least one nucleotide in a template-dependent
fashion. In some embodiments, the modified polymerase includes one
or more amino acid substitutions relative to a reference polymerase
that does not include the one or more amino acid substitutions.
[0123] In some embodiments, the method further includes hybridizing
a primer to the template prior to, during, or after the contacting.
The polymerizing can include polymerizing the at least one
nucleotide onto an end of the primer using the modified
polymerase.
[0124] In some embodiments, the polymerizing is performed in the
proximity of a sensor that is capable of detecting the
polymerization of the at least one nucleotide by the modified
polymerase.
[0125] In some embodiments, the method further includes detecting a
signal indicating the polymerization of the at least one of the one
or more nucleotides by the modified polymerase using the
sensor.
[0126] In some embodiments, the modified polymerase, the reference
polymerase, or both the modified and reference polymerase is a DNA
polymerase. The DNA polymerase can include, without limitation, a
bacterial DNA polymerase, prokaryotic DNA polymerase, eukaryotic
DNA polymerase, archaeal DNA polymerase, viral DNA polymerase or
phage DNA polymerase.
[0127] In some embodiments, the DNA polymerase is selected from the
group consisting of an A family DNA polymerase; a B family DNA
polymerase; a mixed-type polymerase; an unclassified DNA polymerase
and RT family polymerase; and variants and derivatives thereof.
[0128] In some embodiments, the DNA polymerase is an A family DNA
polymerase selected from the group consisting of a Pol I-type DNA
polymerase such as E. coli DNA polymerase, the Klenow fragment of
E. coli DNA polymerase, Bst DNA polymerase, Taq DNA polymerase,
Platinum Taq DNA polymerase series, Omni Klen Taq DNA polymerase
series, Klen Taq DNA polymerase series, T7 DNA polymerase, and Tth
DNA polymerase. In some embodiments, the DNA polymerase is Bst DNA
polymerase. In other embodiments, the DNA polymerase is E. coli DNA
polymerase I. In some embodiments, the DNA polymerase is the Klenow
fragment of E. coli DNA polymerase. In some embodiments, the
polymerase is Taq DNA polymerase. In some embodiments, the
polymerase is T7 DNA polymerase.
[0129] In other embodiments, the DNA polymerase is a B family DNA
polymerase selected from the group consisting of Bst polymerase,
Tli polymerase, Pfu polymerase, Pfu turbo polymerase, Pyrobest
polymerase, Pwo polymerase, KOD polymerase, Sac polymerase, S so
polymerase, Poc polymerase, Pab polymerase, Mth polymerase, Pho
polymerase, ES4 polymerase, VENT polymerase, DEEPVENT polymerase,
Therminator.TM. polymerase, phage Phi29 polymerase, and phage B103
polymerase. In some embodiments, the polymerase is KOD polymerase.
In some embodiments, the polymerase is Therminator.TM. polymerase.
In some embodiments, the polymerase is phage Phi29 DNA polymerase.
In some embodiments the polymerase is phage B103 polymerase,
including, for example, the variants disclosed in U.S. Patent
Publication No. 20110014612 which is incorporated by reference
herein.
[0130] In other embodiments, the DNA polymerase is a mixed-type
polymerase selected from the group consisting of EX-Taq polymerase,
LA-Taq polymerase, Expand polymerase series, and Hi-Fi polymerase.
In yet other embodiments, the DNA polymerase is an unclassified DNA
polymerase selected from the group consisting of Tbr polymerase,
Tfl polymerase, Tru polymerase, Tac polymerase, Tne polymerase, Tma
polymerase, Tih polymerase, and Tfi polymerase.
[0131] In other embodiments, the DNA polymerase is an RT polymerase
selected from the group consisting of HIV reverse transcriptase,
M-MLV reverse transcriptase and AMV reverse transcriptase. In some
embodiments, the polymerase is HIV reverse transcriptase or a
fragment thereof having DNA polymerase activity.
[0132] Suitable bacterial DNA polymerases include without
limitation E. coli DNA polymerases I, II and III, IV and V, the
Klenow fragment of E. coli DNA polymerase, Clostridium stercorarium
(Cst) DNA polymerase, Clostridium thermocellum (Cth) DNA
polymerase, Bacillus stearothermophilus (Bst) DNA polymerase and
Sulfolobus solfataricus (Sso) DNA polymerase.
[0133] Suitable eukaryotic DNA polymerases include without
limitation the DNA polymerases .alpha., .delta., .epsilon., .eta.,
.zeta., .gamma., .beta., .sigma., .lamda., .mu., , and .kappa., as
well as the Rev 1 polymerase (terminal deoxycytidyl transferase)
and terminal deoxynucleotidyl transferase (TdT).
[0134] Suitable viral and/or phage DNA polymerases include without
limitation T4 DNA polymerase, T5 DNA polymerase, T7 DNA polymerase,
Phi-15 DNA polymerase, Phi-29 DNA polymerase (see, e.g., U.S. Pat.
No. 5,198,543; also referred to variously as .PHI.29 polymerase,
phi29 polymerase, phi 29 polymerase, Phi 29 polymerase, and Phi29
polymerase); .PHI.15 polymerase (also referred to herein as Phi-15
polymerase); .PHI.21 polymerase (Phi-21 polymerase); PZA
polymerase; PZE polymerase, PRD1 polymerase; Nf polymerase; M2Y
polymerase; SF5 polymerase; f1 DNA polymerase, Cp-1 polymerase;
Cp-5 polymerase; Cp-7 polymerase; PR4 polymerase; PR5 polymerase;
PR722 polymerase; L17 polymerase; M13 DNA polymerase, RB69 DNA
polymerase, G1 polymerase; GA-1 polymerase, BS32 polymerase; B103
polymerase; a polymerase obtained from any phi-29 like phage or
derivatives thereof, etc. See, e.g., U.S. Pat. No. 5,576,204, filed
Feb. 11, 1993; U.S. Pat. Appl. No. 2007/0196846, published Aug. 23,
2007.
[0135] Suitable archaeal DNA polymerases include without limitation
the thermostable and/or thermophilic DNA polymerases such as, for
example, DNA polymerases isolated from Thermus aquaticus (Taq) DNA
polymerase, Thermus filiformis (Tfi) DNA polymerase, Thermococcus
zilligi (Tzi) DNA polymerase, Thermus thermophilus (Tth) DNA
polymerase, Thermus flavus (Tfl) DNA polymerase, Pyrococcus woesei
(Pwo) DNA polymerase, Pyrococcus furiosus (Pfu) DNA polymerase as
well as Turbo Pfu DNA polymerase, Thermococcus litoralis (Tli) DNA
polymerase or Vent DNA polymerase, Pyrococcus sp. GB-D polymerase,
"Deep Vent" DNA polymerase, New England Biolabs), Thermotoga
maritima (Tma) DNA polymerase, Bacillus stearothermophilus (Bst)
DNA polymerase, Pyrococcus Kodakaraensis (KOD) DNA polymerase, Pfx
DNA polymerase, Thermococcus sp. JDF-3 (JDF-3) DNA polymerase,
Thermococcus gorgonarius (Tgo) DNA polymerase, Thermococcus
acidophilium DNA polymerase; Sulfolobus acidocaldarius DNA
polymerase; Thermococcus sp. 9.degree. N-7 DNA polymerase;
Thermococcus sp. NA1; Pyrodictium occultum DNA polymerase;
Methanococcus voltae DNA polymerase; Methanococcus
thermoautotrophicum DNA polymerase; Methanococcus jannaschii DNA
polymerase; Desulfurococcus strain TOK DNA polymerase (D. Tok Pol);
Pyrococcus abyssi DNA polymerase; Pyrococcus horikoshii DNA
polymerase; Pyrococcus islandicum DNA polymerase; Thermococcus
fumicolans DNA polymerase; Aeropyrum pernix DNA polymerase; the
heterodimeric DNA polymerase DP1/DP2, etc.
[0136] In some embodiments, the modified polymerase is an RNA
polymerase. Suitable RNA polymerases include, without limitation,
T3, T5, T7, and SP6 RNA polymerases.
[0137] In some embodiments, the polymerase is a reverse
transcriptase. Suitable reverse transcriptases include without
limitation reverse transcriptases from HIV, HTLV-I, HTLV-II, FeLV,
FIV, SIV, AMV, MMTV and MoMuLV, as well as the commercially
available "Superscript" reverse transcriptases, (Life Technologies
Corp., Carlsbad, Calif.) and telomerases.
[0138] In some embodiments, the modified polymerase is derived from
a known DNA polymerase. The DNA polymerases have been classified
into seven different families, based upon both amino acid sequence
comparisons and three-dimensional structure analyses. The DNA
polymerase I (pol I) or type A polymerase family includes the
repair polymerases E. coli DNA pol I, Thermus aquaticus pol I, and
Bacillus stearothermophilus pol I, replicative DNA polymerases from
some bacteriophages (T3, T5 and T7) and eukaryotic mitochondrial
DNA polymerases. The DNA polymerase .alpha. (pol .alpha.) or type B
polymerase family includes all eukaryotic replicating DNA
polymerases as well as archaebacterial DNA polymerases, viral DNA
polymerases, DNA polymerases encoded in mitochondrial plasmids of
various fungi and plants, and the polymerases from bacteriophages
T4 and RB69. Family C polymerases are the primary bacterial
chromosome replicative enzymes. These are sometimes considered a
subset of family Y, which contains the eukaryotic polymerase pol
.beta., as well as other eukaryotic polymerases such as pol
.sigma., pol .lamda., pol .mu., and terminal deoxynucleotidyl
transferase (TdT). Family D polymerases are all found in the
Euryarchaeota subdomain of Archaea and are thought to be
replicative polymerases. The family Y polymerases are called
translesion synthesis (TLS) polymerases due to their ability to
replicate through damaged DNA. They are also known as error-prone
polymerases since they have a low fidelity on undamaged templates.
This family includes Pol .eta., Pol.zeta., Pol (iota), Pol .kappa.
(kappa), and Rev1, and Pol IV and PolV from E coli. Finally, the
reverse transcriptase family includes reverse transcriptases from
retroviruses and eukaryotic polymerases, usually restricted to
telomerases. These polymerases use an RNA template to synthesize
the DNA strand, and are also known as RNA-dependent DNA
polymerases.
[0139] In some embodiments, a modified polymerase or biologically
active fragment thereof can be prepared using any suitable method
or assay known to one of skill in the art. In some embodiments, any
suitable method of protein engineering to obtain a modified
polymerase or biologically active fragment thereof is encompassed
by the disclosure. For example, site-directed mutagenesis is a
technique that can be used to introduce one or more known or random
mutations within a DNA construct. The introduction of the one or
more amino acid mutations can be verified for example, against a
standard or reference polymerase or via nucleic acid sequencing.
Once verified, the construct containing the one or more of the
amino acid mutations can be transformed into bacterial cells and
expressed.
[0140] Typically, colonies containing mutant expression constructs
are inoculated in media, induced, and grown to a desired optical
density before collection (often via centrifugation) and
purification of the supernatant. It will be readily apparent to the
skilled artisan that the supernatant can be purified by any
suitable means. Typically, a column for analytical or preparative
protein purification is selected. In some embodiments, a modified
polymerase or biologically active fragment thereof prepared using
the methods can be purified, without limitation, over a heparin
column essentially according to the manufacturer's
instructions.
[0141] Once purified, the modified polymerase or biologically
active fragment thereof can be assessed using any suitable method
for various polymerase activities. In some embodiments, the
polymerase activity being assessed will depend on the application
of interest. For example a polymerase used to amplify or sequence a
nucleic acid molecule of about 400 by in length may include
polymerase activities such as increased processivity and/or
increased dissociation time constant relative to a reference
polymerase. In another example, an application requiring deep
targeted-resequencing of a nucleic acid molecule of about 100 by in
length may include a polymerase with increased proofreading
activity or increased minimum read length. In some embodiments, the
one or more polymerase activities assessed can be related to
polymerase performance or polymerase activity in the presence of
high salt.
[0142] In some embodiments, a modified polymerase or biologically
active fragment thereof prepared according to the methods can be
assessed for DNA binding activity, nucleotide polymerization
activity, primer extension activity, strand displacement activity,
reverse transcriptase activity, 3'-5' exonuclease (proofreading)
activity, and the like.
[0143] In some embodiments, a modified polymerase or biologically
active fragment thereof prepared according to the methods can be
assessed for increased accuracy, increase processivity, increased
average read length, increased minimum read length, increased AQ20,
increased 200Q17 value or the ability to perform nucleotide
polymerization as compared to a reference polymerase. In some
embodiments, the modified polymerase or the biologically active
fragment thereof can be assessed for any one of the polymerase
activities in the presence of a high ionic strength solution.
[0144] In some embodiments, a modified polymerase or biologically
active fragment thereof is optionally characterized by a change
(e.g., increase or decrease) in any one or more of the following
properties (often, relative to a polymerase lacking the one or more
amino acid mutations): dissociation time constant, rate of
dissociation of polymerase from a given nucleic acid template,
binding affinity of the polymerase for a given nucleic acid
template, average read length, minimum read length, accuracy, total
number of perfect reads, fold-increase in throughput of a
sequencing reaction, performance in salt (i.e., ionic strength),
AQ20, average error-free read length, error-rate, 100Q17 value,
200Q17 value, Q score, raw read accuracy, and processivity.
[0145] In some embodiments, a modified polymerase or biologically
active fragment thereof can be assessed individually with respect
to known values in the art for an analogous polymerase. In some
embodiments, a modified polymerase or biologically active fragment
thereof prepared according to the methods can be assessed against a
known or reference polymerase under similar or identical
conditions. In some embodiments, the conditions can include
amplifying or sequencing a nucleic acid molecule in the presence of
a high ionic strength solution.
[0146] In some embodiments, the disclosure relates generally to
methods for producing a plurality of modified polymerases or
biologically active fragments. In some embodiments, the disclosure
relates generally to methods for producing a plurality of modified
polymerases or biologically active fragments using a
high-throughput or automated system. In some embodiments, the
methods comprise mixing a plurality of modified polymerases or
biologically active fragments with a series of reagents necessary
for protein purification and extracting the purified polymerases or
biologically active fragments from the mixture. In one example, a
plurality of random or site-directed mutagenesis reactions can be
prepared in a 96- or 384-well plate. Optionally, the contents of
the 96- or 384-well plate can undergo an initial screen to identify
polymerase mutant constructs. The contents of each individual well
(or the contents of each well from an initial screen) can be
delivered to a series of flasks, tubes or shakers for inoculation
and induction. Once at the required optical density, the flask,
tubes or shakers can be centrifuged and the supernatants recovered.
Each supernatant can undergo protein purification, for example via
fully automated column purification (for example see, Camper and
Viola, Analytical Biochemistry, 2009, p 176-181). The purified
modified polymerases or biologically active fragments can be
assessed for one, or a combination of polymerase activities, such
as DNA binding, primer extension, strand displacement, reverse
transcriptase activity, and the like. It is envisaged that the
skilled artisan can use the method (or variations of the methods
that are within the scope of the disclosure) to identify a
plurality of modified polymerases or biologically active fragments.
In some aspects, the methods can be used to identify a plurality of
modified polymerases or biologically active fragments having
enhanced accuracy as compared to a reference polymerase. In some
embodiments, the methods can be used to identify a plurality of
modified polymerases or biologically active fragments thereof
having enhanced accuracy in the presence of a high ionic strength
solution. In some embodiments, the high ionic strength solution can
include a KCl and/or NaCl salt. In some embodiments, the high ionic
strength solution can be about 10, 20, 30, 40, 50, 60, 80, 100,
150, 200, 225, 250, 275, 300, 350, 400, 450, 500, 550, 600, 700,
750 mM or greater salt concentration. In some embodiments, the high
ionic strength solution can be about 100 mM to about 500 mM salt.
In some embodiments, the high ionic strength solution can be about
125 mM to about 400 mM salt. In some embodiments, the high ionic
strength solution can be about 200 mM to about 275 mM salt. In some
embodiments, the high ionic strength solution can be about 225 mM
to about 250 mM salt. It will be apparent to the skilled artisan
that various other suitable salts can be used in place, or in
combination with KCl and/or NaCl. In some embodiments, the ionic
strength solution can further include a sulfate.
[0147] As will be readily apparent to the skilled artisan, the
disclosure outlines an exemplary automated and high-throughput
method to generate a library of modified polymerases or biological
active fragments. The disclosure also outlines methods to assess
such modified polymerases or biologically active fragments for
polymerase activity. It is also encompassed by the disclosure that
the skilled artisan can readily produce a mutagenized library of
constructs wherein every amino acid within the polymerase of
interest can be mutated. In some embodiments, a mutagenized library
can be prepared wherein each amino acid within the polymerase is
mutated by every possible amino acid combination. In some
embodiments, a mutagenized library can be prepared where each amino
acid within the polymerase is mutated, and where the combination of
possible amino acid mutations is limited to conservative or
non-conservative amino acid substitutions. In both examples,
mutagenized libraries can be created containing vast numbers of
mutant constructs that can be applied through an automated or
high-throughput system for purification or for initial screening.
Once purified, the mutagenized library of proteins can be assessed
for one, or a combination of polymerase activities, such as DNA
binding, primer extension, strand displacement, reverse
transcriptase, nick-initiated polymerase activity, and the like.
Optionally, the purified modified polymerases or biologically
active fragments thereof can be further assessed for other
properties such as the ability to amplify or sequence a nucleic
acid molecule in the presence of high salt. The source or origin of
the polymerase to be mutated is generally not considered critical.
For example, eukaryotic, prokaryotic, archaeal, bacterial, phage or
viral polymerases can be used in the methods. In some embodiments,
the polymerase can be a DNA or RNA polymerase. In some embodiments,
the DNA polymerase can include a family A or family B polymerase.
The exemplary methods provided herein are to be considered
illustrative in view of the field of protein engineering and
enzymatics and should not be construed as in any way limiting.
[0148] In some embodiments, the modified polymerase or a
biologically active fragment thereof, includes one or more amino
acid mutations that are located inside the catalytic domain of the
modified polymerase. In some embodiments, the modified polymerase
or biologically active fragment thereof can include at least 25,
50, 75, 100, 150, or more amino acid residues of the catalytic
domain. In some embodiments, the modified polymerase or
biologically active fragment thereof can include any part of the
catalytic domain that comprises at least 25, 50, 75, 100, 150, or
more contigiuous amino acid residues. In some embodiments, the
modified polymerase or biologically active fragment thereof can
include at least 25 contiguous amino acid residues of the catalytic
domain and can optionally include one or more amino acid residues
at the C-terminal or the N-terminal that are outside the catalytic
domain. In some embodiments, the modified polymerase or a
biologically active fragment can include any 25, 50, 75, 100, 150,
or more contiguous amino acid residues of the catalytic domain
coupled to any one or more non-catalytic domain amino acid
residues.
[0149] In some embodiments, the modified polymerase (or
biologically active fragment thereof) includes one or more amino
acid mutations that are located inside the catalytic domain of the
modified polymerase, and wherein the polymerase has at least 80%,
85%, 90%, 95%, 96%, 97%, 98%, 99%, or more identity to any one of
the modified polymerases disclosed herein. In some embodiments, the
modified polymerase (or biologically active fragment thereof)
includes one or more amino acid mutations that are located inside
the catalytic domain of the modified polymerase, and wherein the
polymerase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
more identity to any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:
4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ
ID NO: 20 and SEQ ID NO: 24.
[0150] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the catalytic domain and has at least 80% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0151] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the catalytic domain and has at least 85% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0152] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the catalytic domain and has at least 90% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0153] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the catalytic domain and has at least 95% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0154] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the catalytic domain and has at least 98% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0155] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the catalytic domain and has at least 80% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0156] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the catalytic domain and has at least 85% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0157] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the catalytic domain and has at least 90% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0158] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the catalytic domain and has at least 95% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0159] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the catalytic domain and has at least 98% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0160] In some embodiments, the modified polymerase or a
biologically active fragment thereof, includes one or more amino
acid mutations that are located inside the DNA binding domain of
the polymerase. In some embodiments, the modified polymerase or
biologically active fragment thereof can include at least 25, 50,
75, 100, 150, or more amino acid residues of the DNA binding domain
of the modified polymerase. In some embodiments, the modified
polymerase or biologically active fragment thereof can include any
part of the DNA binding domain that comprises at least 25, 50, 75,
100, 150, or more contigiuous amino acid residues. In some
embodiments, the modified polymerase or biologically active
fragment thereof can include at least 25 contiguous amino acid
residues of the binding domain and can optionally include one or
more amino acid residues at the C-terminal or the N-terminal that
are outside of the binding domain. In some embodiments, the
modified polymerase or a biologically active fragment can include
any 25, 50, 75, 100, 150 or more contiguous amino acid residues of
the binding domain coupled to any one or more non-binding domain
amino acid residues. In some embodiments, the modified polymerase
(or biologically active fragment thereof) includes one or more
amino acid mutations that are located inside the DNA binding domain
of the modified polymerase, and wherein the polymerase has at least
80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more identity to any one
of the modified polymerases disclosed herein. In some embodiments,
the modified polymerase (or biologically active fragment thereof)
includes one or more amino acid mutations that are located inside
the DNA binding domain of the modified polymerase, and wherein the
polymerase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or
more identity to any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:
4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ
ID NO: 20 and SEQ ID NO: 24.
[0161] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the DNA binding domain and has at least 80% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0162] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the DNA binding domain and has at least 85% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0163] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the DNA binding domain and has at least 90% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0164] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the DNA binding domain and has at least 95% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0165] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues of the DNA binding domain and has at least 98% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0166] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the DNA binding domain and has at least 80% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0167] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the DNA binding domain and has at least 85% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0168] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the DNA binding domain and has at least 90% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0169] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the DNA binding domain and has at least 95% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0170] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues of the DNA binding domain and has at least 98% identity to
any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15,
SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ
ID NO: 24.
[0171] In some embodiments, the modified polymerase or a
biologically active fragment thereof, includes one or more amino
acid mutations that are located outside the catalytic domain (also
referred to herein as the DNA binding cleft) of the polymerase. The
catalytic domains of the A family DNA polymerases, B family DNA
polymerases and reverse transcriptases, as well as the
RNA-dependent RNA polymerases are well known; all share a common
overall structure and catalytic mechanism. The catalytic domains of
all these polymerases have a shape that has been compared to a
right hand and consists of "palm", "thumb" and "finger" domains.
The palm domain typically contains the catalytic site for the
phosphoryl transfer reaction. The thumb is thought to play a role
positioning the duplex DNA and in processivity and translocation.
The fingers interact with the incoming nucleotide as well as the
template base with which it is paired. The palm domains are
homologous in the A, B and RT families, but the arrangements of the
fingers and thumb are different. The thumb domains of the different
polymerase families do share common features, containing parallel
or anti-parallel .alpha.-helices, with at least one .alpha.-helix
interacting with the minor groove of the primer-template complex.
The fingers domain also conserves an .alpha.-helix positioned at
the blunt end of the primer-template complex. This helix contains
highly conserved side chains (the B motif).
[0172] Three conserved motifs, A, B, and C have been identified for
the A family polymerases. The A and C motifs are typically
conserved in both the B family polymerases and the RT polymerases.
(Delarue et al., Protein Engineering 3: 461-467 (1990)).
[0173] In some embodiments, for the A family polymerases, the A
motif comprises the consensus sequence:
TABLE-US-00001 DXSXXE. (SEQ ID NO: 5)
[0174] In some embodiments, for the A family polymerases, the B
motif comprises the consensus sequence:
TABLE-US-00002 KXXXXXXYG (SEQ ID NO: 6)
[0175] In some embodiments, for the A family polymerases, the C
motif comprises the consensus sequence:
TABLE-US-00003 VHDE (SEQ ID NO: 7)
[0176] In some embodiments, the polymerase optionally comprises any
A family polymerase, or biologically active fragment, mutant,
variant or truncation thereof, wherein the linking moiety is linked
to any amino acid residue of the A family polymerase, or
biologically active fragment mutant, variant or truncation thereof,
that is situated outside the A, B or C motifs. In some embodiments,
the linking moiety is linked to any amino acid residue of the A
family polymerase, or biologically active fragment, that is
situated outside the A motif, the B motif or the C motif.
[0177] The A and C motifs typically form part of the palm domain,
and each motif typically contains a strictly conserved aspartic
acid residue, which are involved in the catalytic mechanism common
to all the DNA polymerases. DNA synthesis can be mediated by
transfer of a phosphoryl group from the incoming nucleotide to the
3' OH of the DNA, releasing a polyphosphate moiety and forming a
new DNA phosphodiester bond. This reaction is typically catalyzed
by a mechanism involving two metal ions, normally Mg.sup.2+, and
the two conserved aspartic acid residues.
[0178] In some embodiments, the conserved glutamic acid residue in
motif A of the A family DNA polymerases plays an important role in
incorporation of the correct nucleotide, as does the corresponding
conserved tyrosine in B family members (Minnick et al., Proc. Natl.
Acad. Sci. USA 99: 1194-1199 (2002); Parsell et al, Nucleic Acids
Res. 35: 3076-3086 (2002). Mutations at the conserved Leu of motif
A affect replication fidelity (Venkatesan et al., J. Biol. Chem.
281: 4486-4494 (2006)).
[0179] In some embodiments, the B motif contains conserved lysine,
tyrosine and glycine residues. The B motif of E coli pol I has been
shown to bind nucleotide substrates and contains a conserved
tyrosine which has been shown to be in the active site.
[0180] In some embodiments, for the B family polymerases, the A
motif comprises the consensus sequence:
TABLE-US-00004 DXXSLYPS. (SEQ ID NO: 8)
[0181] In some embodiments, for the B family polymerases, the B
motif comprises the consensus sequence:
TABLE-US-00005 KXXXNSXYG (SEQ ID NO: 9)
[0182] In some embodiments, for the B family polymerases, the C
motif comprises the consensus sequence:
TABLE-US-00006 YGDTDS (SEQ ID NO: 10)
[0183] The residues in bold indicate invariant residues.
[0184] In some embodiments, the modified polymerase optionally
comprises any B family polymerase, or biologically active fragment,
mutant, variant or truncation thereof, wherein the linking moiety
is linked to any amino acid residue of the B family polymerase, or
biologically active fragment, mutant, variant or truncation thereof
that is situated outside the A, B or C motifs. In some embodiments,
the linking moiety is linked to any amino acid residue of the B
family polymerase, or biologically active fragment, that is
situated outside the A motif, the B motif or the C motif.
[0185] In some embodiments, the B family polymerases contain six
conserved motifs, of which regions I and II correspond to the A and
C motifs of the A family. Region III is involved in nucleotide
binding and is functionally homologous to motif B. Regions I, II
and III converge at the center of the active site from the palm
(I), the fingers (II), and base of the thumb (III) to produce a
contiguous conserved surface. Within these regions, a set of highly
conserved residues form three chemically distinct clusters
consisting of exposed aromatic residues, negatively charged
residues, and positively charged residues, respectively. For
example, in the replication polymerase of the bacteriophage RB69,
these three clusters corresponds to the following amino acid
residues: Y416, Y567, and Y391 (exposed aromatic residues), D621,
D623, D411, D684, and E686 (negatively charged residues), and K560,
R482, and K486 (positively charged residues). See Wang et al, Cell
89: 1087-1099 (1997). These three clusters typically encompass the
region in which the primer terminus and the incoming nucleotide
would be expected to bind. In some embodiments, the modified
polymerase optionally comprises any B family polymerase, or
biologically active fragment, mutant, variant or truncation
thereof, wherein the linking moiety is linked to any amino acid
residue of the B family polymerase, or biologically active
fragment, mutant, variant or truncation thereof that is situated
outside one or more of these conserved amino acid clusters or
motifs. In some embodiments, the linking moiety is linked to any
amino acid residue of the B family polymerase, or biologically
active fragment, mutant, variant or truncation thereof that is
situated outside any of these conserved amino acid clusters or
motifs.
[0186] The RT polymerases contain four conserved sequence motifs
(Poch et al., EMBO J. 12: 3867-3874 (1989)), with motifs A and C
containing the conserved catalytic aspartates. The integrity of
motif B is also required for reverse transcriptase function.
TABLE-US-00007 The consensus sequence for motif A is DXXXXF/Y (SEQ
ID NO: 11) The consensus sequence for motif B is FXGXXXS/A (SEQ ID
NO: 12) The consensus sequence for motif C is YXDD (SEQ ID NO: 13)
The consensus sequence for motif D is GXXXXXXXK. (SEQ ID NO:
14)
[0187] Mutations in the YXDD motif (motif C), the most highly
conserved of these motifs, can abolish polymerase activity and
alter the processivity and fidelity (Sharma et al., Antiviral
Chemistry and Chemotherapy 16: 169-182 (2005)). In addition, the
conserved lysine residue in motif D, a loop that is unique to the
RT polymerases, is an invariant residue important for nucleotide
binding (Canard et al., J. Biol. Chem. 274: 35768-35776
(1999)).
[0188] In some embodiments, the modified polymerase optionally
comprises any RT polymerase, or biologically active fragment,
mutant, variant or truncation thereof, wherein the linking moiety
is linked to any amino acid residue of the RT polymerase, or
biologically active fragment, mutant, variant or truncation thereof
that is situated outside one or more of the A, B, C and D motifs.
In some embodiments, the linking moiety is linked to any amino acid
residue of the RT polymerase, or biologically active fragment,
mutant, variant or truncation thereof that is situated outside any
of these motifs.
[0189] In some embodiments, the modified polymerase includes one or
more modifications (including amino acid substitutions, deletions,
additions or chemical modifications) located at any position other
than at the conserved or invariant residues.
[0190] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues having at least 80% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0191] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues having at least 85% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0192] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues having at least 85% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0193] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues having at least 90% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0194] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 100 contiguous amino acid
residues having at least 90% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0195] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 100 contiguous amino acid
residues having at least 95% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0196] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 150 contiguous amino acid
residues having at least 95% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0197] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues having at least 98% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0198] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues having at least 98% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0199] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 25 contiguous amino acid
residues having at least 99% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0200] In some embodiments, the modified polymerase or biologically
active fragment thereof includes at least 50 contiguous amino acid
residues having at least 99% identity to any one of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID
NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 24.
[0201] In some embodiments, in addition to the polymerase domains,
the modified polymerase can include one or more additional
functional domains, including domains required for 3'->5'
(reverse) exonuclease activity that mediates proofreading of the
newly synthesized DNA strand, or for 5'->3' (forward)
exonuclease activity that mediates nick translation during DNA
repair, or for FLAP endonuclease activity. In some embodiments, the
modified polymerase has strand-displacing activity, and can
catalyze nucleic acid synthesis by polymerizing nucleotides into
the 3' end of a nick within a double stranded nucleic acid template
while simultaneously displacing the nucleic acid located downstream
of the nick. The modified polymerase optionally has any one or more
of these activities as well.
[0202] The 3' to 5' exonuclease proofreading domains of both A and
B family DNA polymerases contain three conserved motifs, called Exo
I, Exo II and Exo III, each of which contains an invariant aspartic
acid residue essential for metal binding and exonuclease function.
Alterations of these conserved aspartic acid residues result in
proteins which retain polymerase activity, but are deficient in
exonuclease activity (Hall et al., J. Gen. Virol. 76: 2999-3008
(1995)). Conserved motifs in the 5' to 3' exonuclease domains and
amino acid alterations that affect exonuclease activity have also
been identified (U.S. Pat. No. 5,466,591).
[0203] Representative examples of A family enzymes are E. coli. Pol
I, or the Klenow fragment of E coli. Pol I, Bst DNA polymerase, Taq
DNA polymerase, T7 DNA polymerase and Tth DNA polymerase. A family
enzymes also include the Platinum Taq DNA polymerase series.
[0204] In some embodiments, the A family enzymes are characterized
by high DNA elongation rates but can have poor fidelity because of
the lack of 3'-5' exonuclease activity. In some embodiments, the B
family enzymes can have high fidelity owing to their 3'-5'
exonuclease activity but can achieve low DNA elongation rates.
[0205] Other types of polymerases include, for example, Tbr
polymerase, Tfl polymerase, Tru polymerase, Tac polymerase, Tne
polymerase, Tma polymerase, Tih polymerase, Tfi polymerase and the
like. RT polymerases include HIV reverse transcriptase, Moloney
Murine Leukemia Virus (M-MLV) reverse transcriptase, Avian
Myeloblastosis Virus (AMV) reverse transcriptase or Rous Sarcoma
Virus (RSV) reverse transcriptase. Variants, modified products and
derivatives thereof are also usable. Similarly, Taq, Platinum Taq,
Tth, Tli, Pfu, Pfutubo, Pyrobest, Pwo and KOD, VENT, DEEPVENT,
EX-Taq, LA-Taq, Therminator.TM., the Expand series and Platinum Taq
Hi-Fi are all commercially available. Other enzymes can be readily
isolated from specific bacteria by those of ordinary skill in the
art.
[0206] One exemplary polymerase, E coli DNA polymerase I ("Pol I")
possesses three enzymatic activities: a 5' to 3' DNA polymerase
activity; a 3' to 5' exonuclease activity that mediates
proofreading; and a 5' to 3' exonuclease activity mediating nick
translation during DNA repair. The Klenow fragment is a large
protein fragment produced when E. coli Pol I is proteolytically
cleaved by subtilisin. It retains the polymerase and proofreading
exonuclease activities, but lacks the 5' to 3' exonuclease
activity. An exo-Klenow fragment which has been mutated to remove
the proofreading exonuclease activity is also available. The
structure of the Klenow fragment shows that highly conserved
residues that interact with DNA include N675, N678, K635, R631,
E611, T609, R835, D827, 5562 and N579 (Beese et al, Science 260:
352-355 (1993)).
[0207] Arg682 in the Klenow fragment of E. coli DNA polymerase I
(pol I) is important for the template-dependent nucleotide-binding
function, and appears to maintain high processivity of the DNA
polymerase (Pandey et al., European Journal of Biochemistry,
214:59-65 (1993)).
[0208] In some embodiments, the polymerase is derived from Taq DNA
polymerase, which is an A family DNA polymerase derived from the
thermophilic bacterium Thermus aquaticus. It is best known for its
use in the polymerase chain reaction. Taq polymerase lacks a
proofreading activity, and thus has a relatively low replication
fidelity (Kim et al., Nature 376: 612-616 (2002).
[0209] In some embodiments, the polymerase is derived from the T7
DNA polymerase of bacteriophage T7, which is an A family DNA
polymerase that consists of a 1:1 complex of the viral T7 gene 5
protein (80 k Da) and the E. coli thioredoxin (12 k Da). It lacks a
5'->3' exonuclease domain, but the 3'->5' exonuclease
activity is approximately 1000-fold greater than that of E coli
Klenow fragment. The exonuclease activity appears to be responsible
for the high fidelity of this enzyme and prevents strand
displacement synthesis. This polymerase typically exhibits high
levels of processivity.
[0210] In some embodiments, the polymerase is derived from KOD DNA
polymerase, which is a B family DNA polymerase derived from
Thermococcus kodakaraensis. KOD polymerase is a thermostable DNA
polymerase with high fidelity and processivity.
[0211] In some embodiments, the polymerase is derived from the
Therminator.TM. DNA polymerase, which is also a B family DNA
polymerase. Therminator.TM. is an A485L point mutation of the DNA
polymerase from Thermococcus species 9oN-7 (Ichida et al., Nucleic
Acids Res. 33: 5214-5222 (2005)). Therminator.TM. polymerase has an
enhanced ability to incorporate modified substrates such as
dideoxynucleotides, ribonucleotides, and acyclonucleotides.
[0212] In some embodiments, the polymerase is derived from a Phi29
polymerase or a Phi29-type polymerase, for example a polymerase
derived from the bacteriophage B103. The Phi29 and B103 DNA
polymerases are B family polymerases from related bacteriophages.
In addition to the A, B and C motifs, the Phi29 family of DNA
polymerases contain an additional conserved motif, KXY in region Y
(Blanco et al., J. Biol. Chem. 268: 16763-16770 (1993). Mutations
to Phi29 and B103 polymerases that affect polymerase activity and
nucleotide binding affinity are described in U.S. Patent
Publication No. 20110014612 and its priority documents U.S.
Provisional Application Nos. 61/307,356; 61/299,917; 61/299,919;
61/293,616; 61/293,618; 61/289,388; 61/263,974; 61/245,457;
61/242,771; 61/184,770; and 61/164,324, herein incorporated by
reference in their entireties.
[0213] In some embodiments, the polymerase is derived from the
reverse transcriptase from human immunodeficiency virus type 1
(HIV-1), which is a heterodimer consisting of one 66-kDa and one
51-kDa subunit. The p66 subunit contains both a polymerase and an
RNase H domain; proteolytic cleavage of p66 removes the RNase H
domain to yield the p51 subunit (Wang et al., PNAS 91:7242-7246
(1994)). The structure of the HIV-1 reverse transcriptase show
multiple interactions between the 2'-OH groups of the RNA template
and the reverse transcriptase. Residues Ser280 and Arg284 of helix
I in the p66 thumb are involved in the RNA-RT interactions, as well
as residues Glu89 and Gln91 of the template grip in the p66 palm.
The p51 subunit also plays a role in the interactions between the
RNA-DNA duplex and the RT, with residues Lys395, Glu396, Lys22 and
Lys390 of the p51 subunit also interacting with the DNA:RNA duplex
(Kohlstaedt et al, Science 256: 1783-1790 (1992) and Safarianos et
al, The EMBO Journal 20:1449-1461 (2001)).
[0214] In some embodiments, the polymerase is derived from the Bst
DNA polymerase of Bacillus stearothermophilus, or any biologically
active fragment thereof. The Bst polymerase can be a family A DNA
polymerase. The large fragment of the naturally occurring Bst DNA
polymerase is equivalent to the Klenow fragment of E. coli Pol I,
retaining the polymerase and proofreading exonuclease activities
while lacking the 5' to 3' exonuclease activity. In some
embodiments, the polymerase derived from Bst DNA polymerase can
lack 3' to 5' exonuclease activity. As used herein, the term "Bst
DNA polymerase" may refer to a full length protein or to a Bst
large fragment.
[0215] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consist
of, or comprise, an isolated variant of a Bst DNA polymerase
having, or comprising, the amino acid sequence of SEQ ID NO: 1,
which is the amino acid sequence of the large fragment (C-terminal
portion) of the Bst DNA polymerase:
TABLE-US-00008 (SEQ ID NO: 1) MAKMAFTLAD RVTEEMLADK AALVVEVVEE
NYHDAPIVGI AVVNEHGRFF LRPETALADP 60 QFVAWLGDET KKKSMFDSKR
AAVALKWKGI ELCGVSFDLL LAAYLLDPAQ GVDDVAAAAK 120 MKQYEAVRPD
EAVYGKGAKR AVPDEPVLAE HLVRKAAAIW ELERPFLDEL RRNEQDRLLV 180
ELEQPLSSIL AEMEFAGVKV DTKRLEQMGK ELAEQLGTVE QRIYELAGQE FNINSPKQLG
240 VILFEKLQLP VLKKTKTGYS TSADVLEKLA PYHEIVENIL HYRQLGKLQS
TYIEGLLKVV 300 RPDTKKVHTI FNQALTQTGR LSSTEPNLQN IPIRLEEGRK
IRQAFVPSES DWLIFAADYS 360 QIELRVLAHI AEDDNLMEAF RRDLDIHTKT
AMDIFQVSED EVTPNMRRQA KAVNFGIVYG 420 ISDYGLAQNL NISRKEAAEF
IERYFESFPG VKRYMENIVQ EAKQKGYVTT LLHRRRYLPD 480 ITSRNFNVRS
FAERMAMNTP IQGSAADIIK KAMIDLNARL KEERLQAHLL LQVHDELILE 540
APKEEMERLC RLVPEVMEQA VTLRVPLKVD YHYGSTWYDA K
[0216] SEQ ID NO: 1 corresponds to the large fragment of Bst DNA
polymerase and includes the DNA polymerase motifs A, B, and C (see,
e.g., Delarue, supra) at residues 358-363, 411-420 and 533-536,
respectively, as shown in SEQ ID No: 1. The motifs are underlined,
and the invariant residues within each motif are indicated in bold.
In some embodiments, to retain the polymerase activity of a Bst
polymerase, any substitutions, deletions or chemical modifications
can be made to amino acid residues that are not highly conserved
within motifs A, B or C, such as the invariant aspartic acid
residues D358 and D535 required for polymerase activity. In some
embodiments, the modified polymerase includes a mutant or variant
form of a Bst DNA polymerase that retains a detectable level of
polymerase activity.
[0217] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a polymerase having or
comprising an amino acid sequence that is at least 80% identical to
the amino acid sequence of SEQ ID NO: 1. In some embodiments, the
reference polymerase or the modified polymerase is an isolated
variant of a Bst DNA polymerase comprising the amino acid sequence
of SEQ ID NO: 1, wherein the variant comprises an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
SEQ ID NO: 1.
[0218] In some embodiments, the reference polymerase is a Bst DNA
polymerase having, or comprising, the amino acid sequence of SEQ ID
NO: 1, and the modified polymerase includes one or more amino acid
modifications (e.g., amino acid substitutions, deletions, additions
or chemical modifications) relative to the reference polymerase. In
some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases include
a deletion or substitution of the methionine residue at position 1,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1.
[0219] In some embodiments, the reference polymerase and/or the
modified polymerase can include the amino acid sequence of any
biologically active fragment of a polymerase having or comprising
the amino acid sequence of SEQ ID NO: 1. In some embodiments, the
reference polymerase and/or the modified polymerase can include the
amino acid sequence of any biologically active fragment of a
polymerase having or comprising an amino acid sequence that is at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
at least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to the amino acid sequence of SEQ ID NO: 1.
[0220] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a Bst DNA polymerase having
or comprising the amino acid sequence of SEQ ID NO: 2:
TABLE-US-00009 (SEQ ID NO: 2) 10 20 30 40 50 60 MAKMAFTLAD
RVTEEMLADK AALVVEVVEE NYHDAPIVGI AVVNERGRFF LRPETALADP 70 80 90 100
110 120 QFVAWLGDET KKKSMFDSKR AAVALKWKGI ELCGVSFDLL LAAYLLDPAQ
GVDDVAAAAK 130 140 150 160 170 180 MKQYEAVRPD EAVYGKGAKR AVPDEPVLAE
HLVRKAAAIW ELERPFLDEL RRNEQDRLLV 190 200 210 220 230 240 ELEQPLSSIL
AEMEFAGVKV DTKRLEQMGK ELAEQLGTVE QRIYELAGQE FNINSPKQLG 250 260 270
280 290 300 VILFEKLQLP VLKKTKTGYS TSADVLEKLA PYHEIVENIL HYRQLGKLQS
TYIEGLLKVV 310 320 330 340 350 360 RPDTKKVHTI FNQALTQTGR LSSTEPNLQN
IPIRLEEGRK IRQAFVPSES DWLIFAADYS 370 380 390 400 410 420 QIELRVLAHI
AEDDNLMEAF RRDLDIHTKT AMDIFQVSED EVTPNMRRQA KAVNFGIVYG 430 440 450
460 470 480 ISDYGLAQNL NISRKEAAEF IERYFQSFPG VKRYMENIVQ EAKQKGYVTT
LLHRRRYLPD 490 500 510 520 530 540 ITSRNFNVRS FAERMAMNTP IQGSAADIIK
KAMIDLNARL KEERLQAHLL LQVHDELILE 550 560 570 580 APKEEMERLC
RLVPEVMEQA VTLRVPLKVD YRYGSTWYDA K
[0221] SEQ ID NO: 2 includes three amino acid substitutions
relative to SEQ ID NO: 1, namely: His46Arg (H46R), Glu446Gln
(E446Q), and His572Arg (H572R), wherein the numbering is relative
to the amino acid sequence of SEQ ID NO: 1.
[0222] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a polymerase having or
comprising an amino acid sequence that is at least 90% identical to
the amino acid sequence of SEQ ID NO: 2. In some embodiments, the
polymerase is a variant of a Bst DNA polymerase comprising the
amino acid sequence of SEQ ID NO: 2, wherein the variant comprises
an amino acid sequence that is at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to SEQ ID NO: 2.
[0223] In some embodiments, the reference polymerase is a Bst DNA
polymerase having, or comprising, the amino acid sequence of SEQ ID
NO: 2, and the modified polymerase includes one or more amino acid
modifications (e.g., amino acid substitutions, deletions, additions
or chemical modifications) relative to the reference polymerase. In
some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases include
a deletion or substitution of the methionine residue at position 1,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 2.
[0224] In some embodiments, the reference polymerase and/or the
modified polymerase can include the amino acid sequence of any
biologically active fragment of a polymerase having the amino acid
sequence of SEQ ID NO: 2 and further including any one or more
amino acid mutations selected from the group consisting of: D264S,
D423K, and D480R.
[0225] In some embodiments, the reference polymerase and/or the
modified polymerase can include the amino acid sequence of any
biologically active fragment of a polymerase having or comprising
the amino acid sequence of SEQ ID NO: 2. In some embodiments, the
reference polymerase and/or the modified polymerase can include the
amino acid sequence of any biologically active fragment of a
polymerase having or comprising an amino acid sequence that is at
least 90% identical to the amino acid sequence of SEQ ID NO: 2.
[0226] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a Bst DNA polymerase having
or comprising the amino acid sequence of SEQ ID NO: 3:
TABLE-US-00010 (SEQ ID NO: 3)
MAKMAFTLADRVTEEMLADKAALVVEVVEENYHDAPIVGIAVVNERGRFFLRPETALADPQFVAWLGDETK
KKSMFDSKRAAVALKWKGIELCGVSFDLLLAAYLLDPAQGVDDVAAAAKMKQYEAVRPDEAVYGKGAKRAV
PDEPVLAEHLVRKAAAIWELERPFLDELRRNEQDRLLVELEQPLSSILAEMEFAGVKVDTKRLEQMGKELA
EQLGTVEQRIYELAGQEFNINSPKQLGVILFEKLQLPVLKKTKTGYSTSADVLEKLAPYHEIVENILHYRQ
LGKLQSTYIEGLLKVVRPDTKKVHTIFNQALTQTGRLSSTEPNLQNIPIRLEEGRKIRQAFVPSESDWLIF
AADYSQIELRVLAHIAEDDNLMEAFRRDLDIHTKTAMDIFQVSEDEVTPNMRRQAKAVNFGIVYGISDYGL
AQNLNISRKEAAEFIERYFQSFPGVKRYMENIVQEAKQKGYVTTLLRRRRYLPDITSRNFNVRSFAERMAM
NTPIQGSAADIIKKAMIDLNARLKEERLQAALLLQVHDELILEAPKEEMERLCRLVPEVMEQAVTLRVPLK
VDYRYGSTWYDAK
[0227] SEQ ID NO: 3 includes two further amino acid substitutions
as compared to SEQ ID NO: 2, namely: His473Arg (H473R) and
His528Ala (H528A), wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 2. Thus SEQ ID NO: 3 contains a total
of five amino acid substitutions as compared to the reference
wild-type sequence of SEQ ID NO:1. The substituted amino acids as
compared to SEQ ID NO: 1 are underlined and in bold.
[0228] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a polymerase having or
comprising an amino acid sequence that is at least 90% identical to
the amino acid sequence of SEQ ID NO: 3. In some embodiments, the
polymerase is a variant of a Bst DNA polymerase comprising the
amino acid sequence of SEQ ID NO: 3, wherein the variant comprises
an amino acid sequence that is at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to SEQ ID NO: 3.
[0229] In some embodiments, the reference polymerase is a Bst DNA
polymerase having, or comprising, the amino acid sequence of SEQ ID
NO: 3, and the modified polymerase includes one or more amino acid
modifications (e.g., amino acid substitutions, deletions, additions
or chemical modifications) relative to the reference polymerase. In
some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases include
a deletion or substitution of the methionine residue at position 1,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 3.
[0230] In some embodiments, the reference polymerase and/or the
modified polymerase can include the amino acid sequence of any
biologically active fragment of a polymerase having or comprising
the amino acid sequence of SEQ ID NO: 3. In some embodiments, the
reference polymerase and/or the modified polymerase can include the
amino acid sequence of any biologically active fragment of a
polymerase having or comprising an amino acid sequence that is at
least 90% identical to the amino acid sequence of SEQ ID NO: 3.
[0231] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a Bst DNA polymerase having
or comprising the amino acid sequence of SEQ ID NO: 4:
TABLE-US-00011 (SEQ ID NO: 4)
MAKMAFTLADRVTEEMLADKAALVVEVVEENYHDAPIVGIAVVNERGRFFLRPETALADPQFVAWLGDETK
KKSMFDSKRAAVALKWKGIELCGVSFDLLLAAYLLDPAQGVDDVAAAAKMKQYEAVRPDEAVYGKGAKRAV
PDEPVLAEHLVRKAAAIWELERPFLDELRRNEQDRLLVELEQPLSSILAEMEFAGVKVDTKRLEQMGKELA
EQLGTVEQRIYELAGQEFNINSPKQLGVILFEKLQLPVLKKTKTGYSTSADVLEKLAPYREIVENILAYRQ
LGKLQSTYIEGLLKVVRPDTKKVHTIFNQALTQTGRLSSTEPNLQNIPIRLEEGRKIRQAFVPSESDWLIF
AADYSQIELRVLAHIAEDDNLMEAFRRDLDIHTKTAMDIFQVSEDEVTPNMRRQAKAVNFGIVYGISDYGL
AQNLNISRKEAAEFIERYFQSFPGVKRYMENIVQEAKQKGYVTTLLRRRRFLPDITSRNFNVRSFAERMAM
NTPIQGSAADIIKKAMIDLNARLKEERLQAALLLQVHDELILEAPKEEMERLCRLVPEVMEQAVTLRVPLK
VDYRYGSTWYDAK
[0232] SEQ ID NO: 4 contains three additional amino acid
substitutions as compared to SEQ ID NO: 3, namely: H281A, H273R and
Y477F, wherein the numbering is relative to the amino acid sequence
of SEQ ID NO: 3. Thus SEQ ID NO: 4 contains a total of eight amino
acid substitutions as compared to the reference wild-type sequence
of SEQ ID NO: 1. The substituted amino acids as compared to SEQ ID
NO: 1 are underlined and in bold.
[0233] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a polymerase having or
comprising an amino acid sequence that is at least 90% identical to
the amino acid sequence of SEQ ID NO: 4. In some embodiments, the
polymerase is a variant of a Bst DNA polymerase comprising the
amino acid sequence of SEQ ID NO: 4, wherein the variant comprises
an amino acid sequence that is at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to SEQ ID NO: 4.
[0234] In some embodiments, the reference polymerase is a Bst DNA
polymerase having, or comprising, the amino acid sequence of SEQ ID
NO: 4, and the modified polymerase includes one or more amino acid
modifications (e.g., amino acid substitutions, deletions, additions
or chemical modifications) relative to the reference polymerase. In
some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases include
a deletion or substitution of the methionine residue at position 1,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 4.
[0235] In some embodiments, the reference polymerase and/or the
modified polymerase can include the amino acid sequence of any
biologically active fragment of a polymerase having or comprising
the amino acid sequence of SEQ ID NO: 4. In some embodiments, the
reference polymerase and/or the modified polymerase can include the
amino acid sequence of any biologically active fragment of a
polymerase having or comprising an amino acid sequence that is at
least 90% identical to the amino acid sequence of SEQ ID NO: 4.
[0236] In some embodiments, the disclosure relates generally to a
modified polymerase that includes an isolated variant of a Bst DNA
polymerase comprising an amino acid sequence selected from the
group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and
SEQ ID NO: 4, and further including one or more amino acid
modifications. Optionally, the modified polymerase includes one,
two, three, four or more amino acid substitutions relative to the
amino acid sequence of SEQ ID NO: 1, 2, 3 or 4.
[0237] In some embodiments, the reference polymerase is a Bst DNA
polymerase having, or comprising the amino acid sequence of SEQ ID
NO: 1, 2, 3 or 4, and the modified polymerase is a mutant or
variant of the reference polymerase and further includes one or
more amino acid mutations relative to the reference polymerase. In
some embodiments, the modified polymerase comprises an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of the reference polymerase. The one or
more amino acid substitutions present in the modified polymerase
relative to the reference polymerase can include at least one
conservative amino acid substitution.
[0238] In some embodiments, the reference polymerase can have or
comprise the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase can have or comprise the amino acid
sequence of the reference polymerase, further including one or more
amino acid mutations as compared to the reference polymerase. In
some embodiments, the modified polymerase comprises an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of the reference polymerase. In some
embodiments, the modified polymerase can further include any one or
more amino acid mutations selected from the group consisting of:
H46R, C93R, Q238C, H273R, H281A, E446Q, H473R, Y477F, H528A, C550Q
and H572R, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 1. In some embodiments, the modified
polymerase has a reduced buffering capacity relative to the
reference polymerase. Without being bound to any particular theory
of operation, it can be observed that in some embodiments one or
more of the aforementioned mutations can alter, e.g., increase or
decrease the buffering capacity of the modified polymerase relative
to the unmodified polymerase. Such mutations can therefore be
referred to as "buffering" mutations. In some embodiments, such
increase or decrease in buffering capacity can increase the
observed signal in an ion-based sequencing reaction. Further
information about such mutations and their possible effect on the
buffering capacity of the polymerase can be found, for example, in
U.S. Provisional Appl. No. 60/308,863 filed Feb. 26, 2010; U.S.
patent application Ser. Nos. 13/035,081 filed Feb. 25, 2011;
13/035,177 filed Feb. 25, 2011; 13/036,526 filed Feb. 28, 2011; and
13/036,623 filed Feb. 25, 2011; as well as in International PCT
Appl. Nos. PCT/US2011/026219 filed Feb. 25, 2011; PCT/US2011/026228
filed Feb. 25, 2011; PCT/US2011/026450 filed Feb. 28, 2011; and
PCT/US2011/026468 filed Feb. 28, 2011; all of which aforementioned
applications are hereby incorporated by reference in their
entireties. In some embodiments, the reference polymerase, the
modified polymerase, or both the reference and modified polymerases
can further include a deletion of the methionine residue at
position 1, or a substitution of the methionine residue at position
1 with any other amino acid residue, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 1. Optionally,
the reference polymerase, the modified polymerase, or both the
reference and modified polymerases can further include one or more
amino acid mutations that decrease or eliminate exonuclease
activity. Some exemplary mutations that can reduce or eliminate the
exonuclease activity of the polymerase are described further
herein.
[0239] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase has or comprises the amino acid sequence of
the reference polymerase, further including one or more amino acid
mutations as compared to the reference polymerase. In some
embodiments, the modified polymerase comprises an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of the reference polymerase. In some
embodiments, the modified polymerase further includes amino acid
substitutions at any one or more positions selected from the group
consisting of: 46, 93, 238, 273, 281, 446, 473, 477, 528, 550 and
572, wherein the numbering is relative of the amino acid sequence
of SEQ ID NO: 1. In some embodiments one or more of the
aforementioned substitutions can alter, e.g., increase or decrease
the buffering capacity of the modified polymerase relative to the
corresponding unmodified polymerase, or to a reference polymerase
having the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4. Such
mutations can therefore be referred to as "buffering" mutations. In
some embodiments, such increase or decrease in buffering capacity
can increase the observed signal in an ion-based sequencing
reaction. In some embodiments, the amino acid substitutions include
the substitution of the existing amino acid residue at the
indicated position with any other amino acid residue (including
both naturally occurring and non-natural amino acid residues). In
some embodiments, the amino acid substitution is a conservative
substitution; alternatively, the amino acid substitution can be a
non-conservative substitution. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: average read length, minimum read length, enhanced
performed in higher ionic strength solution, improved processivity,
performance in polymerase chain reaction, performance in emulsion
polymerase chain reaction, buffering capacity, off-rate,
dissociation time constant, AQ20, 100Q17 value and 200Q17 value,
relative to the reference polymerase. Optionally, the change is
observed by comparing the performance of the reference and modified
polymerases in an ion-based sequencing reaction. Optionally, the
reference polymerase, the modified polymerase, or both the
reference and modified polymerases can further include one or more
amino acid mutations that decrease or eliminate exonuclease
activity.
[0240] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase has or comprises the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes any one or more amino acid mutations
selected from the group consisting of: N31R, N31K, D77K, D77H,
D113N, D114R, D130A, D130H, D144M, D144K, L212A, E220K, N234R,
N234K, V241K, V251K, D264Q, D264S, D264K, Y272R, H273R, L280R,
H281A, H281M, E294S, E294F, E294G, E294K, V299K, V299H, V299F,
D303R, I331Q, E325R, L335T, E336P, I354W, I354F, I370A, Q409R,
G416K, V418M, V418I, G420K, D423S, D423K, D423N, D423R, D423T,
D423G, D423I, D423K, G425R, Q428W, N429R, N429K, E446Q, F448K,
N457T, A462T, H473R, Y477F, D480R, D480F, D480H, D480A, D480S,
D480N, D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R,
E493Q, M495Q, H528A, H528R, H528K, V533I, H572R, W577Y and D579F,
wherein the numbering is relative of the amino acid sequence of SEQ
ID NO: 1. Without being bound to any particular theory of
operation, it can be observed that in some embodiments a modified
polymerase including one or more of these mutations exhibits an
altered (e.g., increased or decreased) binding affinity for a
nucleic acid template relative to an unmodified polymerase, or an
altered (e.g., increased or decreased) rate of dissociation from
the nucleic acid template ("off-rate") relative to the unmodified
polymerase, or relative to a reference polymerase having the amino
acid sequence of SEQ ID NO: 1, 2, 3 or 4. In some embodiments, the
modified polymerase exhibits an altered, e.g., increased or
decreased average read length, or an altered minimum read length,
or an altered average error-free read length, or altered (e.g.,
increased or decreased) observed AQ20, 100Q17 or 200Q17 values
relative to the reference polymerase. In some embodiments, the
modified polymerase exhibits a change in any one or more of the
following kinetic parameters: average read length, minimum read
length, enhanced performed in higher ionic strength solution,
improved processivity, performance in polymerase chain reaction,
performance in emulsion polymerase chain reaction, dissociation
time constant, off-rate, AQ20, 100Q17 value, and 200Q17 value,
relative to the reference polymerase. Optionally, the change is
observed by comparing the performance of the reference and modified
polymerases in an ion-based sequencing reaction. The Examples
provided herein illustrate the change in off-rate and in
dissociation time constant observed in various exemplary modified
polymerase having the amino acid sequence of SEQ ID NO: 2 and
further including various exemplary amino acid substitutions from
the list above, relative to the off-rate and dissociation time
constant of a reference polymerase having the amino acid sequence
of SEQ ID NO: 2. In some embodiments, the reference polymerase, the
modified polymerase, or both the reference and modified polymerases
can further include a deletion of the methionine residue at
position 1, or a substitution of the methionine residue at position
1 with any other amino acid residue, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 1. Optionally,
the reference polymerase, the modified polymerase, or both the
reference and modified polymerases can further include one or more
amino acid mutations that decrease or eliminate exonuclease
activity.
[0241] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase has or comprises the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes amino acid substitutions at any one or
more positions selected from the group consisting of: 31, 77, 113,
114, 130, 144, 212, 220, 234, 241, 251, 264, 272, 280, 294, 299,
303, 331, 325, 335, 336, 354, 370, 409, 416, 418, 420, 423, 425,
428, 429, 448, 457, 462, 480, 485, 487, 488, 493, 495, 533, 577 and
579, wherein the numbering is relative of the amino acid sequence
of SEQ ID NO: 1. In some embodiments a modified polymerase
including one or more of these mutations exhibits an altered (e.g.,
increased or decreased) binding affinity for a nucleic acid
template relative to the corresponding unmodified polymerase or to
a reference polymerase including the amino acid sequence of SEQ ID
NO: 1, 2, 3 or 4. In some embodiments, the modified polymerase has
an altered (e.g., increased or decreased) rate of dissociation from
the nucleic acid template ("off-rate") relative to the unmodified
polymerase or to a reference polymerase including the amino acid
sequence of SEQ ID NO: 1, 2, 3 or 4. In some embodiments, the
modified polymerase exhibits an altered, e.g., increased or
decreased read length, or an altered average error-free read
length, or altered (e.g., increased or decreased) observed 100Q17
or 200Q17 values relative to the reference polymerase. In some
embodiments, the modified polymerase exhibits a change in any one
or more of the following kinetic parameters: average read length,
minimum read length, enhanced performed in higher ionic strength
solution, improved processivity, performance in polymerase chain
reaction, performance in emulsion polymerase chain reaction,
dissociation time constant, off-rate, AQ20, 100Q17 value, and
200Q17 value, relative to the reference polymerase. Optionally, the
change is observed by comparing the performance of the reference
and modified polymerases in an ion-based sequencing reaction. In
some embodiments, the amino acid substitutions include the
substitution of the existing amino acid residue at the indicated
position with any other amino acid residue (including both
naturally occurring and non-natural amino acid residues). In some
embodiments, the amino acid substitution is a conservative
substitution; alternatively, the amino acid substitution can be a
non-conservative substitution. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: average read length, minimum read length, enhanced
performed in higher ionic strength solution, improved processivity,
performance in polymerase chain reaction, performance in emulsion
polymerase chain reaction, buffering capacity, off-rate, 100Q17
value, AQ20 and 200Q17 value, relative to the reference polymerase.
Optionally, the change is observed by comparing the performance of
the reference and modified polymerases in an ion-based sequencing
reaction. Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate exonuclease activity.
[0242] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase has or comprises the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes amino acid substitutions at any one or
more positions selected from the group consisting of: 31, 46, 77,
93, 113, 114, 130, 144, 212, 220, 234, 238, 241, 251, 264, 272,
273, 280, 281, 294, 299, 303, 331, 325, 335, 336, 354, 370, 409,
416, 418, 420, 423, 425, 428, 429, 446, 448, 457, 462, 473, 477,
480, 485, 487, 488, 493, 495, 528, 533, 550, 572, 577 and 579,
wherein the numbering is relative of the amino acid sequence of SEQ
ID NO: 1. In some embodiments, the amino acid substitutions include
the substitution of the existing amino acid residue at the
indicated position with any other amino acid residue (including
both naturally occurring and non-natural amino acid residues). In
some embodiments, the amino acid substitution is a conservative
substitution; alternatively, the amino acid substitution can be a
non-conservative substitution. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: binding affinity for a nucleic acid template,
buffering capacity, average read length, minimum read length,
enhanced performed in higher ionic strength solution, improved
processivity, performance in polymerase chain reaction, performance
in emulsion polymerase chain reaction, AQ20, dissociation time
constant, off-rate, 100Q17 value and 200Q17 value, relative to the
reference polymerase. The reference polymerase can have the amino
acid sequence of SEQ ID NO: 1, 2, 3 or 4. Optionally, the change is
observed by comparing the performance of the reference and modified
polymerases in an ion-based sequencing reaction. Optionally, the
reference polymerase, the modified polymerase, or both the
reference and modified polymerases can further include one or more
amino acid mutations that decrease or eliminate exonuclease
activity.
[0243] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase has or comprises the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes any one or more amino acid mutations
selected from the group consisting of: N31R, N31K, H46A, H46R,
D77K, D77H, C93R, D113N, D114R, D130A, D130H, D144M, D144K, L212A,
E220K, N234R, N234K, Q238C, V241K, V251K, D264Q, D264S, D264K,
Y272R, H273A, H273R, L280R, H281A, H281R, H281M, E294S, E294F,
E294G, E294K, V299K, V299H, V299F, D303R, I331Q, E325R, L335T,
E336P, I354W, I354F, I370A, Q409R, G416K, V418M, V418I, G420K,
D423S, D423K, D423N, D423R, D423T, D423G, D423I, D423K, G425R,
Q428W, N429R, N429K, E446Q, F448K, N457T, A462T, H473A, H473R,
Y477F, D480R, D480F, D480H, D480A, D480S, D480N, D480Q, N485W,
N485Y, N487H, N487W, N487F, N487I, V488R, E493Q, M495Q, H528A,
H528R, H528K, V533I, C550Q, H572A, H572R, W577Y and D579F, wherein
the numbering is relative of the amino acid sequence of SEQ ID NO:
1. Without being bound to any particular theory of operation, it
can be observed that in some embodiments a modified polymerase
including one or more of these mutations exhibits an altered (e.g.,
increased or decreased) binding affinity for a nucleic acid
template relative to an unmodified polymerase, or an altered (e.g.,
increased or decreased) rate of dissociation from the nucleic acid
template ("off-rate") relative to the unmodified polymerase. In
some embodiments, the modified polymerase exhibits an altered
(e.g., increased or decreased) buffering capacity relative to the
unmodified polymerase. In some embodiments, the modified polymerase
exhibits an altered, e.g., increased or decreased read length, or
an altered average error-free read length, or altered dissociation
time constant, or altered (e.g., increased or decreased) observed
100Q17 or 200Q17 values relative to the reference polymerase. In
some embodiments, the modified polymerase exhibits an altered,
e.g., increased or decreased read length, or an altered average
error-free read length, or altered (e.g., increased or decreased)
observed 100Q17 or 200Q17 values relative to the reference
polymerase. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: buffering capacity, off-rate, average read length,
minimum read length, enhanced performed in higher ionic strength
solution, improved processivity, performance in polymerase chain
reaction, performance in emulsion polymerase chain reaction, AQ20,
100Q17 value and 200Q17 value, relative to the reference
polymerase. Optionally, the change is observed by comparing the
performance of the reference and modified polymerases in an
ion-based sequencing reaction. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1. Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate exonuclease activity.
[0244] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase has or comprises the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes amino acid substitutions at any one or
more positions selected from the group consisting of: 46, 93, 238,
273, 281, 446, 473, 477, 528, 550 and 572, as well as one or more
amino acid substitutions selected from the group consisting of 31,
77, 113, 114, 130, 144, 212, 220, 234, 241, 251, 264, 272, 280,
294, 299, 303, 331, 325, 335, 336, 354, 370, 409, 416, 418, 420,
423, 425, 428, 429, 448, 457, 462, 480, 485, 487, 488, 493, 495,
533, 577 and 579, wherein the numbering is relative of the amino
acid sequence of SEQ ID NO: 1. In some embodiments, the amino acid
substitutions include the substitution of the existing amino acid
residue at the indicated position with any other amino acid residue
(including both naturally occurring and non-natural amino acid
residues). In some embodiments, the amino acid substitution is a
conservative substitution; alternatively, the amino acid
substitution can be a non-conservative substitution. In some
embodiments, the reference polymerase, the modified polymerase, or
both the reference and modified polymerases can further include a
deletion of the methionine residue at position 1, or a substitution
of the methionine residue at position 1 with any other amino acid
residue, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 1. In some embodiments, the modified
polymerase exhibits a change in any one or more parameters selected
from the group consisting of: binding affinity for a nucleic acid
template, buffering capacity, average read length, minimum read
length, enhanced performed in higher ionic strength solution,
improved processivity, performance in polymerase chain reaction,
performance in emulsion polymerase chain reaction, AQ20,
dissociation time constant, off-rate, 100Q17 value and 200Q17
value, relative to the reference polymerase. Optionally, the change
is observed by comparing the performance of the reference and
modified polymerases in an ion-based sequencing reaction.
Optionally, the reference polymerase, the modified polymerase, or
both the reference and modified polymerases can further include one
or more amino acid mutations that decrease or eliminate exonuclease
activity.
[0245] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4, and
the modified polymerase has or comprises the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes one or more amino acid substitutions
selected from the group consisting of: H46A, H46R, C93R, Q238C,
H273A, H273R, H281A, H281R, H281M, E446Q, H473A, H473R, Y477F,
H528A, H528R, H528K, C550Q, H572A and H572R, as well as one or more
amino acid substitutions selected from the group consisting of
N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H, D144M, D144K,
L212A, E220K, N234R, N234K, V241K, V251K, D264Q, D264S, D264K,
Y272R, L280R, E294S, E294F, E294G, E294K, V299K, V299H, V299F,
D303R, E325R, I331Q, L335T, E336P, I354W, I354F, I370A, Q409R,
G416K, V418M, V418I, G420K, D423S, D423K, D423N, D423R, D423T,
D423G, D423I, D423K, G425R, Q428W, N429R, N429K, F448K, N457T,
A462T, D480R, D480F, D480H, D480A, D480S, D480N, D480Q, N485W,
N485Y, N487H, N487W, N487F, N487I, V488R, E493Q, M495Q, V533I,
W577Y and D579F, wherein the numbering is relative of the amino
acid sequence of SEQ ID NO: 1. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: buffering capacity, average read length, minimum
read length, enhanced performed in higher ionic strength solution,
improved processivity, performance in polymerase chain reaction,
performance in emulsion polymerase chain reaction, AQ20,
dissociation time constant, off-rate, 100Q17 value and 200Q17
value, relative to the reference polymerase. Optionally, the change
is observed by comparing the performance of the reference and
modified polymerases in an ion-based sequencing reaction.
Optionally, the reference polymerase, the modified polymerase, or
both the reference and modified polymerases can further include one
or more amino acid mutations that decrease or eliminate exonuclease
activity.
[0246] In some embodiments, the disclosure relates generally to a
modified polymerase having or comprising the amino acid sequence of
SEQ ID NO: 1, 2, 3 or 4, or the amino acid sequence of any
biologically active fragment of a polymerase having or comprising
the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4 and further
including at least one amino acid mutation relative to the amino
acid sequence of a reference polymerase having the amino acid
sequence of SEQ ID NO: 1, 2, 3 or 4. In some embodiments, the
modified polymerase comprises an amino acid sequence that is at
least 80%, at least 85%, at least 90%, at least 91%, at least 92%,
at least 93%, at least 94%, at least 95%, at least 96%, at least
97%, at least 98%, or at least 99% identical to the amino acid
sequence of the reference polymerase.
[0247] In some embodiments, the modified polymerase according to
the disclosure can include at least amino acid mutation, D480R,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 2. In some embodiments, the modified polymerase according to
the disclosure can include amino acid mutations D264K and E493Q,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 2. In some embodiments, the modified polymerase according to
the disclosure can include amino acid mutations E220K, N234R and
D423K, wherein the numbering is relative to the amino acid sequence
of SEQ ID NO: 2. In some embodiments, the modified polymerase
according to the disclosure can include amino acid mutations E220K,
N234R, D423K, and H528A, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 2. In some embodiments, the
modified polymerase according to the disclosure can include amino
acid mutations E220K, N234R, D423K, H473R, and H528A, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 2
(see SEQ ID NO: 20).
TABLE-US-00012 (SEQ ID NO: 20) 10 20 30 40 50 60 MAKMAFTLAD
RVTEEMLADK AALVVEVVEE NYHDAPIVGI AVVNERGRFF LRPETALADP 70 80 90 100
110 120 QFVAWLGDET KKKSMFDSKR AAVALKWKGI ELCGVSFDLL LAAYLLDPAQ
GVDDVAAAAK 130 140 150 160 170 180 MKQYEAVRPD EAVYGKGAKR AVPDEPVLAE
HLVRKAAAIW ELERPFLDEL RRNEQDRLLV 190 200 210 220 230 240 ELEQPLSSIL
AEMEFAGVKV DTKRLEQMGK ELAEQLGTVK QRIYELAGQE FNIRSPKQLG 250 260 270
280 290 300 VILFEKLQLP VLKKTKTGYS TSADVLEKLA PYHEIVENIL HYRQLGKLQS
TYIEGLLKVV 310 320 330 340 350 360 RPDTKKVHTI FNQALTQTGR LSSTEPNLQN
IPIRLEEGRK IRQAFVPSES DWLIFAADYS 370 380 390 400 410 420 QIELRVLAHI
AEDDNLMEAF RRDLDIHTKT AMDIFQVSED EVTPNMRRQA KAVNFGIVYG 430 440 450
460 470 480 ISKYGLAQNL NISRKEAAEF IERYFQSFPG VKRYMENIVQ EAKQKGYVTT
LLRRRRYLPD 490 500 510 520 530 540 ITSRNFNVRS FAERMAMNTP IQGSAADIIK
KAMIDLNARL KEERLQAALL LQVHDELILE 550 560 570 580 APKEEMERLC
RLVPEVMEQA VTLRVPLKVD YRYGSTWYDA K
[0248] In some embodiments, the modified polymerase according to
the disclosure can include any one or more amino acid mutations
selected from the group consisting of: E220K, N234R, V241K, D264K,
D423K, D480R, N487W, V488R, H473R, H528A and E493Q, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 2.
In some embodiments a modified polymerase including one or more of
these mutations exhibits an altered (e.g., increased or decreased)
binding affinity for a nucleic acid template relative to the
corresponding unmodified polymerase or to a reference polymerase
including the amino acid sequence of SEQ ID NO: 1, 2, 3 or 4. In
some embodiments, the modified polymerase has an altered (e.g.,
increased or decreased) rate of dissociation from the nucleic acid
template ("off-rate") relative to the unmodified polymerase or to a
reference polymerase including the amino acid sequence of SEQ ID
NO: 1, 2, 3 or 4. In some embodiments, the modified polymerase
exhibits an altered, e.g., increased or decreased read length, or
an altered average error-free read length, or altered (e.g.,
increased or decreased) observed 100Q17 or 200Q17 values relative
to the reference polymerase. In some embodiments, the modified
polymerase exhibits a change in any one or more of the following
kinetic parameters: average read length, minimum read length,
enhanced performed in higher ionic strength solution, improved
processivity, performance in polymerase chain reaction, performance
in emulsion polymerase chain reaction, dissociation time constant,
off-rate, AQ20, 100Q17 value, and 200Q17 value, relative to the
reference polymerase. Optionally, the change is observed by
comparing the performance of the reference and modified polymerases
in an ion-based sequencing reaction. In some embodiments, the amino
acid substitutions include the substitution of the existing amino
acid residue at the indicated position with any other amino acid
residue (including both naturally occurring and non-natural amino
acid residues). In some embodiments, the amino acid substitution is
a conservative substitution; alternatively, the amino acid
substitution can be a non-conservative substitution. In some
embodiments, the reference polymerase, the modified polymerase, or
both the reference and modified polymerases can further include a
deletion of the methionine residue at position 1, or a substitution
of the methionine residue at position 1 with any other amino acid
residue. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: buffering capacity, average read length, minimum
read length, enhanced performed in higher ionic strength solution,
improved processivity, performance in polymerase chain reaction,
performance in emulsion polymerase chain reaction, off-rate, AQ20,
100Q17 value and 200Q17 value, relative to the reference
polymerase. Optionally, the change is observed by comparing the
performance of the reference and modified polymerases in an
ion-based sequencing reaction. Optionally, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include one or more amino acid
mutations that decrease or eliminate exonuclease activity.
[0249] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 1, or the amino acid sequence of
any biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 1. The modified polymerase can further
include one or more amino acid mutations relative to the amino acid
sequence of SEQ ID NO: 1.
[0250] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of
any biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 2. The modified polymerase can further
include one or more amino acid mutations relative to the amino acid
sequence of SEQ ID NO: 2.
[0251] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 3, or the amino acid sequence of
any biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 3. The modified polymerase can further
include one or more amino acid mutations relative to the amino acid
sequence of SEQ ID NO: 3.
[0252] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 4, or the amino acid sequence of
any biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 4. The modified polymerase can further
include one or more amino acid mutations relative to the amino acid
sequence of SEQ ID NO: 4.
[0253] In some embodiments, the modified polymerase has polymerase
activity. The polymerase or biologically active fragment can have
primer extension activity in vivo or in vitro.
[0254] In some embodiments, the modified polymerase comprises an
amino acid sequence that is at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to the amino acid sequence of SEQ ID NO: 1, 2, 3, 4
or 25.
[0255] In some embodiments, the one or more mutations in the
modified polymerase can include at least one amino acid
substitution. The at least one amino acid substitution can
optionally occur at any one or more positions selected from the
group consisting of: 46, 273, 281, 446, 473, 477, 528 and 572,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1. In some embodiments, the modified polymerase includes at
least two, three, four, five, or more amino acid substitutions
occurring at positions selected from this group. Without intending
to be bound to any particular theory of action, it can be observed
that in some embodiments, amino acid substitution at such positions
can alter, e.g., increase or decrease the buffering capacity of the
modified polymerase relative to the corresponding unmodified
polymerase, or relative to a reference polymerase having the amino
acid sequence of SEQ ID NO: 1, 2, 3 or 4. Such mutations can
therefore be referred to as "buffering" mutations. In some
embodiments, such increase or decrease in buffering capacity can
increase the observed signal in an ion-based sequencing
reaction.
[0256] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 1, or includes the amino acid
sequence of a biologically active fragment of a polymerase having
the amino acid sequence of SEQ ID NO: 1, or includes an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of SEQ ID NO: 1, and further includes at
least one amino acid substitution selected from the group
consisting of: H46A, H46R, H273A, H273R, H281A, H281R, E446Q,
H473A, H473R, Y477F, H528A, H528R, H572A and H572R, wherein the
numbering is relative of the amino acid sequence of SEQ ID NO: 1.
In some embodiments, the modified polymerase includes any two,
three, four, five or more of these amino acid substitutions.
[0257] In some embodiments, the one or more mutations in the
modified polymerase can include at least one amino acid
substitution. The at least one amino acid substitution can
optionally occur at any one or more positions selected from the
group consisting of: 31, 77, 113, 114, 130, 144, 212, 220, 234,
241, 251, 264, 272, 280, 294, 299, 303, 331, 325, 335, 336, 354,
370, 409, 416, 418, 420, 423, 425, 428, 429, 448, 457, 462, 480,
485, 487, 488, 493, 495, 533, 577 and 579, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 1. In some
embodiments, the modified polymerase includes at least two, three,
four, five, or more amino acid substitutions occurring at positions
selected from this group. Without being bound to any particular
theory of operation, it can be observed that in some embodiments a
modified polymerase including any one of such amino acid
substitutions exhibits an altered (e.g., increased or decreased)
binding affinity for a nucleic acid template relative to an
unmodified polymerase, or an altered (e.g., increased or decreased)
rate of dissociation from the nucleic acid template ("off-rate")
relative to the corresponding unmodified polymerase, or relative to
a reference polymerase. The reference polymerase can include the
amino acid of SEQ ID NO: 1, 2, 3 or 4. In some embodiments, the
modified polymerase exhibits an altered (e.g., increased or
decreased) read length, or an altered (e.g., increased or
decreased) average error-free read length, or altered (e.g.,
increased or decreased) dissociation time constant, or altered
(e.g., increased or decreased) observed 100Q17 or 200Q17 values
relative to the reference polymerase. In some embodiments, the
modified polymerase exhibits a change (e.g., increase or decrease)
in any one or more properties selected from the group consisting
of: DNA binding affinity, off-rate, 100Q17 value and 200Q17 value,
relative to the reference polymerase. Optionally, the change is
observed by comparing the properties of the reference and modified
polymerases in an ion-based sequencing reaction.
[0258] In some embodiments, the one or more mutations in the
modified polymerase can include at least one amino acid
substitution. The at least one amino acid substitution can
optionally occur at any one or more positions selected from the
group consisting of: 31, 46, 77, 113, 114, 130, 144, 212, 220, 234,
241, 251, 264, 272, 273, 280, 281, 294, 299, 303, 331, 325, 335,
336, 354, 370, 409, 416, 418, 420, 423, 425, 428, 429, 446, 448,
457, 462, 473, 477, 480, 485, 487, 488, 493, 495, 528, 533, 572,
577 and 579, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 1. In some embodiments, the modified
polymerase includes at least two, three, four, five, or more amino
acid substitutions occurring at positions selected from this
group.
[0259] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 1, or includes the amino acid
sequence of a biologically active fragment of a polymerase having
the amino acid sequence of SEQ ID NO: 1, or includes the amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of SEQ ID NO: 1, and further includes at
least one amino acid substitution at any one or more positions
selected from the group consisting of: 46, 273, 281, 446, 473, 477,
528 and 572, as well as at least one amino acid substitution at any
one or more positions selected from the group consisting of: 31,
77, 113, 114, 130, 144, 212, 220, 234, 241, 251, 264, 272, 280,
294, 299, 303, 331, 325, 335, 336, 354, 370, 409, 416, 418, 420,
423, 425, 428, 429, 448, 457, 462, 480, 485, 487, 488, 493, 495,
533, 577 and 579, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 1, In some embodiments, the modified
polymerase includes at least two, three, four, five, or more amino
acid substitutions occurring at positions selected from each of
these two groups of amino acid substitutions.
[0260] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 1, or includes the amino acid
sequence of a biologically active fragment of a polymerase having
the amino acid sequence of SEQ ID NO: 1, or includes an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of SEQ ID NO: 1, and further includes at
least one amino acid substitution selected from the group
consisting of: N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H,
D144M, D144K, L212A, E220K, N234R, N234K, V241K, V251K, D264Q,
D264S, D264K, Y272R, L280R, E294S, E294F, E294G, E294K, V299K,
V299H, V299F, D303R, I331Q, E325R, L335T, E336P, I354W, I354F,
I370A, Q409R, G416K, V418M, V418I, G420K, D423S, D423K, D423N,
D423R, D423T, D423G, D423I, D423K, G425R, Q428W, N429R, N429K,
F448K, N457T, A462T, D480R, D480F, D480H, D480A, D480S, D480N,
D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R, E493Q,
M495Q, V533I, W577Y and D579F, wherein the numbering is relative of
the amino acid sequence of SEQ ID NO: 1. In some embodiments, the
modified polymerase includes any two, three, four, five or more of
these amino acid substitutions.
[0261] In some embodiments, the modified polymerase includes at
least one amino acid substitution designed to replace a preexisting
cysteine residue with a different amino acid residue, or to replace
a non-cysteine amino acid residue with a cysteine residue. The at
least one amino acid substitution optionally includes one or more
amino acid substitutions selected from the group consisting of:
C93R, Q238C and C550Q, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 1.
[0262] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 1, or includes the amino acid
sequence of a biologically active fragment of a polymerase having
the amino acid sequence of SEQ ID NO: 1, or includes an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of SEQ ID NO: 1, and further includes at
least one amino acid substitution selected from the group
consisting of: N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H,
D144M, D144K, L212A, E220K, N234R, N234K, V241K, V251K, D264Q,
D264S, D264K, Y272R, L280R, E294S, E294F, E294G, E294K, V299K,
V299H, V299F, D303R, I331Q, E325R, L335T, E336P, I354W, I354F,
I370A, Q409R, G416K, V418M, V418I, G420K, D423S, D423K, D423N,
D423R, D423T, D423G, D423I, D423K, G425R, Q428W, N429R, N429K,
F448K, N457T, A462T, D480R, D480F, D480H, D480A, D480S, D480N,
D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R, E493Q,
M495Q, V533I, W577Y and D579F, wherein the numbering is relative of
the amino acid sequence of SEQ ID NO: 1. Optionally, the modified
polymerase can further include at least one amino acid substitution
selected from the group consisting of: H46A, H46R, H273A, H273R,
H281A, H281R, H281M, E446Q, H473A, H473R, Y477F, H528A, H528R,
H528K, H572A and H572R, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 1. In some embodiments, the
modified polymerase includes any two, three, four, five or more
amino acid substitutions selected from each of these two groups of
amino acid substitutions.
[0263] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 1, or includes the amino acid
sequence of a biologically active fragment of a polymerase having
the amino acid sequence of SEQ ID NO: 1, or includes an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of SEQ ID NO: 1, and further includes at
least one amino acid substitution selected from the group
consisting of: N31R, N31K, H46A, H46R, D77K, D77H, D113N, D114R,
D130A, D130H, D144M, D144K, L212A, E220K, N234R, N234K, V241K,
V251K, D264Q, D264S, D264K, Y272R, H273A, H273R, L280R, H281A,
H281R, E294S, E294F, E294G, E294K, V299K, V299H, V299F, D303R,
I331Q, E325R, L335T, E336P, I354W, I354F, I370A, Q409R, G416K,
V418M, V418I, G420K, D423S, D423K, D423N, D423R, D423T, D423G,
D423I, D423K, G425R, Q428W, N429R, N429K, E446Q, F448K, N457T,
A462T, H473A, H473R, Y477F, D480R, D480F, D480H, D480A, D480S,
D480N, D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R,
E493Q, M495Q, H528A, H528R, V533I, H572R, H578A, W577Y and D579F,
wherein the numbering is relative of the amino acid sequence of SEQ
ID NO: 1. In some embodiments, the modified polymerase includes any
two, three, four, five or more of these amino acid
substitutions.
[0264] In some embodiments, the modified polymerase has an altered
(e.g., increased or decreased) binding affinity for a nucleic acid
template relative to a reference polymerase. In some embodiments,
the modified polymerase has an altered (e.g., increased or
decreased) rate of dissociation from the nucleic acid template
("off-rate") relative to a reference polymerase. The reference
polymerase can optionally have the amino acid sequence of SEQ ID
NO: 1, 2, 3 or 4. In some embodiments, the modified polymerase
exhibits an altered (e.g., increased or decreased) read length, or
an altered (e.g., increased or decreased) average error-free read
length, or an altered (e.g., increased or decreased) observed
100Q17 or 200Q17 value relative to the reference polymerase. In
some embodiments, the modified polymerase exhibits a change (e.g.,
increase or decrease) in any one or more of the following
properties: binding affinity for a nucleic acid template,
dissociation time constant, off-rate, 100Q17 value, and 200Q17
value, relative to the reference polymerase. In some embodiments,
the altered property is increased or decreased by at least 10%,
20%, 30%, 40%, 50%, 75%, 90%, 100%, 200%, 300%, 500%, 750%, 1000%,
3000% or greater, relative to the corresponding unmodified
polymerase, or to the reference polymerase. Optionally, the change
is observed by comparing the properties of the reference and
modified polymerases in an ion-based sequencing reaction.
[0265] In some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include a deletion of the methionine residue at position 1,
or a substitution of the methionine residue at position 1 with any
other amino acid residue, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 16.
[0266] Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate any exonuclease activity of the polymerase.
[0267] In some embodiments, the reference polymerase, the modified
polymerase or both the reference and modified polymerase consists
of or comprises an isolated variant of a Bst DNA polymerase having
or comprising the amino acid sequence of SEQ ID NO: 16:
TABLE-US-00013 (SEQ ID NO: 16) 10 20 30 40 50 60 MKKKLVLIDG
SSVAYRAFFA LPLLHNDKGI HTNAVYGFTM MLNKILAEEE PTHMLVAFDA 70 80 90 100
110 120 GKTTFRHEAF QEYKGGRQQT PPELSEQFPL LRELLRAYRI PAYELENYEA
DDIIGTLAAR 130 140 150 160 170 180 AEQEGFEVKV ISGDRDLTQL ASPHVTVDIT
KKGITDIEPY TPETVREKYG LTPEQIVDLK 190 200 210 220 230 240 GLMGDKSDNI
PGVPGIGEKT AVKLLRQFGT VENVLASIDE IKGEKLKETL RQHREMALLS 250 260 270
280 290 300 KKLAAIRRDA PVELSLDDIA YQGEDREKVV ALFKELGFQS FLEKMESPSS
EEEKPLAKMA 310 320 330 340 350 360 FTLADRVTEE MLADKAALVV EVVEENYHDA
PIVGIAVVNE HGRFFLRPET ALADPQFVAW 370 380 390 400 410 420 LGDETKKKSM
FDSKRAAVAL KWKGIELCGV SFDLLLAAYL LDPAQGVDDV AAAAKMKQYE 430 440 450
460 470 480 AVRPDEAVYG KGAKRAVPDE PVLAEHLVRK AAAIWELERP FLDELRRNEQ
DRLLVELEQP 490 500 510 520 530 540 LSSILAEMEF AGVKVDTKRL EQMGKELAEQ
LGTVEQRIYE LAGQEFNINS PKQLGVILFE 550 560 570 580 590 600 KLQLPVLKKT
KTGYSTSADV LEKLAPYHEI VENILHYRQL GKLQSTYIEG LLKVVRPDTK 610 620 630
640 650 660 KVHTIFNQAL TQTGRLSSTE PNLQNIPIRL EEGRKIRQAF VPSESDWLIF
AADYSQIELR 670 680 690 700 710 720 VLAHIAEDDN LMEAFRRDLD IHTKTAMDIF
QVSEDEVTPN MRRQAKAVNF GIVYGISDYG 730 740 750 760 770 780 LAQNLNISRK
EAAEFIERYF ESFPGVKRYM ENIVQEAKQK GYVTTLLHRR RYLPDITSRN 790 800 810
820 830 840 FNVRSFAERM AMNTPIQGSA ADIIKKAMID LNARLKEERL QAHLLLQVHD
ELILEAPKEE 850 860 870 MERLCRLVPE VMEQAVTLRV PLKVDYHYGS TWYDAK
[0268] SEQ ID NO: 16 comprises the amino acid sequence of a
naturally occurring Bst DNA polymerase.
[0269] In some embodiments, the reference polymerase is a Bst DNA
polymerase having, or comprising the amino acid sequence of SEQ ID
NO: 16, and the modified polymerase is a mutant or variant of the
reference polymerase and further includes one or more amino acid
mutations relative to the reference polymerase. In some
embodiments, the modified polymerase comprises an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of the reference polymerase. The one or
more amino acid substitutions present in the modified polymerase
relative to the reference polymerase can include at least one
conservative amino acid substitution.
[0270] In some embodiments, the reference polymerase can have or
comprise the amino acid sequence of SEQ ID NO: 16, and the modified
polymerase can have or comprise the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
comprises an amino acid sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
or at least 99% identical to the amino acid sequence of the
reference polymerase. The modified polymerase can further include
any one or more amino acid mutations selected from the group
consisting of: H341R, C388R, Q533C, H568R, H576A, E741Q, H768R,
Y772F, H823A, C845Q and H867R, wherein the numbering is relative to
the amino acid sequence of SEQ ID NO: 16. In some embodiments, the
modified polymerase has a reduced buffering capacity relative to
the reference polymerase. Without being bound to any particular
theory of operation, it can be observed that in some embodiments
one or more of the aforementioned mutations can decrease the
buffering capacity of the modified polymerase relative to the
unmodified polymerase. In some embodiments, such decrease in
buffering capacity can increase the observed signal in an ion-based
sequencing reaction. Further information about such mutations and
their possible effect on the buffering capacity of the polymerase
can be found, for example, in U.S. Provisional Appl. No. 60/308,863
filed Feb. 26, 2010; U.S. patent application Ser. Nos. 13/035,081
filed Feb. 25, 2011; 13/035,177 filed Feb. 25, 2011; 13/036,526
filed Feb. 28, 2011; and 13/036,623 filed Feb. 25, 2011; as well as
in International PCT Appl. Nos. PCT/US2011/026219 filed Feb. 25,
2011; PCT/US2011/026228 filed Feb. 25, 2011; PCT/US2011/026450
filed Feb. 28, 2011; and PCT/US2011/026468 filed Feb. 28, 2011; all
of which aforementioned applications are hereby incorporated by
reference in their entireties. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16. Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate exonuclease activity. Some exemplary mutations that can
reduce or eliminate the exonuclease activity of the polymerase are
described further herein.
[0271] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 16, and the
modified polymerase has or comprises the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
comprises an amino acid sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
or at least 99% identical to the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
further includes any one or more amino acid mutations selected from
the group consisting of: N326R, N326K, D372K, D372H, D408N, D409R,
D425A, D425H, D439M, D439K, L507A, E515K, N529R, N529K, V536K,
V546K, D559Q, D559S, Y567R, L575R, E589S, E589F, E589G, V594K,
V594H, V594F, D598R, I626Q, L630T, E631P, I649W, I649F, I665A,
Q704R, G711K, V713M, V713I, G715K, D718S, D718K, D718N, D718R,
D718T, D718G, D718I, D718K, G720R, Q723W, N724R, N724K, F743K,
N752T, A757T, D775R, D775F, D775H, D775A, D775S, D775N, D775Q,
N780W, N780Y, N782H, N782W, N782F, N782I, E782Q, V783R, E788Q,
M790Q, V828I, W872Y and D874F, wherein the numbering is relative of
the amino acid sequence of SEQ ID NO: 16. Without being bound to
any particular theory of operation, it can be observed that in some
embodiments a modified polymerase including one or more of these
mutations exhibits an altered (e.g., increased or decreased) rate
of dissociation from the nucleic acid template ("off-rate")
relative to the unmodified polymerase. In some embodiments, the
modified polymerase exhibits an altered, e.g., increased or
decreased dissociation time constant relative to the reference
polymerase. In some embodiments, the modified polymerase exhibits
an altered, e.g., increased or decreased read length, or an altered
average error-free read length, or altered (e.g., increased or
decreased) observed 100Q17 or 200Q17 values relative to the
reference polymerase. In some embodiments, the modified polymerase
exhibits a change in any one or more of the following kinetic
parameters: average read length, minimum read length, enhanced
performed in higher ionic strength solution, improved processivity,
performance in polymerase chain reaction, performance in emulsion
polymerase chain reaction, dissociation time constant, off-rate,
AQ20, 100Q17 value, and 200Q17 value, relative to the reference
polymerase. Optionally, the change is observed by comparing the
performance of the reference and modified polymerases in an
ion-based sequencing reaction. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16. Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate exonuclease activity.
[0272] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 16, and the
modified polymerase has or comprises the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
comprises an amino acid sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
or at least 99% identical to the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
further includes an amino acid substitution at any one or more
positions selected from the group consisting of: 326, 341, 372,
388, 408, 409, 425, 439, 507, 515, 529, 533, 536, 546, 559, 567,
568, 575, 576, 589, 594, 598, 626, 630, 631, 649, 665, 704, 711,
713, 715, 718, 720, 723, 724, 741, 743, 752, 757, 768, 772, 775,
780, 782, 783, 788, 790, 823, 828, 845, 867, 872 and 874, wherein
the numbering is relative of the amino acid sequence of SEQ ID NO:
16.
[0273] In some embodiments, the reference polymerase and/or the
modified polymerase can include the amino acid sequence of any
biologically active fragment of a polymerase having the amino acid
sequence of SEQ ID NO: 16 and further including any one or more
amino acid mutations selected from the group consisting of: D559S,
D718K, and D775R.
[0274] In some embodiments, the amino acid substitutions include
the substitution of the existing amino acid residue at the
indicated position with any other amino acid residue (including
both naturally occurring and non-natural amino acid residues). In
some embodiments, the amino acid substitution is a conservative
substitution; alternatively, the amino acid substitution can be a
non-conservative substitution. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: average read length, minimum read length, enhanced
performed in higher ionic strength solution, improved processivity,
performance in polymerase chain reaction, performance in emulsion
polymerase chain reaction, AQ20, buffering capacity, off-rate,
100Q17 value and 200Q17 value, relative to the reference
polymerase. Optionally, the change is observed by comparing the
performance of the reference and modified polymerases in an
ion-based sequencing reaction. Optionally, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include one or more amino acid
mutations that decrease or eliminate exonuclease activity.
[0275] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 16, and the
modified polymerase has or comprises the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
comprises an amino acid sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
or at least 99% identical to the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
further includes any one or more amino acid mutations selected from
the group consisting of: N326R, N326K, H341R, D372K, D372H, C388R,
D408N, D409R, D425A, D425H, D439M, D439K, L507A, E515K, N529R,
N529K, V536K, V546K, Q533C, D559Q, D559S, Y567R, H568R, L575R,
H576A, E589S, E589F, E589G, V594K, V594H, V594F, D598R, I626Q,
L630T, E631P, I649W, I649F, I665A, Q704R, G711K, V713M, V713I,
G715K, D718S, D718K, D718N, D718R, D718T, D718G, D718I, D718K,
G720R, Q723W, N724R, N724K, E741Q, F743K, N752T, A757T, H768R,
Y772F, D775R, D775F, D775H, D775A, D775S, D775N, D775Q, N780W,
N780Y, N782H, N782W, N782F, N782I, E782Q, V783R, E788Q, M790Q,
H823A, V828I, C845Q, H867R, W872Y and D874F, wherein the numbering
is relative of the amino acid sequence of SEQ ID NO: 16. Without
being bound to any particular theory of operation, it can be
observed that in some embodiments a modified polymerase including
one or more of these mutations exhibits an altered (e.g., increased
or decreased) rate of dissociation from the nucleic acid template
("off-rate") relative to the unmodified polymerase. In some
embodiments, the modified polymerase exhibits an altered (e.g.,
increased or decreased) dissociation time constant relative to the
unmodified polymerase. In some embodiments, the modified polymerase
exhibits an altered (e.g., increased or decreased) buffering
capacity relative to the unmodified polymerase. In some
embodiments, the modified polymerase exhibits an altered, e.g.,
increased or decreased read length, or an altered average
error-free read length, or altered (e.g., increased or decreased)
observed 100Q17 or 200Q17 values relative to the reference
polymerase. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: buffering capacity, average read length, minimum
read length, enhanced performed in higher ionic strength solution,
improved processivity, performance in polymerase chain reaction,
performance in emulsion polymerase chain reaction, off-rate, AQ20,
100Q17 value and 200Q17 value, relative to the reference
polymerase. Optionally, the change is observed by comparing the
performance of the reference and modified polymerases in an
ion-based sequencing reaction. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16. Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate exonuclease activity.
[0276] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 16, and the
modified polymerase has or comprises the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
comprises an amino acid sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
or at least 99% identical to the amino acid sequence of the
reference polymerase. In some embodiments, the modified polymerase
further includes at least one amino acid substitution. The at least
one amino acid substitution can optionally occur at any one or more
positions selected from the group consisting of: 341, 388, 533,
568, 576, 741, 768, 772, 823, 845 and 867. In some embodiments, the
modified polymerase can further include at least one amino acid
substitution at one or more positions selected from the group
consisting of: 326, 372, 408, 409, 425, 439, 507, 515, 529, 536,
546, 559, 567, 575, 589, 594, 598, 626, 630, 631, 649, 665, 704,
711, 713, 715, 718, 720, 723, 724, 743, 752, 757, 775, 780, 782,
783, 788, 790, 828, 872 and 874, wherein the numbering is relative
of the amino acid sequence of SEQ ID NO: 16. In some embodiments,
the amino acid substitutions include the substitution of the
existing amino acid residue at the indicated position with any
other amino acid residue (including both naturally occurring and
non-natural amino acid residues). In some embodiments, the amino
acid substitution is a conservative substitution; alternatively,
the amino acid substitution can be a non-conservative substitution.
In some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include a deletion of the methionine residue at position 1,
or a substitution of the methionine residue at position 1 with any
other amino acid residue, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 16. In some embodiments, the
modified polymerase exhibits a change in any one or more parameters
selected from the group consisting of: buffering capacity, average
read length, minimum read length, enhanced performed in higher
ionic strength solution, improved processivity, performance in
polymerase chain reaction, performance in emulsion polymerase chain
reaction, dissociation time constant, off-rate, AQ20, 100Q17 value
and 200Q17 value, relative to the reference polymerase. Optionally,
the change is observed by comparing the performance of the
reference and modified polymerases in an ion-based sequencing
reaction. Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate exonuclease activity.
[0277] In some embodiments, the reference polymerase has or
comprises the amino acid sequence of SEQ ID NO: 16, and the
modified polymerase has or comprises the amino acid sequence of the
reference polymerase.
[0278] In some embodiments, the modified polymerase comprises an
amino acid sequence that is at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to the amino acid sequence of the reference
polymerase.
[0279] In some embodiments, the modified polymerase further
includes one or more amino acid substitutions selected from the
group consisting of: H341A, H341R, C388R, Q533C, H568A, H568R,
H576A, H576M, H576R, E741Q, H768A, H768R, Y772F, H823A, H823R,
H823K, C845Q, H867A and H867R, as well as one or more amino acid
substitutions selected from the group consisting of: N326R, N326K,
D372K, D372H, D408N, D409R, D425A, D425H, D439M, D439K, L507A,
E515K, N529R, N529K, V536K, V546K, D559Q, D559S, D559K, Y567R,
L575R, E589S, E589F, E589G, E589K, V594K, V594H, V594F, D598R,
I626Q, L630T, E631P, I649W, I649F, I665A, Q704R, G711K, V713M,
V713I, G715K, D718S, D718K, D718N, D718R, D718T, D718G, D718I,
D718K, G720R, Q723W, N724R, N724K, F743K, N752T, A757T, D775R,
D775F, D775H, D775A, D775S, D775N, D775Q, N780W, N780Y, N782H,
N782W, N782F, N782I, E782Q, V783R, E788Q, M790Q, V828I, W872Y and
D874F, wherein the numbering is relative of the amino acid sequence
of SEQ ID NO: 16.
[0280] In some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include a deletion of the methionine residue at position 1,
or a substitution of the methionine residue at position 1 with any
other amino acid residue, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 16.
[0281] In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: buffering capacity, average read length, minimum
read length, enhanced performed in higher ionic strength solution,
improved processivity, performance in polymerase chain reaction,
performance in emulsion polymerase chain reaction, AQ20,
dissociation time constant, off-rate, 100Q17 value and 200Q17
value, relative to the reference polymerase. Optionally, the change
is observed by comparing the performance of the reference and
modified polymerases in an ion-based sequencing reaction.
Optionally, the reference polymerase, the modified polymerase, or
both the reference and modified polymerases can further include one
or more amino acid mutations that decrease or eliminate exonuclease
activity.
[0282] In some embodiments, the disclosure relates generally to a
modified polymerase comprising the amino acid sequence of SEQ ID
NO: 16, or the amino acid sequence of any biologically active
fragment of a polymerase having or comprising the amino acid
sequence of SEQ ID NO: 16, and further including at least one amino
acid mutation relative to the amino acid sequence of a reference
polymerase having the amino acid sequence of SEQ ID NO: 16.
[0283] In some embodiments, the modified polymerase comprises an
amino acid sequence that is at least 80%, at least 85%, at least
90%, at least 91%, at least 92%, at least 93%, at least 94%, at
least 95%, at least 96%, at least 97%, at least 98%, or at least
99% identical to the amino acid sequence of the reference
polymerase.
[0284] In some embodiments, the modified polymerase has polymerase
activity. The polymerase or biologically active fragment can have
primer extension activity in vivo or in vitro.
[0285] In some embodiments, the one or more mutations in the
modified polymerase can include at least one amino acid
substitution. The at least one amino acid substitution can
optionally occur at any one or more positions selected from the
group consisting of: 341, 388, 533, 568, 576, 741, 768, 772, 823,
845 and 867, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 16. In some embodiments, the modified
polymerase includes at least two, three, four, five, or more amino
acid substitutions occurring at positions selected from this group.
Without intending to be bound to any particular theory of action,
it can be observed that in some embodiments, amino acid
substitution at such positions can alter, e.g., increase or
decrease the buffering capacity of the modified polymerase relative
to the corresponding unmodified polymerase, or relative to a
reference polymerase having the amino acid sequence of SEQ ID NO:
1, 2, 3 or 4. Such mutations can therefore be referred to as
"buffering" mutations. In some embodiments, such increase or
decrease in buffering capacity can increase the observed signal in
an ion-based sequencing reaction.
[0286] In some embodiments, the one or more mutations in the
modified polymerase can include at least one amino acid
substitution. The at least one amino acid substitution can
optionally occur at any one or more positions selected from the
group consisting of: 326, 372, 408, 409, 425, 439, 507, 515, 529,
536, 546, 559, 567, 575, 589, 594, 598, 626, 630, 631, 649, 665,
704, 711, 713, 715, 718, 720, 723, 724, 743, 752, 757, 775, 780,
782, 783, 788, 790, 828, 872 and 874, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 16. In some
embodiments, the modified polymerase includes at least two, three,
four, five, or more amino acid substitutions occurring at positions
selected from this group. Without being bound to any particular
theory of operation, it can be observed that in some embodiments a
modified polymerase including any one of such amino acid
substitutions exhibits an altered (e.g., increased or decreased)
binding affinity for a nucleic acid template relative to an
unmodified polymerase, or an altered (e.g., increased or decreased)
rate of dissociation from the nucleic acid template ("off-rate")
relative to the corresponding unmodified polymerase, or relative to
a reference polymerase. The reference polymerase can include the
amino acid of SEQ ID NO: 1, 2, 3 or 4. In some embodiments, the
modified polymerase exhibits an altered (e.g., increased or
decreased) read length, or an altered (e.g., increased or
decreased) average error-free read length, or altered (e.g.,
increased or decreased) dissociation time constant, or altered
(e.g., increased or decreased) observed 100Q17 or 200Q17 values
relative to the reference polymerase. In some embodiments, the
modified polymerase exhibits a change (e.g., increase or decrease)
in any one or more properties selected from the group consisting
of: DNA binding affinity, off-rate, 100Q17 value and 200Q17 value,
relative to the reference polymerase. Optionally, the change is
observed by comparing the properties of the reference and modified
polymerases in an ion-based sequencing reaction.
[0287] In some embodiments, the one or more mutations in the
modified polymerase can include at least one amino acid
substitution. The at least one amino acid substitution can
optionally occur at any one or more positions selected from the
group consisting of: 326, 341, 372, 408, 409, 425, 439, 507, 515,
529, 536, 546, 559, 567, 568, 575, 576, 589, 594, 598, 626, 630,
631, 649, 665, 704, 711, 713, 715, 718, 720, 723, 724, 741, 743,
752, 757, 768, 772, 775, 780, 782, 783, 788, 790, 823, 828, 867,
872 and 874, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 16. In some embodiments, the modified
polymerase includes at least two, three, four, five, or more amino
acid substitutions occurring at positions selected from this
group.
[0288] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 16, or the amino acid sequence of
a biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 16 and further includes at least one
amino acid substitution at any one or more positions selected from
the group consisting of: 341, 568, 576, 741, 768, 772, 823, 845 and
867, as well as at least one amino acid substitution at any one or
more positions selected from the group consisting of: 326, 372,
408, 409, 425, 439, 507, 515, 529, 536, 546, 559, 567, 575, 589,
594, 598, 626, 630, 631, 649, 665, 704, 711, 713, 715, 718, 720,
723, 724, 743, 752, 757, 775, 780, 782, 783, 788, 790, 828, 872 and
874, wherein the numbering is relative to the amino acid sequence
of SEQ ID NO: 16, In some embodiments, the modified polymerase
includes at least two, three, four, five, or more amino acid
substitutions occurring at positions selected from each of these
two groups of amino acid substitutions.
[0289] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 16, or the amino acid sequence of
a biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 16. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes at least one amino acid substitution
selected from the group consisting of: H341A, H341R, H568A, H568R,
H576A, H576R, E741Q, H768A, H768R, Y772F, H823A, H823R, H867A and
H867R, wherein the numbering is relative of the amino acid sequence
of SEQ ID NO: 16. In some embodiments, the modified polymerase
includes any two, three, four, five or more of these amino acid
substitutions.
[0290] In some embodiments, the modified polymerase includes at
least one amino acid substitution designed to replace a preexisting
cysteine residue with a different amino acid residue, or to replace
a non-cysteine amino acid residue with a cysteine residue. The at
least one amino acid substitution optionally includes one or more
amino acid substitutions selected from the group consisting of:
C388R, Q533C, C845Q, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 16.
[0291] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 16, or the amino acid sequence of
a biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 16. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes at least one amino acid substitution
selected from the group consisting of: H341A, H341R, H568A, H568R,
H576A, H576R, H576M, E741Q, H768A, H768R, Y772F, H823A, H823R,
H823K, H867A and H867R, wherein the numbering is relative of the
amino acid sequence of SEQ ID NO: 16. In some embodiments, the
modified polymerase includes any two, three, four, five or more of
these amino acid substitutions.
[0292] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 16, or the amino acid sequence of
a biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 16. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes at least one amino acid substitution
selected from the group consisting of: N326R, N326K, D372K, D372H,
D408N, D409R, D425A, D425H, D439M, D439K, L507A, E515K, N529R,
N529K, V536K, V546K, D559Q, D559S, D559K, Y567R, L575R, E589S,
E589F, E589G, E589K, V594K, V594H, V594F, D598R, I626Q, L630T,
E631P, I649W, I649F, I665A, Q704R, G711K, V713M, V713I, G715K,
D718S, D718K, D718N, D718R, D718T, D718G, D718I, D718K, G720R,
Q723W, N724R, N724K, F743K, N752T, A757T, D775R, D775F, D775H,
D775A, D775S, D775N, D775Q, N780W, N780Y, N782H, N782W, N782F,
N782I, E782Q, V783R, E788Q, M790Q, V828I, W872Y and D874F, wherein
the numbering is relative of the amino acid sequence of SEQ ID NO:
16. Optionally, the modified polymerase can further include at
least one amino acid substitution selected from the group
consisting of: H341A, H341R, H568A, H568R, H576A, H576R, H576M,
E741Q, H768A, H768R, Y772F, H823A, H823R, H823K, H867A and H867R,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16. In some embodiments, the modified polymerase includes
any two, three, four, five or more amino acid substitutions
selected from each of these two groups of amino acid
substitutions.
[0293] In some embodiments, the modified polymerase includes the
amino acid sequence of SEQ ID NO: 16, or the amino acid sequence of
a biologically active fragment of a polymerase having the amino
acid sequence of SEQ ID NO: 16. In some embodiments, the modified
polymerase comprises an amino acid sequence that is at least 80%,
at least 85%, at least 90%, at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at
least 98%, or at least 99% identical to the amino acid sequence of
the reference polymerase. In some embodiments, the modified
polymerase further includes at least one amino acid substitution
selected from the group consisting of: N326R, N326K, H341A, H341R,
D372K, D372H, D408N, D409R, D425A, D425H, D439M, D439K, L507A,
E515K, N529R, N529K, V536K, V546K, D559Q, D559S, D559K, Y567R,
H568A, H568R, L575R, H576A, H576R, E589S, E589F, E589G, E589K,
V594K, V594H, V594F, D598R, I626Q, L630T, E631P, 1649W, I649F,
I665A, Q704R, G711K, V713M, V713I, G715K, D718S, D718K, D718N,
D718R, D718T, D718G, D718I, D718K, G720R, Q723W, N724R, N724K,
E741Q, F743K, N752T, A757T, H768A, H768R, Y772F, D775R, D775F,
D775H, D775A, D775S, D775N, D775Q, N780W, N780Y, N782H, N782W,
N782F, N782I, E782Q, V783R, E788Q, M790Q, H823A, H823R, V828I,
H867A, H867R, W872Y and D874F, wherein the numbering is relative of
the amino acid sequence of SEQ ID NO: 16. In some embodiments, the
modified polymerase includes any two, three, four, five or more of
these amino acid substitutions.
[0294] In some embodiments, the modified polymerase according to
the disclosure can include at least amino acid mutation, D775R,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16. In some embodiments, the modified polymerase according
to the disclosure can include amino acid mutations D559K and E788Q,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16. In some embodiments, the modified polymerase according
to the disclosure can include amino acid mutations E515K, N529R and
D718K, wherein the numbering is relative to the amino acid sequence
of SEQ ID NO: 16. In some embodiments, the modified polymerase
according to the disclosure can include amino acid mutations E515K,
N529R, D718K, and H823A, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 16. In some embodiments, the
modified polymerase according to the disclosure can include amino
acid mutations E515K, N529R, D718K, H768R and H823A, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 16.
In some embodiments, the modified polymerase according to the
disclosure can include any one or more amino acid mutations
selected from the group consisting of: E515K, N529R, V536K, D559K,
D718K, H768R, D775R, N782W, V783R, E788Q, and H823A) wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 16.
In some embodiments a modified polymerase including one or more of
these mutations exhibits an altered (e.g., increased or decreased)
binding affinity for a nucleic acid template relative to the
corresponding unmodified polymerase or to a reference polymerase
including the amino acid sequence of SEQ ID NO: 16. In some
embodiments, the modified polymerase has an altered (e.g.,
increased or decreased) rate of dissociation from the nucleic acid
template ("off-rate") relative to the unmodified polymerase or to a
reference polymerase including the amino acid sequence of SEQ ID
NO: 16. In some embodiments, the modified polymerase exhibits an
altered, e.g., increased or decreased read length, or an altered
average error-free read length, or altered (e.g., increased or
decreased) observed 100Q17 or 200Q17 values relative to the
reference polymerase. In some embodiments, the modified polymerase
exhibits a change in any one or more of the following kinetic
parameters: average read length, minimum read length, enhanced
performed in higher ionic strength solution, improved processivity,
performance in polymerase chain reaction, performance in emulsion
polymerase chain reaction, dissociation time constant, off-rate,
AQ20, 100Q17 value, and 200Q17 value, relative to the reference
polymerase. Optionally, the change is observed by comparing the
performance of the reference and modified polymerases in an
ion-based sequencing reaction. In some embodiments, the amino acid
substitutions include the substitution of the existing amino acid
residue at the indicated position with any other amino acid residue
(including both naturally occurring and non-natural amino acid
residues). In some embodiments, the amino acid substitution is a
conservative substitution; alternatively, the amino acid
substitution can be a non-conservative substitution. In some
embodiments, the reference polymerase, the modified polymerase, or
both the reference and modified polymerases can further include a
deletion of the methionine residue at position 1, or a substitution
of the methionine residue at position 1 with any other amino acid
residue, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 16. In some embodiments, the modified
polymerase exhibits a change in any one or more parameters selected
from the group consisting of: buffering capacity, average read
length, minimum read length, enhanced performed in higher ionic
strength solution, improved processivity, performance in polymerase
chain reaction, performance in emulsion polymerase chain reaction,
off-rate, AQ20, 100Q17 value and 200Q17 value, relative to the
reference polymerase. Optionally, the change is observed by
comparing the performance of the reference and modified polymerases
in an ion-based sequencing reaction. Optionally, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include one or more amino acid
mutations that decrease or eliminate exonuclease activity.
[0295] In some embodiments, the modified polymerase has an altered
(e.g., increased or decreased) binding affinity for a nucleic acid
template relative to a reference polymerase. In some embodiments,
the modified polymerase has an altered (e.g., increased or
decreased) rate of dissociation from the nucleic acid template
("off-rate") relative to a reference polymerase. The reference
polymerase can optionally have the amino acid sequence of SEQ ID
NO: 16, 1, 2, 3 or 4. In some embodiments, the modified polymerase
exhibits an altered (e.g., increased or decreased) read length, or
an altered (e.g., increased or decreased) average error-free read
length, or an altered (e.g., increased or decreased) observed
100Q17 or 200Q17 value relative to the reference polymerase. In
some embodiments, the modified polymerase exhibits a change (e.g.,
increase or decrease) in any one or more of the following
properties: binding affinity for a nucleic acid template,
dissociation time constant, off-rate, 100Q17 value, and 200Q17
value, relative to the reference polymerase. In some embodiments,
the altered property is increased or decreased by at least 10%,
20%, 30%, 40%, 50%, 75%, 90%, 100%, 200%, 300%, 500%, 750%, 1000%,
3000% or greater, relative to the corresponding unmodified
polymerase, or to the reference polymerase. Optionally, the change
is observed by comparing the properties of the reference and
modified polymerases in an ion-based sequencing reaction.
[0296] In some embodiments, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include a deletion of the methionine residue at position 1,
or a substitution of the methionine residue at position 1 with any
other amino acid residue, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 16.
[0297] Optionally, the reference polymerase, the modified
polymerase, or both the reference and modified polymerases can
further include one or more amino acid mutations that decrease or
eliminate any exonuclease activity of the polymerase. In some
embodiments, the reference polymerase, the modified polymerase, or
both the reference and modified polymerase is a Bst DNA polymerase
that has proofreading exonuclease activity. In various embodiments,
the proofreading exonuclease activity of a modified Bst DNA
polymerase is at least about 40%, 50%, 60%, 70%, 80% or 90% that of
the corresponding wild type protein. In order to retain the
proofreading exonuclease activity of a modified Bst DNA polymerase,
the skilled artisan will understand that any substitutions,
deletions or chemical modifications should be made to amino acid
residues that are not highly conserved within the Exo I, Exo II and
Exo III motifs.
[0298] In some embodiments, the modified polymerase is a Taq DNA
polymerase. In some embodiments, the polymerase is a Taq DNA
polymerase commercially available as Platinum Taq High Fidelity DNA
polymerase (Life Technologies, CA), that includes one or more amino
acid mutations as compared to the reference Platinum Taq High
Fidelity DNA polymerase. In some embodiments, the modified
polymerase is a Taq DNA polymerase having, or comprising, the amino
acid sequence of SEQ ID NO: 15, which is the amino acid sequence of
the large fragment of the Taq Pol A polymerase:
TABLE-US-00014 (SEQ ID NO: 15) 1 MRGMLPLFEP KGRVLLVDGH HLAYRTFHAL
KGLTTSRGEP VQAVYGFAKS LLKALKEDGD 61 AVIVVFDAKA PSFRHEAYGG
YKAGRAPTPE DFPRQLALIK ELVDLLGLAR LEVPGYEADD 121 VLASLAKKAE
KEGYEVRILT ADKDLYQLLS DRIHVLHPEG YLITPAWLWE KYGLRPDQWA 181
DYRALTGDES DNLPGVKGIG EKTARKLLEE WGSLEALLKN LDRLKPAIRE KILAHMDDLK
241 LSWDLAKVRT DLPLEVDFAK RREPDRERLR AFLERLEFGS LLHEFGLLES
PKALEEAPWP 301 PPEGAFVGFV LSRKEPMWAD LLALAAARGG RVHRAPEPYK
ALRDLKEARG LLAKDLSVLA 361 LREGLGLPPG DDPMLLAYLL DPSNTTPEGV
ARRYGGEWTE EAGERAALSE RLFANLWGRL 421 EGEERLLWLY REVERPLSAV
LAHMEATGVR LDVAYLRALS LEVAEEIARL EAEVFRLAGH 481 PFNLNSRDQL
ERVLFDELGL PAIGKTEKTG KRSTSAAVLE ALREAHPIVE KILQYRELTK 541
LKSTYIDPLP DLIHPRTGRL HTRFNQTATA TGRLSSSDPN LQNIPVRTPL GQRIRRAFIA
601 EEGWLLVALD YSQIELRVLA HLSGDENLIR VFQEGRDIHT ETASWMFGVP
REAVDPLMRR 661 AAKTINFGVL YGMSAHRLSQ ELAIPYEEAQ AFIERYFQSF
PKVRAWIEKT LEEGRRRGYV 721 ETLFGRRRYV PDLEARVKSV REAAERMAFN
MPVQGTAADL MKLAMVKLFP RLEEMGARML 781 LQVHDELVLE APKERAEAVA
RLAKEVMEGV YPLAVPLEVE VGIGEDWLSA KE
[0299] In some embodiments, the modified polymerase includes a
mutant or variant form of a Taq DNA polymerase that retains a
detectable level of polymerase activity. In order to retain the
polymerase activity of the Taq DNA polymerase, any substitutions,
deletions or chemical modifications will be made to amino acid
residues that are not highly conserved, such as the invariant
aspartic acid residues required for polymerase activity. In some
embodiments, the modified polymerase can include Taq DNA
polymerase, a hot-start Taq DNA polymerase, a chemical hot-start
Taq DNA polymerase, Platinum Taq DNA polymerase and the like.
[0300] In some embodiments, the modified polymerase can include an
isolated variant of a polymerase having or comprising an amino acid
sequence that is at least 90% identical to the amino acid sequence
of SEQ ID NO: 15. In some embodiments, the polymerase is a variant
of a Taq DNA polymerase comprising the amino acid sequence of SEQ
ID NO: 15, wherein the variant comprises an amino acid sequence
that is at least 80%, at least 85%, at least 90%, at least 91%, at
least 92%, at least 93%, at least 94%, at least 95%, at least 96%,
at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:
15.
[0301] In some embodiments, the modified polymerase includes a
mutant or variant form of Taq DNA polymerase having amino acid
mutation, E471K, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 15. In some embodiments, the modified
Taq DNA polymerase can include amino acid mutation, N485R, wherein
the numbering is relative to the amino acid sequence of SEQ ID NO:
15. In some embodiments, the modified Taq DNA polymerase can
include amino acid mutation, R492K, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 15. In some
embodiments, the modified Taq DNA polymerase can include amino acid
mutation, D513K, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 15. In some embodiments, the modified
Taq DNA polymerase can include amino acid mutation, A675K, wherein
the numbering is relative to the amino acid sequence of SEQ ID NO:
15. In some embodiments, the modified Taq DNA polymerase can
include amino acid mutation, D732R, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 15. In some
embodiments, the modified Taq DNA polymerase can include amino acid
mutation S739W, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 15. In some embodiments, the modified Taq
DNA polymerase can include amino acid mutation V740R, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 15.
In some embodiments, the modified Taq DNA polymerase can include
amino acid mutation E745Q, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 15. In some embodiments, the
modified polymerase can include a variant or mutant of Taq DNA
polymerase having or comprising one or more of the following amino
acid mutations selected from the group consisting of: E471K, N485R,
R492K, D513K, A675K, D732R, S739W, V740R and E745Q, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 15.
In some embodiments a modified polymerase including one or more of
these mutations exhibits an altered (e.g., increased or decreased)
binding affinity for a nucleic acid template relative to the
corresponding unmodified polymerase or to a reference polymerase
including the amino acid sequence of SEQ ID NO: 15. In some
embodiments, the modified Taq polymerase has an altered (e.g.,
increased or decreased) rate of dissociation from the nucleic acid
template ("off-rate") relative to the unmodified polymerase or to a
reference polymerase including the amino acid sequence of SEQ ID
NO: 15. In some embodiments, the modified Taq polymerase exhibits
an altered, e.g., increased or decreased read length, or an altered
average error-free read length, or altered (e.g., increased or
decreased) observed 100Q17 or 200Q17 values relative to the
reference polymerase. In some embodiments, the modified Taq
polymerase exhibits a change in any one or more of the following
kinetic parameters: average read length, minimum read length,
enhanced performed in higher ionic strength solution, improved
processivity, performance in polymerase chain reaction, performance
in emulsion polymerase chain reaction, dissociation time constant,
off-rate, AQ 20, 100Q17 value, and 200Q17 value, relative to the
reference polymerase. Optionally, the change is observed by
comparing the performance of the reference and modified polymerases
in an ion-based sequencing reaction. In some embodiments, the amino
acid substitutions include the substitution of the existing amino
acid residue at the indicated position with any other amino acid
residue (including both naturally occurring and non-natural amino
acid residues). In some embodiments, the amino acid substitution is
a conservative substitution; alternatively, the amino acid
substitution can be a non-conservative substitution. In some
embodiments, the reference polymerase, the modified Taq polymerase,
or both the reference and modified Taq polymerases can further
include a deletion of the methionine residue at position 1, or a
substitution of the methionine residue at position 1 with any other
amino acid residue, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 15. In some embodiments, the modified
Taq polymerase exhibits a change in any one or more parameters
selected from the group consisting of: buffering capacity, average
read length, minimum read length, enhanced performed in higher
ionic strength solution, improved processivity, performance in
polymerase chain reaction, performance in emulsion polymerase chain
reaction, AQ20, off-rate, 100Q17 value and 200Q17 value, relative
to the reference polymerase. Optionally, the change is observed by
comparing the performance of the reference and modified Taq
polymerases in an ion-based sequencing reaction. Optionally, the
reference polymerase, the modified Taq polymerase, or both the
reference and modified Taq polymerases can further include one or
more amino acid mutations that decrease or eliminate exonuclease
activity.
[0302] In some embodiments, the modified polymerase is a Taq DNA
polymerase having, or comprising, the amino acid sequence of SEQ ID
NO: 15 except for the first residue (N-terminal methionine) of SEQ
ID NO: 15, which is not included in the modified polymerase.
[0303] As the skilled artisan will readily appreciate, the scope of
the present disclosure encompasses not only the specific amino acid
and/or nucleotide sequences disclosed herein, but also, for
example, many related sequences encoding genes and/or peptides with
the functional properties described herein. For example, the scope
and spirit of the disclosure encompasses any nucleotide and amino
acid sequences encoding conservative variants of the various
polymerases disclosed herein. It will also be readily apparent to
the skilled artisan that the modified polymerases disclosed herein
by amino acid sequence can be converted to the corresponding
nucleotide sequence without undue experimentation, for example
using a number of freely available sequence conversion applications
(e.g., "in-silco").
[0304] In some embodiments, the modified polymerase is the Klenow
Fragment of E. coli DNA polymerase I. DNA polymerase I from E. coli
contains a 5' to 3' exonuclease domain (typically corresponding to
amino acid resides: 7-252). However, in order to generate the
Klenow fragment, these and additional amino acid resides (1-323)
are cleaved. Amino acid residues 324-928 of E. coli DNA polymerase
I constitute the Klenow fragment (provided herein as SEQ ID NO:
23). Both E. coli DNA polymerase I and the Klenow fragment contain
a 3' to 5' exonuclease (proofreading) domain located at amino acid
residues 345-539; and a polymerase domain responsible for
polymerization of a new DNA strand (amino acid residues 547-926).
Overall, the Klenow fragment as compared to E. coli polymerase I
generally lacks amino acids 1-323.
[0305] In some embodiments, the modified polymerase is a Klenow
Fragment of E. coli DNA polymerase having, or comprising, the amino
acid sequence of SEQ ID NO: 18.
TABLE-US-00015 (SEQ ID NO: 18) 1 MVISYDNYVT ILDEETLKAW IAKLEKAPVF
AFDTETDSLD NISANLVGLS FAIEPGVAAY 60 61 IPVAHDYLDA PDQISRERAL
ELLKPLLEDE KALKVGQNLK YDRGILANYG IELRGIAFDT 120 121 MLESYILNSV
AGRHDMDSLA ERWLKHKTIT FEEIAGKGKN QLTFNQIALE EAGRYAAEDA 180 181
DVTLQLHLKM WPDLQKHKGP LNVFENIEMP LVPVLSRIER NGVKIDPKVL HNHSEELTLR
240 241 LAELEKKAHE IAGEEFNLSS TKQLQTILFE KQGIKPLKKT PGGAPSTSEE
VLEELALDYP 300 301 LPKVILEYRG LAKLKSTYTD KLPLMINPKT GRVHTSYHQA
VTATGRLSST DPNLQNIPVR 360 361 NEEGRRIRQA FIAPEDYVIV SADYSQIELR
IMAHLSRDKG LLTAFAEGKD IHRATAAEVF 420 421 GLPLETVTSE QRRSAKAINF
GLIYGMSAFG LARQLNIPRK EAQKYMDLYF ERYPGVLEYM 480 481 ERTRAQAKEQ
GYVETLDGRR LYLPDIKSSN GARRAAAERA AINAPMQGTA ADIIKRAMIA 540 541
VDAWLQAEQP RVRMIMQVHD ELVFEVHKDD VDAVAKQIHQ LMENCTRLDV PLLVEVGSGE
600 601 NWDQAH 606
[0306] In some embodiments, the modified polymerase includes a
mutant or variant form of the Klenow fragment of DNA polymerase I
that retains a detectable level of polymerase activity. In order to
retain the polymerase activity of the Klenow fragment, any
substitutions, deletions or chemical modifications will be made to
amino acid residues that are not highly conserved, such as the
invariant aspartic acid residues required for polymerase
activity.
[0307] In some embodiments, the modified polymerase can include an
isolated variant of a polymerase having or comprising an amino acid
sequence that is at least 90% identical to the amino acid sequence
of SEQ ID NO: 18. In some embodiments, the polymerase is a variant
of a Klenow fragment of DNA polymerase I comprising the amino acid
sequence of SEQ ID NO: 18, wherein the variant comprises an amino
acid sequence that is at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, or at least 99% identical
to SEQ ID NO: 18.
[0308] In some embodiments, the modified polymerase includes a
mutant or variant form of the Klenow fragment of DNA polymerase I
having amino acid mutation, E245K, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 18. In some
embodiments, the modified polymerase includes a mutant or variant
form of the Klenow fragment of DNA polymerase I having amino acid
mutation, S259R, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 18. In some embodiments, the modified
polymerase includes a mutant or variant form of the Klenow fragment
of DNA polymerase I having amino acid mutation, T266K, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 18.
In some embodiments, the modified polymerase includes a mutant or
variant form of the Klenow fragment of DNA polymerase I having
amino acid mutation, E290K, wherein the numbering is relative to
the amino acid sequence of SEQ ID NO: 18. In some embodiments, the
modified polymerase includes a mutant or variant form of the Klenow
fragment of DNA polymerase I having amino acid mutation, A448K,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 18. In some embodiments, the modified Klenow fragment of DNA
polymerase I can include amino acid mutation, D505R, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 18.
In some embodiments, the modified polymerase includes a mutant or
variant form of the Klenow fragment of DNA polymerase I having
amino acid mutation, A512W, wherein the numbering is relative to
the amino acid sequence of SEQ ID NO: 18. In some embodiments, the
modified Klenow fragment of DNA polymerase I can include amino acid
mutation E518Q, wherein the numbering is relative to the amino acid
sequence of SEQ ID NO: 18. In some embodiments, the modified
polymerase can include a variant or mutant of Klenow fragment of
DNA polymerase I having or comprising one or more of the following
amino acid mutations selected from the group consisting of: E245K,
S259R, T266K, E290K, A448K, D505R, A512W, and E518Q, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 18.
In some embodiments a modified Klenow fragment of DNA polymerase I
including one or more of these mutations exhibits an altered (e.g.,
increased or decreased) binding affinity for a nucleic acid
template relative to the corresponding unmodified polymerase or to
a reference polymerase including the amino acid sequence of SEQ ID
NO: 18. In some embodiments, the modified Klenow fragment of DNA
polymerase I has an altered (e.g., increased or decreased) rate of
dissociation from the nucleic acid template ("off-rate") relative
to the unmodified polymerase or to a reference polymerase including
the amino acid sequence of SEQ ID NO: 18. In some embodiments, the
modified polymerase exhibits an altered, e.g., increased or
decreased read length, or an altered average error-free read
length, or altered (e.g., increased or decreased) observed 100Q17
or 200Q17 values relative to the reference polymerase. In some
embodiments, the modified polymerase exhibits a change in any one
or more of the following kinetic parameters: average read length,
minimum read length, enhanced performed in higher ionic strength
solution, improved processivity, performance in polymerase chain
reaction, performance in emulsion polymerase chain reaction,
dissociation time constant, off-rate, AQ 20, 100Q17 value, and
200Q17 value, relative to the reference polymerase. Optionally, the
change is observed by comparing the performance of the reference
and modified polymerases in an ion-based sequencing reaction. In
some embodiments, the amino acid substitutions include the
substitution of the existing amino acid residue at the indicated
position with any other amino acid residue (including both
naturally occurring and non-natural amino acid residues). In some
embodiments, the amino acid substitution is a conservative
substitution; alternatively, the amino acid substitution can be a
non-conservative substitution. In some embodiments, the reference
polymerase, the modified polymerase, or both the reference and
modified polymerases can further include a deletion of the
methionine residue at position 1, or a substitution of the
methionine residue at position 1 with any other amino acid residue,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 18. In some embodiments, the modified polymerase exhibits a
change in any one or more parameters selected from the group
consisting of: average read length, minimum read length, enhanced
performed in higher ionic strength solution, improved processivity,
performance in polymerase chain reaction, performance in emulsion
polymerase chain reaction, buffering capacity, off-rate, 100Q17
value and 200Q17 value, relative to the reference polymerase.
Optionally, the change is observed by comparing the performance of
the reference and modified polymerases in an ion-based sequencing
reaction.
[0309] In one aspect of the disclosure, it has been found that
amino acids of a polymerase (for example, a reference polymerase)
can be mutated to generate modified polymerases with altered
catalytic properties. In some embodiments, SEQ ID NO: 16
(corresponding to full-length wild-type Bst DNA polymerase) can be
mutated at one or more of the amino acids provided in Table 1 to
obtain one or more polymerases with altered catalytic properties as
compared to the reference polymerase (full-length wild-type Bst
polymerase). In some embodiments, SEQ ID NO: 1 (corresponding to a
truncated version of wild-type Bst DNA polymerase) can be mutated
at one or more of the amino acids provided in Table 1 to obtain one
or more polymerases with altered catalytic properties as compared
to the reference polymerase (truncated wild-type Bst polymerase).
In some embodiments, SEQ ID NO: 18 (corresponding to the Klenow
fragment of DNA polymerase I from E. coli) can be mutated at one or
more of the amino acids provided in Table 1 to obtain one or more
polymerases with altered catalytic properties as compared to the
reference polymerase (Klenow fragment of DNA polymerase I). In some
embodiments, SEQ ID NO: 15 (corresponding to wild-type Taq DNA
polymerase) can be mutated at one or more of the amino acids
provided in Table 1 to obtain one or more polymerases with altered
catalytic properties as compared to the reference polymerase (Taq
DNA polymerase). In some embodiments, incorporating one or more of
the amino acid mutations identified in Table 1 can produce a
modified polymerase with enhanced catalytic properties. In some
embodiments, the modified polymerase exhibits an altered, e.g.,
increased or decreased read length, or an altered average
error-free read length, or altered (e.g., increased or decreased)
observed 100Q17 or 200Q17 values relative to the reference
polymerase. In some embodiments, the modified polymerase exhibits a
change in any one or more of the following kinetic parameters:
average read length, minimum read length, enhanced performed in
higher ionic strength solution, improved processivity, performance
in polymerase chain reaction, performance in emulsion polymerase
chain reaction, dissociation time constant, off-rate, AQ20 100Q17
value, and 200Q17 value, relative to the reference polymerase.
TABLE-US-00016 TABLE 1 SEQ ID SEQ ID SEQ ID NO: 16 NO: 1 SEQ ID NO:
18 NO: 20 E515K E220K E245 E471 N529R N234R S259R N485R V536K V241K
T266K R492K D559K D264 E290K D513K D718K D423K A448K A675K D775R
D480R D505R D732R N782W N487W A512W S739W V783R V488R V740R E788Q
E493Q E518 E745
[0310] While not wishing to be bound by any particular theory, it
was observed that nine different amino acid mutations per
polymerase (of Table) were transferable (homologous) among the four
polymerases. As a result, it is reasonable to suggest that once an
amino acid mutation is identified in a polymerase that provides
altered catalytic properties, the amino acid mutation can be
screened using methods known to one of ordinary skill in the art
(such as amino acid or nucleotide sequence alignment), to determine
if the amino acid mutation can be transferred to a different
polymerase, such as a different species, class or polymerase
family. In some embodiments, the transferable (or homologous) amino
acid mutation can include an amino acid mutation that enhances
catalytic properties such as increased read-length, increased
error-free read length, enhanced processivity, increased 100Q17
value, increased 200Q17 value, and the like. In some embodiments,
the transferable (or homologous) amino acid mutation can include an
amino acid mutation that decrease catalytic properties such as
decreased read-length, decreased error-free read length, decreased
processivity, decreased 100Q17 value, decreased 200Q17 value, and
the like. In some embodiments, a transferable (or homologous) amino
acid mutation can include transferring one or more amino acid
mutations to another polymerase within, or between, DNA polymerase
families, such as DNA polymerase family A or DNA polymerase family
B. In some embodiments, a transferable (or homologous) amino acid
mutation can include transferring one or more amino acid mutations
to one or more polymerases within, or between, DNA polymerase
families, such as across bacterial, viral, archaeal, eukaryotic or
phage DNA polymerases.
[0311] In some embodiments, a modified polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations (such as a substitution, insertion, or deletion) that are
analogoushomologous to one or more of the amino acid mutations
disclosed herein. For example, the disclosure encompasses modified
polymerases that include one or more amino acid mutations that are
homologous to one or more amino acid mutations provided herein for
Bst DNA polymerase (e.g., SEQ ID NO: 2, 3, or 4). In some
embodiments, a modified polymerase according to the disclosure can
include any polymerase having one or more amino acid mutations that
are homologous to one or more amino acid mutations provided herein
for Taq DNA polymerase (e.g., one or more homologous amino acid
mutations that correspond to one or more amino acid mutations of
SEQ ID NO: 15). In some embodiments, a modified polymerase
according to the disclosure can include any polymerase having one
or more amino acid mutations that are homologous to one or more
amino acid mutations provided herein for the Klenow fragment of E.
Coli DNA polymerase I (e.g., one or more homologous amino acid
mutations that correspond to one or more amino acid mutations of
SEQ ID NO: 18).
[0312] In some embodiments, the disclosure relates to a modified
polymerase or any biologically active fragment of a polymerase
having one or more amino acid mutations that are homologous to one
or more amino acid mutations of Bst DNA polymerase (e.g., H46R;
E446Q; and H572R, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 1). In some embodiments, the disclosure
relates to a modified polymerase or any biologically active
fragment of a polymerase having one or more amino acid mutations
that are homologous to one or more amino acid mutations of Bst DNA
polymerase (H473R and H528A, wherein the numbering is relative to
the amino acid sequence of SEQ ID NO: 1). In some embodiments, the
disclosure relates to a modified polymerase or any biologically
active fragment of a polymerase that contains one or more amino
acid mutations that are homologous to one or more amino acid
mutations of Bst DNA polymerase (H273R; H281A; and Y477F, wherein
the numbering is relative to the amino acid sequence of SEQ ID NO:
1).
[0313] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H46R, C93R, Q238C,
H273R, H281A, H281M, E446Q, H473R, Y477F, H528A, H528R, H528K,
C550Q and H572R, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 1. In some embodiments, a modified
polymerase or any biologically active fragment of a polymerase
according to the disclosure can include any polymerase having one
or more amino acid mutations that are homologous to one or more
amino acid mutations for Bst DNA polymerase including, any one or
more amino acid mutations selected from the group consisting of:
N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H, D144M, D144K,
L212A, E220K, N234R, N234K, V241K, V251K, D264Q, D264S, D264K,
Y272R, H273R, L280R, H281A, E294S, E294F, E294G, E294K, V299K,
V299H, V299F, D303R, I331Q, E325R, L335T, E336P, I354W, I354F,
I370A, Q409R, G416K, V418M, V418I, G420K, D423S, D423K, D423N,
D423R, D423T, D423G, D423I, D423K, G425R, Q428W, N429R, N429K,
E446Q, F448K, N457T, A462T, H473R, Y477F, D480R, D480F, D480H,
D480A, D480S, D480N, D480Q, N485W, N485Y, N487H, N487W, N487F,
N487I, V488R, E493Q, M495Q, H528A, V533I, H572R, W577Y and D579F,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 1. In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: N31R, N31K, H46A,
H46R, D77K, D77H, C93R, D113N, D114R, D130A, D130H, D144M, D144K,
L212A, E220K, N234R, N234K, Q238C, V241K, V251K, D264Q, D264S,
D264K, Y272R, H273A, H273R, L280R, H281A, H281R, E294S, E294F,
E294G, E294K, V299K, V299H, V299F, D303R, I331Q, E325R, L335T,
E336P, I354W, I354F, I370A, Q409R, G416K, V418M, V418I, G420K,
D423S, D423K, D423N, D423R, D423T, D423G, D423I, D423K, G425R,
Q428W, N429R, N429K, E446Q, F448K, N457T, A462T, H473A, H473R,
Y477F, D480R, D480F, D480H, D480A, D480S, D480N, D480Q, N485W,
N485Y, N487H, N487W, N487F, N487I, V488R, E493Q, M495Q, H528A,
H528R, V533I, C550Q, H572A, H572R, W577Y and D579F, wherein the
numbering is relative of the amino acid sequence of SEQ ID NO:
1.
[0314] In some embodiments, a modified polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H46A, H46R, C93R,
Q238C, H273A, H273R, H281A, H281R, H281M, E446Q, H473A, H473R,
Y477F, H528A, H528R, H528K, C550Q, H572A and H572R, as well as one
or more amino acid substitutions selected from the group consisting
of N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H, D144M,
D144K, L212A, E220K, N234R, N234K, V241K, V251K, D264Q, D264S,
D264K, Y272R, L280R, E294S, E294F, E294G, E294K, V299K, V299H,
V299F, D303R, E325R, I331Q, L335T, E336P, I354W, I354F, I370A,
Q409R, G416K, V418M, V418I, G420K, D423S, D423K, D423N, D423R,
D423T, D423G, D423I, D423K, G425R, Q428W, N429R, N429K, F448K,
N457T, A462T, D480R, D480F, D480H, D480A, D480S, D480N, D480Q,
N485W, N485Y, N487H, N487W, N487F, N487I, V488R, E493Q, M495Q,
V533I, W577Y and D579F, wherein the numbering is relative of the
amino acid sequence of SEQ ID NO: 1. Optionally, the modified
polymerase having one or more amino acid mutations homologous to
one or more amino acid mutations of Bst DNA polymerase can further
include at least one amino acid substitution that is homologous to
an amino acid substitution in Bst DNA polymerase selected from the
group consisting of: H46A, H46R, H273A, H273R, H281A, H281R, E446Q,
H473A, H473R, Y477F, H528A, H528R, H572A, and H572R, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO:
1.
[0315] In some embodiments, a modified polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H46A, H46R, H273A,
H273R, H281A, H281R, E446Q, H473A, H473R, Y477F, H528A, H528R,
H572A, and H572R, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 1.
[0316] In some embodiments, a modified polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H46R, E446Q,
H572R, and D775R, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 1.
[0317] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having at least one amino
acid mutation that is homologous to amino acid mutation D775R for
Bst DNA polymerase, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 16.
[0318] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H341R, C388R,
Q533C, H568R, H576A, E741Q, H768R, Y772F, H823A, C845Q and H867R,
wherein the numbering is relative to the amino acid sequence of SEQ
ID NO: 16
[0319] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: N326R, N326K,
D372K, D372H, D408N, D409R, D425A, D425H, D439M, D439K, L507A,
E515K, N529R, N529K, V536K, V546K, D559Q, D559S, Y567R, L575R,
E589S, E589F, E589G, V594K, V594H, V594F, D598R, I626Q, L630T,
E631P, I649W, 1649F, I665A, Q704R, G711K, V713M, V713I, G715K,
D718S, D718K, D718N, D718R, D718T, D718G, D718I, D718K, G720R,
Q723W, N724R, N724K, F743K, N752T, A757T, D775R, D775F, D775H,
D775A, D775S, D775N, D775Q, N780W, N780Y, N782H, N782W, N782F,
N782I, E782Q, V783R, E788Q, M790Q, V828I, W872Y and D874F, wherein
the numbering is relative of the amino acid sequence of SEQ ID NO:
16.
[0320] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: N326R, N326K,
H341R, D372K, D372H, C388R, D408N, D409R, D425A, D425H, D439M,
D439K, L507A, E515K, N529R, N529K, V536K, V546K, Q533C, D559Q,
D559S, Y567R, H568R, L575R, H576A, E589S, E589F, E589G, V594K,
V594H, V594F, D598R, I626Q, L630T, E631P, I649W, I649F, I665A,
Q704R, G711K, V713M, V713I, G715K, D718S, D718K, D718N, D718R,
D718T, D718G, D718I, D718K, G720R, Q723W, N724R, N724K, E741Q,
F743K, N752T, A757T, H768R, Y772F, D775R, D775F, D775H, D775A,
D775S, D775N, D775Q, N780W, N780Y, N782H, N782W, N782F, N782I,
E782Q, V783R, E788Q, M790Q, H823A, V828I, C845Q, H867R, W872Y and
D874F, wherein the numbering is relative of the amino acid sequence
of SEQ ID NO: 16.
[0321] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H341A, H341R,
C388R, Q533C, H568A, H568R, H576A, H576R, E741Q, H768A, H768R,
Y772F, H823A, H823R, C845Q, H867A and H867R, as well as one or more
amino acid substitutions selected from the group consisting of:
N326R, N326K, D372K, D372H, D408N, D409R, D425A, D425H, D439M,
D439K, L507A, E515K, N529R, N529K, V536K, V546K, D559Q, D559S,
D559K, Y567R, L575R, E589S, E589F, E589G, E589K, V594K, V594H,
V594F, D598R, I626Q, L630T, E631P, I649W, I649F, I665A, Q704R,
G711K, V713M, V713I, G715K, D718S, D718K, D718N, D718R, D718T,
D718G, D718I, D718K, G720R, Q723W, N724R, N724K, F743K, N752T,
A757T, D775R, D775F, D775H, D775A, D775S, D775N, D775Q, N780W,
N780Y, N782H, N782W, N782F, N782I, E782Q, V783R, E788Q, M790Q,
V828I, W872Y and D874F, wherein the numbering is relative of the
amino acid sequence of SEQ ID NO: 16.
[0322] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H341A, H341R,
C388R, Q533C, H568A, H568R, H576A, H576R, E741Q, H768A, H768R,
Y772F, H823A, H823R, C845Q, H867A and H867R, wherein the numbering
is relative to the amino acid sequence of SEQ ID NO: 16.
[0323] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: H341A, H341R,
H568A, H568R, H576A, H576R, E741Q, H768A, H768R, Y772F, H823A,
H823R, H867A and H867R, wherein the numbering is relative to the
amino acid sequence of SEQ ID NO: 16.
[0324] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: N326R, N326K,
D372K, D372H, D408N, D409R, D425A, D425H, D439M, D439K, L507A,
E515K, N529R, N529K, V536K, V546K, D559Q, D559S, D559K, Y567R,
L575R, E589S, E589F, E589G, E589K, V594K, V594H, V594F, D598R,
I626Q, L630T, E631P, I649W, I649F, I665A, Q704R, G711K, V713M,
V713I, G715K, D718S, D718K, D718N, D718R, D718T, D718G, D718I,
D718K, G720R, Q723W, N724R, N724K, F743K, N752T, A757T, D775R,
D775F, D775H, D775A, D775S, D775N, D775Q, N780W, N780Y, N782H,
N782W, N782F, N782I, E782Q, V783R, E788Q, M790Q, V828I, W872Y and
D874F, wherein the numbering is relative of the amino acid sequence
of SEQ ID NO: 16. Optionally, the modified polymerase or any
biologically active fragment of a polymerase having one or more
amino acid mutations that are homologous to one or more amino acid
mutations for Bst DNA polymerase can further include at least one
amino acid substitution selected from the group consisting of:
H341A, H341R, H568A, H568R, H576A, H576R, H576M, E741Q, H768A,
H768R, Y772F, H823A, H823R, H823K, H867A and H867R, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 16.
In some embodiments, the modified polymerase or any biologically
active fragment of a polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Bst DNA polymerase includes any two, three, four, five or more
amino acid substitutions selected from each of these two groups of
amino acid substitutions.
[0325] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
of Taq DNA polymerase including, any one or more amino acid
mutations selected from the group consisting of: E471K, N485R,
R492K, D513K, A675K, D732R, S739W, V740R and E745Q, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 15.
In some embodiments, the modified polymerase or any biologically
active fragment of a polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Taq DNA polymerase includes any two, three, four, five, or more
amino acid substitutions.
[0326] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase according to the
disclosure can include any polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
of Klenow fragment DNA polymerase I including, any one or more
amino acid mutations selected from the group consisting of: E245K,
S259K, T266K, E290K, A448K, D505R, A512W, and E518Q, wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 18.
In some embodiments, the modified polymerase or any biologically
active fragment of a polymerase having one or more amino acid
mutations that are homologous to one or more amino acid mutations
for Klenow fragment DNA polymerase I includes any two, three, four,
five, or more amino acid substitutions.
[0327] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase having one or more
amino acid mutations that are homologous to an amino acid mutation
disclosed herein for Bst DNA polymerase, Taq DNA polymerase, or
Klenow fragment DNA polymerase I from E. coli can optionally
include at least one amino acid substitution designed to replace a
non-cysteine amino acid residue with a cysteine residue. For
example, Bst DNA polymerase (e.g., SEQ ID NO: 16), can optionally
include one or more amino acid substitutions selected from the
group consisting of: C388R, Q533C and C845Q, that can optionally be
included in any modified polymerase having one or more homologous
amino acid substitutions.
[0328] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase having one or more
amino acid mutations homologous to one or more amino acid mutations
of Bst DNA polymerase, Taq DNA polymerase or Klenow fragment of E.
coli DNA polymerase I can further include a deletion of the
methionine residue at position 1, or a substitution at position 1
with any other amino acid residue, wherein the numbering is
relative to the amino acid sequences of SEQ ID NO: 1, 20, 21, and
23.
[0329] In some embodiments, a modified polymerase or any
biologically active fragment of a polymerase having one or more
amino acid mutations homologous to one or more amino acid mutations
of Bst DNA polymerase, Taq DNA polymerase, or Klenow fragment DNA
polymerase I can exhibit a change in any one or more parameters
selected from the group consisting of: buffering capacity,
dissociation time constant, off-rate, 100Q17 value and 200Q17
value, relative to the reference polymerase. Optionally, the change
is observed by comparing the performance of a reference and the
modified polymerase in an ion-based sequencing reaction.
Optionally, the reference polymerase, the modified polymerase, or
both the reference and modified polymerases can further include one
or more amino acid mutations that decrease or eliminate exonuclease
activity.
[0330] In some embodiments, the disclosure relates generally to
nucleotide sequences encoding proteins comprising any of the
specific amino acid sequences disclosed herein. For example, in
some embodiments, the disclosure relates generally to nucleotide
sequences encoding proteins having, or comprising, the amino acid
sequences of SEQ ID NO: 1, 2, 3, 4, 20, 21, 23, 25, or any other of
the specific polymerases (including any modified and reference
polymerases) disclosed herein. In some embodiments, the disclosure
relates generally to any nucleotide sequence encoding an amino acid
sequence that is at least 80%, at least 85%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, or at least 99% identical to
the amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 20, 21, 23 or 25.
The person of ordinary skill will be readily able to determine
nucleotide sequences that encode any of the amino acid sequences of
the disclosure based on the known correspondence between the
nucleotide sequence and a corresponding protein sequence.
[0331] In some embodiments, the disclosure relates to a nucleic
acid sequence encoding a modified polymerase that is an isolated
variant of a Bst DNA polymerase having or comprising the amino acid
sequence of SEQ ID NO: 2, wherein the variant comprises an amino
acid sequence that is at least 80%, at least 85%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, or at least 99% identical
to SEQ ID NO: 2.
[0332] For example, the disclosure relates generally to a nucleic
acid sequence having, or comprising the nucleic acid sequence of
SEQ ID NO: 17:
TABLE-US-00017 (SEQ ID NO: 17)
ATGGCAAAAATGGCATTTACCCTGGCAGATCGTGTTACCGAAGAAATGCTGGCAGATAAAGCAGCACTGGTTGT-
TGAAG
TTGTGGAAGAAAACTATCATGATGCACCGATTGTTGGTATTGCCGTTGTTAATGAACGCGGTCGTTTTTTTCTG-
CGTCC
GGAAACCGCACTGGCAGATCCGCAGTTTGTTGCATGGCTGGGTGATGAAACCAAAAAGAAAAGCATGTTCGACA-
GCAAA
CGTGCAGCAGTTGCACTGAAATGGAAAGGTATTGAACTGTGCGGTGTGTCATTTGATCTGCTGCTGGCAGCATA-
TCTGC
TGGATCCGGCACAGGGTGTTGATGATGTTGCAGCAGCAGCAAAAATGAAACAGTATGAAGCAGTTCGTCCGGAT-
GAAGC
AGTTTATGGTAAAGGTGCAAAACGTGCAGTTCCGGATGAACCGGTTCTGGCAGAACATCTGGTTCGTAAAGCAG-
CAGCA
ATTTGGGAACTGGAACGTCCGTTTCTGGATGAACTGCGTCGTAATGAACAGGATCGTCTGCTGGTTGAACTGGA-
ACAGC
CGCTGAGCAGCATTCTGGCAGAAATGGAATTTGCCGGTGTTAAAGTTGATACCAAACGTCTGGAACAAATGGGT-
AAAGA
ACTGGCCGAACAACTGGGCACCGTTGAACAGCGTATTTATGAACTGGCAGGCCAAGAATTTAACATTAATAGCC-
CGAAA
CAGCTGGGCGTTATCCTGTTTGAAAAACTGCAGCTGCCGGTTCTGAAAAAAACCAAAACCGGTTATAGCACCAG-
CGCAG
ATGTTCTGGAAAAACTGGCACCGTATCATGAAATTGTGGAAAACATTCTGCACTATCGTCAGCTGGGTAAACTG-
CAGAG
CACCTATATTGAAGGTCTGCTGAAAGTTGTGCGTCCGGATACCAAAAAAGTGCATACCATTTTTAACCAGGCAC-
TGACC
CAGACCGGTCGTCTGAGCAGCACCGAACCGAATCTGCAGAATATTCCGATTCGTCTGGAAGAAGGTCGTAAAAT-
TCGTC
AGGCATTTGTTCCGAGCGAAAGCGATTGGCTGATTTTTGCAGCAGATTATAGCCAGATTGAACTGCGTGTTCTG-
GCACA
TATTGCCGAAGATGATAATCTGATGGAAGCATTTCGTCGCGATCTGGATATTCATACCAAAACCGCCATGGATA-
TTTTT
CAGGTTAGCGAAGATGAAGTGACCCCGAATATGCGTCGTCAGGCAAAAGCAGTTAATTTTGGTATTGTGTATGG-
CATCA
GCGATTATGGTCTGGCACAGAATCTGAATATTAGCCGTAAAGAAGCAGCCGAATTTATCGAACGTTACTTTCAG-
AGCTT
TCCGGGTGTTAAACGCTATATGGAAAACATTGTCCAAGAAGCCAAACAGAAAGGTTATGTTACCACCCTGCTGC-
ATCGT
CGTCGTTATCTGCCGCGTATTACCAGCCGTAACTTTAATGTTCGTAGCTTTGCAGAACGCATGGCAATGAATAC-
CCCGA
TTCAGGGTAGCGCAGCAGATATTATCAAAAAAGCCATGATCGATCTGAACGCACGTCTGAAAGAAGAACGTCTG-
CAGGC
ACATTTACTGCTGCAGGTTCATGATGAACTGATTCTGGAAGCACCGAAAGAAGAAATGGAACGTCTTTGTCGTC-
TGGTT
CCGGAAGTTATGGAACAGGCAGTTACCCTGCGTGTTCCGCTGAAAGTTGATTATCGTTATGGTAGCACCTGGTA-
TGATG CCAAAtaa
[0333] SEQ ID NO: 17 includes a nucleic acid sequence that encodes
an exemplary modified polymerase that has the amino acid sequence
of SEQ ID NO: 2 and further includes the mutation D775R. It be
readily apparent to the skilled artisan how to modify the nucleic
acid sequence of SEQ ID NO: 17 to generate nucleic acid sequences
encoding any of the other exemplary reference or modified
polymerases disclosed herein.
[0334] In some embodiments, the disclosure relates to a nucleic
acid sequence that is at least 50%, 60%, 70%, 80%, 90%, 95% or 99%
identical to the nucleic acid sequence of SEQ ID NO: 17. In some
embodiments, the nucleic acid sequence encodes a polymerase having
the amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 21 or 25. In some
embodiments, the nucleic acid sequence encodes a polymerase having
the amino acid sequence of SEQ ID NO: 2 and further including any
one or more mutations selected from the group consisting of: N31R,
N31K, H46R, D77K, D77H, C93R, D113N, D114R, D130A, D130H, D144M,
D144K, L212A, E220K, N234R, N234K, Q238C, V241K, V251K, D264Q,
D264S, Y272R, H273R, L280R, H281A, H281M, E294S, E294F, E294G,
V299K, V299H, V299F, D303R, I331Q, E325R, L335T, E336P, I354W,
I354F, I370A, Q409R, G416K, V418M, V418I, G420K, D423S, D423K,
D423N, D423R, D423T, D423G, D423I, D423K, G425R, Q428W, N429R,
N429K, E446Q, F448K, N457T, A462T, H473R, Y477F, D480R, D480F,
D480H, D480A, D480S, D480N, D480Q, N485W, N485Y, N487H, N487W,
N487F, N487I, V488R, E493Q, M495Q, H528A, H528K, V533I, C550Q,
H572R, W577Y and D579F, wherein the numbering is relative of the
amino acid sequence of SEQ ID NO: 2.
[0335] In some embodiments, the nucleic acid sequence encodes a
polymerase having the amino acid sequence of SEQ ID NO: 16 and
further including any one or more mutations selected from the group
consisting of: N326R, N326K, H341R, D372K, D372H, C388R, D408N,
D409R, D425A, D425H, D439M, D439K, L507A, E515K, N529R, N529K,
V536K, V546K, Q533C, D559Q, D559S, Y567R, H568R, L575R, H576A,
H576M, E589S, E589F, E589G, V594K, V594H, V594F, D598R, I626Q,
L630T, E631P, I649W, I649F, I665A, Q704R, G711K, V713M, V713I,
G715K, D718S, D718K, D718N, D718R, D718T, D718G, D718I, D718K,
G720R, Q723W, N724R, N724K, E741Q, F743K, N752T, A757T, H768R,
Y772F, D775R, D775F, D775H, D775A, D775S, D775N, D775Q, N780W,
N780Y, N782H, N782W, N782F, N782I, E782Q, V783R, E788Q, M790Q,
H823A, H823K, V828I, C845Q, H867R, W872Y and D874F, wherein the
numbering is relative of the amino acid sequence of SEQ ID NO:
16.
[0336] In some embodiments, the nucleic acid sequence encodes a
polymerase having the amino acid sequence of SEQ ID NO: 15 and
further including any one or more mutations selected from the group
consisting of: E471K, N485R, R492K, D513K, A675K, D732R, S739W,
V740R and E745Q, wherein the numbering is relative of the amino
acid sequence of SEQ ID NO: 15.
[0337] In some embodiments, the nucleic acid sequence encodes a
polymerase having the amino acid sequence of SEQ ID NO: 18 and
further including any one or more mutations selected from the group
consisting of: E245K, S259R, T266K, E290K, A448K, D505R, A512W,
R513R and E518Q, wherein the numbering is relative of the amino
acid sequence of SEQ ID NO: 18.
[0338] In some embodiments, the nucleotide sequence can be designed
employing principles of codon preference to increase the levels of
protein expression in a given host organism.
[0339] In some embodiments, in order to slow the rate of template
dissociation from the polymerase (and increase its processivity),
the modified polymerase or any biologically active fragment of a
polymerase can include one or more amino acid mutations that cause
the modified to dissociate more slowly from the nucleic acid
template. Such mutations can have the additional effect of
increasing the read length (or the error-free read length) of the
modified polymerase relative to its unmodified counterpart.
[0340] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase can include one or
more introduced cysteines. Such introduced cysteines can serve as
sites for attachment of the polymerase to another moiety,
substrate, or surface. In some embodiments, the cysteine is
introduced at least one position selected from the group consisting
of: Q238 and Q248, wherein the numbering is relative to the amino
acid sequence of SEQ ID NO: 2. For example, the polymerase can
include one or both of the following amino acid substitutions:
Q238C and Q248C.
[0341] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase has or includes the
amino acid sequence of SEQ ID NO: 2 and further includes
replacement of the cysteine residues C93 and C550 with other amino
acid residues that do not include a sulfhydryl side chain. For
example, the polymerase can include one or both of the following
amino acid substitutions: C93R and C550Q.
[0342] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase has (or comprises) the
amino acid sequence of SEQ ID NO: 2, and further includes the amino
acid substitutions C93R, C550Q and Q238C, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 2. In some
embodiments, the introduced cysteine residue (Q238C) is linked to
the bridging moiety, either directly or through a linking moiety.
The bridging moiety can include an avidin. The linking moiety (when
present) can include a biotin. In some embodiments, the introduced
cysteine residue at position 238 can be biotinylated.
[0343] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase has (or comprises) the
amino acid sequence of SEQ ID NO: 2, and further includes the amino
acid substitutions C93R, C550Q and Q248C, wherein the numbering is
relative to the amino acid sequence of SEQ ID NO: 2. In some
embodiments, the introduced cysteine residue (Q248C) is linked to
the bridging moiety, either directly or through a linking moiety.
The bridging moiety can include an avidin. The linking moiety (when
present) can include a biotin. In some embodiments, the introduced
cysteine residue at position 248 can be biotinylated.
[0344] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase has or includes the
amino acid sequence of SEQ ID NO: 2, and further includes the
mutations C93R and C550Q, as well as the cysteine replacement
substitution Q238C.
[0345] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase has or includes the
amino acid sequence of SEQ ID NO: 2, and further includes the
mutations C93R and C550Q, as well as the cysteine replacement
substitution Q248C.
[0346] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase can include one or
more biotin moieties. As used herein, the terms "biotin" and
"biotin moiety" and their variants comprise biotin
(cis-hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-pentanoic acid) and
any derivatives and analogs thereof, including biotin-like
compounds. Such compounds include, for example,
biotin-.epsilon.-N-lysine, biocytin hydrazide, amino or sulfhydryl
derivatives of 2-iminobiotin and biotinyl-.epsilon.-aminocaproic
acid-N-hydroxysuccinimide ester, sulfosuccinimideiminobiotin,
biotinbromoacetylhydrazide, p-diazobenzoyl biocytin,
3-(N-maleimidopropionyl)biocytin, and the like, as well as any
biotin variants that can specifically bind to an avidin moiety. The
terms "avidin" and "avidin moiety" and their variants, as used
herein, comprise the native egg-white glycoprotein avidin, as well
as any derivatives, analogs and other non-native forms of avidin,
which can specifically bind to biotin moieties. In some
embodiments, the avidin moiety can comprise deglycosylated forms of
avidin, bacterial streptavidins produced by selected strains of
Streptomyces, e.g., Streptomyces avidinii, to truncated
streptavidins, and to recombinant avidin and streptavidin as well
as to derivatives of native, deglycosylated and recombinant avidin
and of native, recombinant and truncated streptavidin, for example,
N-acyl avidins, e.g., N-acetyl, N-phthalyl and N-succinyl avidin,
and the commercial products ExtrAvidin.RTM., Captavidin.RTM.,
Neutravidin.RTM. and Neutralite Avidin.RTM.. All forms of
avidin-type molecules, including both native and recombinant avidin
and streptavidin as well as derivatized molecules, e.g.
nonglycosylated avidins, N-acyl avidins and truncated
streptavidins, are encompassed within the terms "avidin" and
"avidin moiety". Typically, but not necessarily, avidin exists as a
tetrameric protein, wherein each of the four tetramers is capable
of binding at least one biotin moiety. As used herein, the term
"biotin-avidin bond" and its variants refers to a specific linkage
formed between a biotin moiety and an avidin moiety. Typically, a
biotin moiety can bind with high affinity to an avidin moiety, with
a dissociation constant K.sub.d typically in the order of
10.sup.-14 to 10.sup.-15 mol/L. Typically, such binding occurs via
non-covalent interactions.
[0347] In some embodiments, the modified polymerase or any
biologically active fragment of a polymerase can include one or
more modified or substituted amino acids relative to the unmodified
or reference polymerase, and can further include a biotin moiety
that is linked to at least one of the one or more modified or
substituted amino acids. The biotin moiety can be linked to the
modified polymerase using any suitable linking method. In some
embodiments, the modified polymerase includes one or more cysteine
replacement substitutions, and the linking moiety includes a biotin
moiety that is linked to at least one of the one or more cysteine
replacement substitutions.
[0348] In some embodiments, the modified polymerase is a
biotinylated polymerase. The term "biotinylated" and its variants,
as used herein, refer to any covalent or non-covalent adduct of
biotin with other moieties such as biomolecules, e.g., proteins,
nucleic acids (including DNA, RNA, DNA/RNA chimeric molecules,
nucleic acid analogs and peptide nucleic acids), proteins
(including enzymes, peptides and antibodies), carbohydrates,
lipids, etc.
[0349] In some embodiments, the disclosure also relates generally
to compositions (as well as related methods, kits and apparatuses)
comprising a modified polymerase including at least one amino acid
modification relative to a reference polymerase, wherein the
modified polymerase has a slower rate of dissociation from a
nucleic acid template relative to the reference polymerase. In some
embodiments, the rate of dissociation can be modified such that the
rate of dissociation increases binding affinity, for example in the
presence of neutral osmolytes such as betaine, trimethylamine
N-oxide, trehalose, sucrose, ethylene glycols, and the like.
[0350] As used herein, the terms "dissociation rate" or "off-rate"
refer to the rate of dissociation of a given polymerase from a
given template nucleic acid. The dissociation rate (off-rate) can
vary with reaction conditions including temperature, salt
concentrations, relative concentrations of polymerase and template,
and the like. In some embodiments, the dissociation rate can be
estimated by measuring the decay in total amount of polymerase
bound to a template nucleic acid under given reaction conditions.
Such assays can optionally be performed using conditions where
re-binding of the polymerase to the template after dissociation of
the polymerase from the template is prevented. For example, in a
typical dissociation binding experiment to measure the "off rate"
for polymerase dissociating from the nucleic acid template, the
polymerase and nucleic acid template are initially allowed to bind,
optionally to equilibrium. Optionally, the polymerase can be
labeled using any suitable label (e.g., radioactive or fluorescent
labels). At this point, further binding of the polymerase to
template can optionally be blocked to simplify measurement of the
rate of dissociation from the template. Such blocking can be
performed using any suitable method. For example, in embodiments
where the template is fixed to a surface and the polymerase is
labeled, blocking can be achieved by (1) removing the buffer
including labeled polymerase and replacing with buffer that does
not include labeled polymerase, or (2) adding to the reaction
mixture a very high concentration of unlabeled polymerase; or (3)
diluting the reaction mixture by a large factor (e.g., at least 20-
or 100-fold), particularly when the initial concentration of
labeled polymerase is low. Following such blocking, the total
amount of polymerase bound to template can be measured at various
times after such blocking to determine how rapidly the polymerase
dissociates from the template. The amount of polymerase bound to
template can be mapped (Y axis) against time (X axis). In some
embodiments, the resulting curve approximates a single exponential
decay curve. FIG. 1 depicts a dissociation rate curve from a
typical experiment.
[0351] In some embodiments, analysis of binding experiments can be
based on a simple model derived from the law of mass action. This
model assumes that binding is reversible and allows calculation of
koff, the dissociation rate constant. (In the following analysis,
the polymerase and nucleic acid template are referred to as
"ligand" and "receptor"):
##STR00001##
[0352] In some embodiments, binding occurs when the polymerase and
template nucleic acid collide due to diffusion, and when the
collision has the correct orientation and enough energy. The rate
of association is:
Number of binding events per unit of
time=[Ligand][Receptor]kon.
[0353] Once binding has occurred, the ligand and receptor can
remain bound together for a random amount of time. The probability
of dissociation is the same at every instant of time.
[0354] The rate of dissociation is:
ti Number of dissociation events per unit
time=[ligandreceptor]koff.
[0355] Equilibrium is reached when the rate at which new ligand
receptor complexes are formed equals the rate at which the ligand
receptor complexes dissociate. At equilibrium:
[Ligand][Receptor]k.sub.on=[LigandReceptor]k.sub.off
[0356] This equation can be rearranged to define the equilibrium
dissociation constant Kd.
[ Ligand ] [ Receptor ] [ Ligand Receptor ] = k off k on = K d
##EQU00001##
[0357] If [Ligand] is set as equal to Kd in the equation above, the
Kd terms cancel out, and
[Receptor]/[LigandReceptor]=1,
[0358] so [Receptor] equals [LigandReceptor]. Since all the
receptors are either free or bound to ligand, this means that half
the receptors are free and half are bound to ligand. In other
words, when the concentration of ligand equals the Kd, half the
receptors will be occupied at equilibrium. If the receptors have a
high affinity for the ligand, the Kd will be low, as it will take a
low concentration of ligand to bind half the receptors.
[0359] In such a model, Kd, the equilibrium dissociation constant,
is different from koff, the dissociation rate constant (also
referred to herein as the "dissociation time constant").
[0360] In one exemplary assay, as described in the Examples herein,
the dissociation time constant of a given polymerase can be
measured by incubating the polymerase with a labeled
oligonucleotide including a fluorescent label (referred to herein
as "oligonucleotide 221") under defined conditions. When the
oligonucleotide is not bound by polymerase, the fluorescence of the
fluorescent label on the oligonucleotide is quenched; binding of
the polymerase to the oligonucleotide results in de-quencing of the
oligonucleotide label and a resulting increase in fluorescence.
Blocking is initiated by adding an unlabeled competitor
oligonucleotide to the reaction mixture; as polymerase dissociates
from the fluorescently labeled oligonucleotide 221, the competitor
oligonucleotide hybridizes to oligonucleotide 221 and prevents
further binding of the polymerase. Fluorescence is monitored over
time. Fluorescence of the reaction mixture is measured at various
time points following addition of the competitor oligonucleotide.
The observed fluorescence (in RFU or relative fluorescence units)
is graphed (Y axis) against time (X axis). To compare the
dissociation rates of two or more different enzymes (e.g.,
reference and modified polymerases), each enzyme can be employed in
a parallel and separate reaction in which the fluorescence of each
reaction mixture is measured at various time points, following
which the dissociation rates for each enzyme can be calculated
using any suitable method, and compared. In the Examples provided
herein, the dissociation rates are calculated according to the
following formula:
Y=(Y0-Plateau)*exp.sup.(-K*X)+Plateau
Where:
[0361] Y0 is the Y value when X (time) is zero. It is expressed in
the same units as Y,
[0362] Plateau is the Y value at infinite times, expressed in the
same units as Y.
[0363] K is the rate constant, expressed in reciprocal of the X
axis time units. If X is in minutes, then K is expressed in inverse
minutes.
[0364] Tau is the time constant, expressed in the same units as the
X axis. It is computed as the reciprocal of K.
[0365] Half-life is in the time units of the X axis. It is computed
as ln(2)/K.
[0366] Span, i.e., (Y0-Plateau), is the difference between Y0 and
Plateau, expressed in the same units as your Y values.
[0367] FIG. 2 depicts the results of an exemplary assay performed
as described in the Examples, where the dissociation time constants
for various exemplary Bst mutants are measured at varying salt
concentrations and compared.
[0368] In some embodiments, the disclosure relates generally to a
method for incorporating at least one nucleotide into a primer,
comprising: contacting a nucleic acid complex including a template
nucleic acid with primer and a modified polymerase in the presence
of one or more nucleotides, and incorporating at least one of the
one or more nucleotides into the primer in a template-dependent
fashion using said modified polymerase.
[0369] Methods for nucleotide incorporation are well known in the
art and typically comprise use of a polymerase reaction mixture in
which the polymerase is contacted with the template nucleic acid
under nucleotide incorporation conditions. When the nucleotide
incorporation reaction comprises polymerization of nucleotides onto
the end of a primer, the process is typically referred to as
"primer extension." Typically but not necessarily such nucleotide
incorporation occurs in a template-dependent fashion. Primer
extension and other nucleotide incorporation assays are typically
performed by contacting the template nucleic acid with a polymerase
in the presence of nucleotides in an aqueous solution under
nucleotide incorporation conditions. In some embodiments, the
nucleotide incorporation reaction can include a primer, which can
optionally be hybridized to the template to form a primer-template
duplex. Typical nucleotide incorporation conditions are achieved
once the template, polymerase, nucleotides and optionally primer
are mixed with each other in a suitable aqueous formulation,
thereby forming a nucleotide incorporation reaction mixture (or
primer extension mixture). The aqueous formulation can optionally
include divalent cations and/or salts, particularly Mg.sup.++
and/or Ca.sup.++ ions. The aqueous formulation can optionally
include divalent anions and/or salts, particularly SO.sub.4.sup.2-.
Typical nucleotide incorporation conditions have included well
known parameters for time, temperature, pH, reagents, buffers,
reagents, salts, co-factors, nucleotides, target DNA, primer DNA,
enzymes such as nucleic acid-dependent polymerase, amounts and/or
ratios of the components in the reactions, and the like. The
reagents or buffers can include a source of monovalent ions, such
as KCl, K-acetate, NH.sub.4-acetate, K-glutamate, NH.sub.4Cl, or
ammonium sulfate. The reagents or buffers can include a source of
divalent ions, such as Mg.sup.2+ and/or Mn.sup.2+, MgCl.sub.2, or
Mg-acetate. In some embodiments, the reagents or buffers can
include a source of detergent such as Triton and/or Tween. Most
polymerases exhibit some levels of nucleotide incorporation
activity over pH range of about 5.0 to about 9.5, more typically
between about pH 7 and about pH 9, sometimes between about pH 6 to
about pH 8, and sometimes between 7 and 8. The buffer can include
chelating agents such as EDTA and EGTA, and the like. Although in
some embodiments, nucleotide incorporation reactions may include
buffering agents, such as Tris, Tricine, HEPES, MOPS, ACES, or MES,
which can provide a pH range of about 5.0 to about 9.5, such
buffering agents can optionally be reduced or eliminated when
performing ion-based reactions requiring detection of ion
byproducts. Methods of performing nucleic acid synthesis are well
known and extensively practiced in the art and references teaching
a wide range of nucleic acid synthesis techniques are readily
available. Some exemplary teachings regarding the performance of
nucleic acid synthesis (including, for example, template-dependent
nucleotide incorporation, as well as primer extension methods) can
be found, for example, in Kim et al., Nature 376: 612-616 (2002);
Ichida et al., Nucleic Acids Res. 33: 5214-5222 (2005); Pandey et
al., European Journal of Biochemistry, 214:59-65 (1993); Blanco et
al., J. Biol. Chem. 268: 16763-16770 (1993); U.S. patent
application Ser. No. 12/002,781, now published as U.S. Patent
Publication No. 2009/0026082; U.S. patent application Ser. No.
12/474,897, now published as U.S. Patent Publication No.
2010/0137143; and U.S. patent application Ser. No. 12/492,844, now
published as U.S. Patent Publication No. 2010/0282617; U.S. patent
application Ser. No. 12/748,359, now published as U.S. Patent
Publication No. 20110014612. Given the ample teaching of primer
extension and other nucleotide incorporation reactions in the art,
suitable reaction conditions for using the modified polymerases of
the disclosure to perform nucleotide incorporation will be readily
apparent to the skilled artisan.
[0370] In some embodiments, the disclosure relates generally to
reagents (e.g., buffer compositions) and kits useful for
performance of nucleotide polymerization reactions using
polymerases, including any of the exemplary polymerases described
here. The nucleotide polymerization reactions can include without
limitation nucleotide incorporation reactions (including both
template-dependent and template-independent nucleotide
incorporation reactions) as well as primer extension reactions). In
some embodiments, the buffer composition can include any one or
more of the following: a monovalent metal salt, a divalent metal
salt, a divalent anion, and a detergent. For example, the buffer
composition can include a potassium or sodium salt. In some
embodiments, the buffer composition can include a manganese or
magnesium salt. In some embodiments, the buffer composition can
include a sulfate such as potassium sulfate and/or magnesium
sulfate. In some embodiments, the buffer composition can include a
detergent selected from the group consisting of: Triton and
Tween.
[0371] In some embodiments, the buffer composition can include at
least one potassium salt, at least one manganese salt, and Triton
X-100 (Pierce Biochemicals). The salt can optionally be a chloride
salt or a sulfate salt.
[0372] In some embodiments, the buffer composition can include at
least one potassium salt, at least one magnesium salt, and Triton
X-100 (Pierce Biochemicals). The salt can optionally be a chloride
salt or a sulfate salt.
[0373] In some embodiments, the buffer composition has a pH of
about 7.3 to about 8.0, typically about 7.4 to about 7.9.
[0374] In some embodiments, the buffer composition includes a
potassium salt at concentrations of between 5-250 mM, typically
12-200 mM, and even more typically 25-125 mM (depending on
divalent).
[0375] In some embodiments, the buffer composition includes
magnesium or manganese salt at a concentration of between 1 mM and
20 mM, particularly 6-15 mM.
[0376] In some embodiments, the buffer composition includes a
sulfate at a concentration of between 1 mM and 100 mM, particularly
5-50 mM.
[0377] In some embodiments, the buffer composition includes a
detergent (e.g., Triton X-100 or Tween-20) at a concentration of
between 0.005% to 1%, typically between 0.01-0.1%.
[0378] In some embodiments, the disclosed modified polymerase
compositions, (as well as related methods, systems, apparatuses and
kits) can be used to obtain sequence information from a nucleic
acid molecule. Many methods of obtaining sequence information from
a nucleic acid molecule are known in the art, and it will be
readily appreciated that all such methods are within the scope of
the present disclosure. Suitable methods of sequencing using the
disclosed modified polymerases include without limitation: Sanger
sequencing, ligation-based sequencing (also known as sequencing by
hybridization) and sequencing by synthesis. Sequencing-by-synthesis
methods typically involve template-dependent nucleic acid synthesis
(e.g., using a primer that is hybridized to a template nucleic acid
or a self-priming template, as will be appreciated by those of
ordinary skill), based on the sequence of a template nucleic acid.
That is, the sequence of the newly synthesized nucleic acid strand
is typically complementary to the sequence of the template nucleic
acid and therefore knowledge of the order and identity of
nucleotide incorporation into the synthesized strand can provide
information about the sequence of the template nucleic acid strand.
Sequencing by synthesis using the modified polymerases of the
disclosure will typically involve detecting the order and identity
of nucleotide incorporation when nucleotides are polymerized in a
template-dependent fashion by the modified polymerase. Some
exemplary methods of sequence-by-synthesis using labeled
nucleotides include single molecule sequencing (see, e.g., U.S.
Pat. No. 7,329,492 and U.S. Pat. No. 7,033,764), which typically
involve the use of labeled nucleotides to detecting nucleotide
incorporation. In some embodiments, the disclosed polymerase
compositions (and related methods, kits, systems and apparatuses)
can be used to obtain sequence information for whole genome
sequencing, amplicon sequencing, targeted re-sequencing, single
molecule sequencing, multiplex or barcoded sequencing, and paired
end sequencing applications.
[0379] In some embodiments, the disclosed modified polymerase
compositions as well as related methods, systems, apparatuses and
kits, can be used to amplify nucleic acid molecules. In some
embodiments, a nucleic acid molecule can be amplified using a
modified polymerase for example by pyrosequencing, polymerase chain
reaction, emulsion polymerase chain reaction or bridge polymerase
chain reaction.
[0380] In some embodiments, the disclosed modified polymerase
compositions (as well as related methods, systems, apparatuses and
kits), can be used to generate nucleic acid libraries. In some
embodiments, the disclosed modified polymerase compositions can be
used to generate nucleic acid libraries for a variety of downstream
processes. Many methods for generating nucleic acid libraries are
known in the art, and it will be readily appreciated that all such
methods are within the scope of the present disclosure. Suitable
methods include, without limitation, nucleic acid libraries
generated using emulsion PCR, bridge PCR, PCR, qPCR, RT-PCR, and
other forms of nucleic acid amplification dependent on
polymerization. In some embodiments, the methods can include
template-dependent nucleic acid amplification. In some embodiments,
the methods can include a primer:template duplex or a nucleic acid
template to which the modified polymerase can perform nucleotide
incorporation. In some embodiments, the nucleic acid can include a
single stranded nucleic acid with a secondary structure such as a
hair-pin or stem-loop that can provide a single-stranded overhang
to which the modified polymerase can incorporate a nucleotide
during polymerization. In some embodiments, methods for generating
nucleic acid libraries using one or more of modified polymerases
according to the disclosure can include the generation of a nucleic
acid library of 50, 100, 200, 300, 400, 500, 600 or more base pairs
in length. In some embodiments, the nucleic acid template to which
the modified polymerase can perform nucleotide incorporation can be
attached, linked or bound to a support, such as a solid support. In
some embodiments, the support can include a planar support such as
slide. In some embodiments, the support can include an particle,
such as an Ion Sphere.TM. particle.
[0381] In some embodiments, the disclosure relates generally to a
method for generating a nucleic acid library comprising contacting
a nucleic acid template with a modified polymerase and one or more
dNTPs under polymerizing conditions; thereby incorporating one or
more dNTPs into the nucleic acid template to generate a nucleic
acid library. In some embodiments, the method can further include
generating a nucleic acid library or sequencing a nucleic acid
library in the presence of a high ionic strength solution. In some
embodiments, the disclosure relates generally to a modified
polymerase that retains polymerase activity in the presence of high
ionic strength solution. In some embodiments, the high ionic
strength solution can be about 50, 75, 100, 150, 200, 250, 300,
400, 500, 750 mM or greater salt. In some embodiments, the high
ionic strength solution can be about 175 mM to about 300 mM salt.
In some embodiments, the high ionic strength solution can be about
200 mM to about 275 mM salt. In some embodiments, the high ionic
strength solution can be about 225 mM to about 250 mM salt. In some
embodiments, the salt can include a potassium and/or sodium salt.
In some embodiments, the ionic strength solution can further
include a sulfate. In some embodiments, a modified polymerase is
capable of amplifying (and/or sequencing) a nucleic acid molecule
in the presence of a high ionic strength solution to a greater
capacity (for example as measured by accuracy) than a reference
polymerase lacking one or more of the same mutations (or homologous
mutations) under identical conditions. In some embodiments, a
modified polymerase is capable of amplifying (and/or sequencing) a
nucleic acid molecule in the presence of a high ionic strength
solution to a greater capacity (for example as measured by
accuracy) than a reference polymerase lacking one or more of the
mutations (or homologous mutations) under standard ionic strength
conditions (i.e., lower than the higher ionic strength solution,
for example 20 mM salt).
[0382] Optionally, the method further includes repeating the
addition of one or more dNTPs under polymerizing conditions to
incorporate a plurality of dNTPs into the nucleic acid template to
generate the nucleic acid library.
[0383] In some embodiments, the method can further include
detecting a nucleotide incorporation by-product during the
polymerization. In some embodiments, the nucleotide incorporation
by-product can include a hydrogen ion.
[0384] In some embodiments, the method further includes determining
the identity of the incorporated dNTPs in the nucleic acid library.
In some embodiments, the method further includes determining the
number of incorporated nucleotides in the nucleic acid library. In
some embodiments, the detecting can further include sequencing the
nucleic acid library.
[0385] In some embodiments, the disclosed modified polymerase
compositions, (as well as related methods, systems, apparatuses and
kits) can be used to detect nucleotide incorporation through the
generation of by-product formation during the nucleotide
incorporation event. Many methods of detecting nucleotide
incorporation by-products are known in the art, and it will be
readily appreciated that all such methods are within the scope of
the present disclosure. Suitable methods of nucleotide by-product
detection include without limitation, detection of hydrogen ion,
inorganic phosphate, inorganic pyrophosphate, and the like. Several
of these by-product detection methods typically involve
template-dependent nucleotide incorporation.
[0386] In some embodiments, the modified polymerases can be used to
perform label-free nucleic acid sequencing, and in particular,
ion-based nucleic acid sequencing. The concept of label-free
nucleic acid sequencing, including ion-based nucleic acid
sequencing, including the following references that are
incorporated by reference: Rothberg et al, U.S. Patent Publication
Nos. 2009/0026082, 2009/0127589, 2010/0301398, 2010/0300895,
2010/0300559, 2010/0197507, and 2010/0137143, which are
incorporated by reference herein in their entireties. Briefly, in
such nucleic acid sequencing applications, nucleotide
incorporations are determined by detecting the presence of natural
byproducts of polymerase-catalyzed nucleic acid synthesis
reactions, including hydrogen ions, polyphosphates, PPi, and Pi
(e.g., in the presence of pyrophosphatase).
[0387] In a typical embodiment of ion-based nucleic acid
sequencing, nucleotide incorporations are detected by detecting the
presence and/or concentration of hydrogen ions generated by
polymerase-catalyzed nucleic acid synthesis reactions, including
for example primer extension reactions. In one embodiment,
templates that are operably bound to a primer and a polymerase and
that are situated within reaction chambers (such as the microwells
disclosed in Rothberg et al, cited above), are subjected to
repeated cycles of polymerase-catalyzed nucleotide addition to the
primer ("adding step") followed by washing ("washing step"). In
some embodiments, such templates may be attached as clonal
populations to a solid support, such as a microparticle, bead, or
the like, and said clonal populations are loaded into reaction
chambers. As used herein, "operably bound" means that a primer is
annealed to a template so that the primer can be extended by a
polymerase and that a polymerase is bound to such primer-template
duplex, or in close proximity thereof so that primer extension
takes place whenever nucleotides are supplied.
[0388] In each adding step of the cycle, the polymerase extends the
primer by incorporating added nucleotide in a template-dependent
fashion, such that the nucleotide is incorporated only if the next
base in the template is the complement of the added nucleotide. If
there is one complementary base, there is one incorporation, if
two, there are two incorporations, if three, there are three
incorporations, and so on. With each such incorporation there is a
hydrogen ion released, and collectively a population of templates
releasing hydrogen ions changes the local pH of the reaction
chamber. In some embodiments, the production of hydrogen ions is
proportional to (e.g., monotonically related) to the number of
contiguous complementary bases in the template (as well as the
total number of template molecules with primer and polymerase that
participate in an extension reaction). Thus, when there are a
number of contiguous identical complementary bases in the template
(i.e. a homopolymer region), the number of hydrogen ions generated,
and therefore the magnitude of the local pH change, is proportional
to the number of contiguous identical complementary bases. If the
next base in the template is not complementary to the added
nucleotide, then no incorporation occurs and no hydrogen ion is
released. In some embodiments, after each step of adding a
nucleotide, a washing step is performed, in which an unbuffered
wash solution at a predetermined pH is used to remove the
nucleotide of the previous step in order to prevent
misincorporations in later cycles. In some embodiments, after each
step of adding a nucleotide, an additional step may be performed
wherein the reaction chambers are treated with a
nucleotide-destroying agent, such as apyrase, to eliminate any
residual nucleotides remaining in the chamber, thereby minimizing
the probability of spurious extensions in subsequent cycles. In
some embodiments, the treatment may be included as part of the
washing step itself.
[0389] In one exemplary embodiment, different kinds (or "types") of
nucleotides are added sequentially to the reaction chambers, so
that each reaction is exposed to the different nucleotide types one
at a time. For example, nucleotide types can be added in the
following sequence: dATP, dCTP, dGTP, dTTP, dATP, dCTP, dGTP, dTTP,
and so on; with each exposure followed by a wash step. The cycles
may be repeated for 50 times, 100 times, 200 times, 300 times, 400
times, 500 times, 750 times, or more, depending on the length of
sequence information desired. In some embodiments, the time taken
to apply each nucleotide sequentially to the reaction chamber (i.e.
flow cycle) can be varied depending on the sequencing information
desired. For example, the flow cycle can in some instances be
reduced when sequencing long nucleic acid molecules to reduce the
overall time needed to sequence the entire nucleic acid molecule.
In some embodiments, the flow cycle can be increased, for example
when sequencing short nucleic acids or amplicons. In some
embodiments, the flow cycle can be about 0.5 seconds to about 3
seconds, and more typically about 1 second to about 1.5
seconds.
[0390] In one exemplary embodiment, the disclosure relates
generally to a method for obtaining sequence information from a
nucleic acid template, comprising:
[0391] (a) providing a reaction mixture including a template
nucleic acid hybridized to a sequencing primer and bound to a
modified polymerase, wherein the modified polymerase comprises a
polymerase linked to a bridging moiety through one or more
attachment sites within the polymerase;
[0392] (b) contacting the template nucleic acid with a nucleotide,
wherein the contacting includes incorporating the nucleotide into
the sequencing primer and generating a sequencing byproduct if the
nucleotide is complementary to a corresponding nucleotide in the
template nucleic acid; and
[0393] (c) detecting the presence of sequencing byproduct in the
reaction mixture, thereby determining whether nucleotide
incorporation has occurred.
[0394] In some embodiments, the method can further include
repeating the contacting and detecting steps at least once.
[0395] In some embodiments, the polymerase of the modified
polymerase includes a single attachment site, and the bridging
moiety is linked to the polymerase through the single attachment
site, either directly or through a linking moiety. In some
embodiments, the single attachment site can be linked to a biotin
moiety, and the bridging moiety can include an avidin moiety. In
some embodiments, the modified polymerase exhibits increased read
length and/or processivity relative to an unmodified form of the
polymerase under otherwise similar or identical reaction
conditions.
[0396] In some embodiments, detecting the presence of the
sequencing byproduct includes contacting the reaction mixture with
a sensor capable of sensing the presence of the sequencing
byproduct. The sensor can include a field effect transistor, for
example a chemFET or an ISFET.
[0397] In some embodiments, the sequencing byproduct includes a
hydrogen ion, a dye-linked moiety, a polyphosphate, a pyrophosphate
or a phosphate moiety, and detecting the presence of the sequencing
byproduct includes using an ISFET to detect the sequencing
byproduct. In some embodiments, the detecting the sequencing
byproduct includes detecting a hydrogen ion using the ISFET.
[0398] In a further embodiment, the disclosure relates generally to
a method of detecting a nucleotide incorporation, comprising:
[0399] (a) performing a nucleotide incorporation using a modified
polymerase and generating one or more byproducts of the nucleotide
incorporation; and
[0400] (b) detecting the presence of at least one of the one or
more byproducts of the nucleotide incorporation, thereby detecting
the nucleotide incorporation.
[0401] In some embodiments, the modified polymerase includes a
polymerase linked to a bridging moiety. The bridging moiety is
optionally linked to the polymerase through one or more attachment
sites within the modified polymerase. In some embodiments, the
bridging moiety is linked to the polymerase through a linking
moiety. The linking moiety can be linked to at least one of the one
or more attachment sites of the polymerase. In some embodiments,
the polymerase of the modified polymerase includes a single
attachment site, and the bridging moiety is linked to the
polymerase through the single attachment site, either directly or
through a linking moiety. In some embodiments, the single
attachment site can be linked to a biotin moiety, and the bridging
moiety can include an avidin moiety. In some embodiments, the
bridging moiety is linked to the polymerase through at least one
biotin-avidin bond. In some embodiments, the modified polymerase
exhibits increased read length and/or processivity relative to a
reference polymerase under otherwise similar or identical reaction
conditions.
[0402] In some embodiments, the method can further include
repeating the performing and detecting steps at least once.
[0403] In some embodiments, detecting the presence of the at least
one byproduct of nucleotide incorporation includes using a sensor
capable of sensing the presence of the byproduct. The sensor can
include a field effect transistor, for example a chemFET or an
ISFET.
[0404] In some embodiments, the at least one byproduct of
nucleotide incorporation includes a hydrogen ion, a dye-linked
moiety, a polyphosphate, a pyrophosphate or a phosphate moiety, and
detecting the presence of the at least one byproduct includes using
an ISFET to detect the at least one byproduct. In some embodiments,
the at least one byproduct includes a hydrogen ion, and detecting
the presence of the sequencing byproduct includes detecting the
hydrogen ion using an ISFET.
[0405] In some embodiments, the disclosure relates generally to a
method of detecting a change in ion concentration during a
nucleotide polymerization reaction, comprising:
[0406] (a) performing a nucleotide polymerization reaction using a
modified polymerase including a polymerase linked to a bridging
moiety, wherein the concentration of at least one type of ion
changes during the course of the nucleotide polymerization
reaction; and
[0407] (b) detecting a signal indicating the change in
concentration of the at least one type of ion.
[0408] In some embodiments, the bridging moiety is linked to the
polymerase through one or more attachment sites within the modified
polymerase. In some embodiments, the bridging moiety is linked to
the polymerase through a linking moiety. The linking moiety can be
linked to at least one of the one or more attachment sites of the
polymerase. In some embodiments, the polymerase of the modified
polymerase includes a single attachment site, and the bridging
moiety is linked to the polymerase through the single attachment
site, either directly or through a linking moiety. In some
embodiments, the single attachment site can be linked to a biotin
moiety, and the bridging moiety can include an avidin moiety. In
some embodiments, the bridging moiety is linked to the polymerase
through at least one biotin-avidin bond. In some embodiments, the
modified polymerase exhibits increased read length and/or
processivity relative to an reference form of the polymerase under
otherwise similar or identical reaction conditions.
[0409] In some embodiments, the method can further include
repeating the performing and detecting steps at least once.
[0410] In some embodiments, detecting the change in concentration
of the at least one type of ion includes using a sensor capable of
sensing the presence of the byproduct. The sensor can include a
field effect transistor, for example a chemFET or an ISFET.
[0411] In some embodiments, the at least type of ion includes a
hydrogen ion, a dye-linked moiety, a polyphosphate, a pyrophosphate
or a phosphate moiety, and detecting the change in concentration of
the at least one type of ion includes using an ISFET to detect the
at least one type of ion. In some embodiments, the at least one
type of ion includes a hydrogen ion, and detecting the presence of
the at least one type of ion includes detecting the hydrogen ion
using an ISFET.
[0412] The following non-limiting examples are provided purely by
way of illustration of exemplary embodiments, and in no way limit
the scope and spirit of the present disclosure. Furthermore, it is
to be understood that any inventions disclosed or claimed herein
encompass all variations, combinations, and permutations of any one
or more features described herein. Any one or more features may be
explicitly excluded from the claims even if the specific exclusion
is not set forth explicitly herein. It should also be understood
that disclosure of a reagent for use in a method is intended to be
synonymous with (and provide support for) that method involving the
use of that reagent, according either to the specific methods
disclosed herein, or other methods known in the art unless one of
ordinary skill in the art would understand otherwise. In addition,
where the specification and/or claims disclose a method, any one or
more of the reagents disclosed herein may be used in the method,
unless one of ordinary skill in the art would understand
otherwise.
EXAMPLES
Example 1
Purification of Exemplary Modified Polymerases
[0413] Various exemplary mutations were introduced via
site-directed mutagenesis into an exemplary reference polymerase
having the amino acid sequence of SEQ ID NO: 2. Recombinant
expression constructs encoding these modified polymerases were
transformed into bacteria. Colonies containing expression
constructs were inoculated into BRM media, grown to OD=0.600 and
induced by adding IPTG to a final concentration of 1 mM. The cells
were then grown for a further 3 hours at 37.degree. C.
[0414] The induced cells were centrifuged for 10 minutes at 6000
rpm, supernatant was discarded, and the cells were resuspended in
resuspension buffer (10 mM Tris, pH 7.5, 100 mM NaCl). The
resuspended cells were sonicated at a setting of 60 (amplitude) for
one minute, and then placed on ice for 1 minute. The sonication was
repeated in this manner for a total of 5 times.
[0415] The samples were incubated at 65.degree. C. for 10 minutes.
The samples were centrifuged at 9000 rpm for 30 minutes. The
supernatant was recovered and further purified over a Heparin
column. Purified polymerase was assayed to measure the dissociation
rate constant as described in the following Example.
Example 2
Measuring Off-Rate of Exemplary Modified And Reference
Polymerases
[0416] The samples of modified polymerases, as well as a reference
polymerase having the amino acid sequence of SEQ ID NO: 2, prepared
according to Example 1, were assayed to measure the dissociation
rate constants. The goal of this assay was to measure the
dissociation rate of a polymerase from a fluorescently labeled DNA
template (oligo 221) having the following nucleotide sequence:
TABLE-US-00018 (SEQ ID NO: 21)
TTTTTTTGCAGGTGACAGGTTTTTCCTGTCACCNGC,
where N is flourescein-dT.
[0417] Dissociation is measured by the decrease in fluorescence
that occurs when the Bst polymerase dissociates from the template.
Dissociation is initiated by adding a vast excess of unlabeled,
competitor DNA (hairpin oligo 173) having the following nucleotide
sequence:
TABLE-US-00019 (SEQ ID NO: 22)
TTTTTTTCCCTTTCCTTTCGGGTGACAGGTTTTTCCTGTCACCC.
[0418] As the polymerase dissociates from oligo 221, it is bound by
the competitor and thus, cannot rebind the original 221
template.
[0419] To perform the assay, reactions (75 .mu.l) containing 30 mM
Tris (pH 7.5), 20 mM NaCl, 50 nM oligo 221, and .about.10-200 nM
partially polymerase samples (prepared according to Example 1) were
assembled in 96-well plates. Baseline readings were then taken on
the spectrophotometer using 490 nm excitation and 525 nm emission
wavelengths. The 173 competitor oligo (2 .mu.M Final concentration)
was then rapidly added to each well and plates were rapidly
returned to the spectrophotometer for readings every 30 seconds for
5 minutes. The dissociation rate was calculated by fitting the data
to a one-phase exponential decay equation using PrismGraph.RTM.
according to the following formula:
Y=(Y0-Plateau)*exp.sup.(-K*X)+Plateau
[0420] where:
[0421] Y0 is the Y value when X (time) is zero. It is expressed in
the same units as Y,
[0422] Plateau is the Y value at infinite times, expressed in the
same units as Y.
[0423] K is the rate constant, expressed in reciprocal of the X
axis time units. If X is in minutes, then K is expressed in inverse
minutes.
[0424] Tau is the time constant, expressed in the same units as the
X axis. It is computed as the reciprocal of K.
[0425] Half-life is in the time units of the X axis. It is computed
as ln(2)/K.
[0426] Span, i.e., (Y0-Plateau)) is the difference between Y0 and
Plateau, expressed in the same units as your Y values.
[0427] Representative results of an assay where the dissociation
rate constant (also referred to as the "dissociation time
constant") of various modified polymerases, as well as a reference
polymerase having the amino acid sequence of SEQ ID NO: 2, was
measured at varying concentrations of salt, are depicted in FIG. 2.
The polymerases included in the assay are represented in FIG. 2 as
follows: Bst 1=Reference polymerase having the amino acid sequence
of SEQ ID NO: 2; 480R=modified polymerase having the amino acid
sequence of SEQ ID NO: 2 and further including the mutation D480R;
425R=modified polymerase having the amino acid sequence of SEQ ID
NO: 2 and further including the mutation G425R; 144K=modified
polymerase having the amino acid sequence of SEQ ID NO: 2 and
further including the mutation D144K; and 488K=modified polymerase
having the amino acid sequence of SEQ ID NO: 2 and further
including the mutation F448K. As indicated in FIG. 2, some of the
modified polymerases exhibited significantly higher dissociation
time constants at a given salt concentration as compared with the
reference polymerase of SEQ ID NO: 2.
[0428] FIG. 3 provides a table listing the relative template
affinity observed for various modified polymerases prepared
according to example 1 and 2, relative to the template affinity
observed for a reference polymerase having the amino acid sequence
of SEQ ID NO: 2 (referred to in FIG. 3 as "Bst 1"). Each modified
polymerase had the amino acid sequence of SEQ ID NO: 2, plus the
amino acid substitution listed in the first column of the table. As
indicated in FIG. 3, some of the modified polymerases exhibited
significantly increased template affinity relative to the reference
polymerase Bst1; in some cases, the increase in template affinity
was 20.times., 100.times., or greater.
Example 3
Comparing Performance of Modified and Reference Polymerases in
Nucleic Acid Sequencing
[0429] A modified polymerase comprising a mutant Bst polymerase
having the amino acid sequence of SEQ ID NO: 2 and further
including the amino acid substitution D480R (wherein the numbering
is relative to the amino acid sequence of SEQ ID NO: 2) was
purified essentially as described in Example 1. Both the modified
polymerase and a reference polymerase having the amino acid
sequence of SEQ ID NO: 2 (control reaction) were then evaluated for
performance in an ion-based sequencing reaction using the Ion
Torrent PGM.TM. Sequencing system (Ion Torrent Systems, Part No.
4462917). Briefly, genomic DNA was purified, adapter-ligated and
size selected as described in User Guide for the Ion Fragment
Library Kit (Ion Torrent Systems, Part No. 4466464; Publication
Part No. 4467320 Rev B). The DNA fragments were then amplified onto
Ion Sphere.TM. particles (Ion Torrent Systems, Part No.
602-1075-01) essentially according to the protocols provided in the
User Guide for the Ion Xpress.TM. Template Kit v 2.0 (Ion Torrent
Systems, Part No. 4469004A) and using the reagents provided in the
Ion Template Preparation Kit (Ion Torrent Systems/Life
Technologies, Part No. 4466461), the Ion Template Reagents Kit (Ion
Torrent Systems/Life Technologies, Part No. 4466462) and the Ion
Template Solutions Kit (Ion Torrent Systems/Life Technologies, Part
No. 4466463). The amplified DNA was then loaded into a PGM.TM. 314
sequencing chip. The chip was loaded into an Ion Torrent PGM.TM.
Sequencing system (Ion Torrent Systems/Life Technologies, Part No.
4462917) and sequenced essentially according to the protocols
provided in User Guide for the Ion Sequencing Kit v2.0 (Ion Torrent
Systems/Life Technologies, Part No. 4469714 Rev A) and using the
reagents provided in the Ion Sequencing Kit v2.0 (Ion Torrent
Systems/Life Technologies, Part No. 4466456) and the Ion Chip Kit
(Ion Torrent Systems/Life Technologies, Part No. 4462923). Ion
Torrent Systems is a subsidiary of Life Technologies Corp.,
Carlsbad, Calif.).
[0430] The resulting sets of sequencing reads using either the
reference or modified polymerase were analyzed to measure the
number of 50Q17 reads, 100Q17 reads, and 200Q17 reads. Using the
standard software supplied with the PGM.TM. sequencing system, the
total number of 100Q17 or 200Q17 reads obtained in sequencing
reactions using reference and modified polymerases were measured
and compared. The exemplary modified polymerase including the
mutation D480R provided significantly increased numbers of 50Q17
reads, 100Q17 reads, and 200Q17 reads relative to the reference
polymerase (data not shown).
Example 4
Comparing Performance of Modified and Reference Polymerases in
Nucleic Acid Sequencing
[0431] A modified polymerase comprising a mutant Bst polymerase
having the amino acid sequence of SEQ ID NO: 2 and further
including the amino acid substitutions D264K and E493Q (wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 2)
was purified essentially as described in Example 1. Both the
modified polymerase and a reference polymerase having the amino
acid sequence of SEQ ID NO: 2 (control reaction) were then
evaluated for performance in an ion-based sequencing reaction using
the Ion Torrent PGM.TM. Sequencing system (Ion Torrent Systems,
Part No. 4462917). Briefly, genomic DNA was purified,
adapter-ligated and size selected as described in User Guide for
the Ion Fragment Library Kit (Ion Torrent Systems, Part No.
4466464; Publication Part No. 4467320 Rev B). The DNA fragments
were then amplified onto Ion Sphere.TM. particles (Ion Torrent
Systems, Part No. 602-1075-01) essentially according to the
protocols provided in the User Guide for the Ion Xpress.TM.
Template Kit v 2.0 (Ion Torrent Systems, Part No. 4469004A) and
using the reagents provided in the Ion Template Preparation Kit
(Ion Torrent Systems/Life Technologies, Part No. 4466461), the Ion
Template Reagents Kit (Ion Torrent Systems/Life Technologies, Part
No. 4466462) and the Ion Template Solutions Kit (Ion Torrent
Systems/Life Technologies, Part No. 4466463). The amplified DNA was
then loaded into a PGM.TM. 314 sequencing chip. The chip was loaded
into an Ion Torrent PGM.TM. Sequencing system (Ion Torrent
Systems/Life Technologies, Part No. 4462917) and sequenced
essentially according to the protocols provided in User Guide for
the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies,
Part No. 4469714 Rev A) and using the reagents provided in the Ion
Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies, Part
No. 4466456) and the Ion Chip Kit (Ion Torrent Systems/Life
Technologies, Part No. 4462923).
[0432] The resulting sets of sequencing reads using reference and
modified polymerase were analyzed to measure the number of 50Q17
reads, 100Q17 reads, and 200Q17 reads. Using the standard software
supplied with the PGM.TM. sequencing system, the total number of
100Q17 or 200Q17 reads obtained in sequencing reactions using
reference and modified polymerases were measured and compared. The
exemplary modified polymerase including the mutations D264K and
E493Q provided significantly increased numbers of 50Q17 reads,
100Q17 reads, and 200Q17 reads relative to the reference polymerase
(data not shown).
Example 5
Comparing Performance of Modified and Reference Polymerases in
Nucleic Acid Sequencing
[0433] A modified polymerase comprising a mutant Bst polymerase
having the amino acid sequence of SEQ ID NO: 2 and further
including the amino acid substitutions E220K, N234R and D423K
(wherein the numbering is relative to the amino acid sequence of
SEQ ID NO: 2) was purified essentially as described in Example 1.
Both the modified polymerase and a reference polymerase having the
amino acid sequence of SEQ ID NO: 2 (control reaction) were then
evaluated for performance in an ion-based sequencing reaction using
the Ion Torrent PGM.TM. Sequencing system (Ion Torrent Systems,
Part No. 4462917). Briefly, genomic DNA was purified,
adapter-ligated and size selected as described in User Guide for
the Ion Fragment Library Kit (Ion Torrent Systems, Part No.
4466464; Publication Part No. 4467320 Rev B). The DNA fragments
were then amplified onto Ion Sphere.TM. particles (Ion Torrent
Systems, Part No. 602-1075-01) essentially according to the
protocols provided in the User Guide for the Ion Xpress.TM.
Template Kit v 2.0 (Ion Torrent Systems, Part No. 4469004A) and
using the reagents provided in the Ion Template Preparation Kit
(Ion Torrent Systems/Life Technologies, Part No. 4466461), the Ion
Template Reagents Kit (Ion Torrent Systems/Life Technologies, Part
No. 4466462) and the Ion Template Solutions Kit (Ion Torrent
Systems/Life Technologies, Part No. 4466463). The amplified DNA was
then loaded into a PGM.TM. 314 sequencing chip. The chip was loaded
into an Ion Torrent PGM.TM. Sequencing system (Ion Torrent
Systems/Life Technologies, Part No. 4462917) and sequenced
essentially according to the protocols provided in User Guide for
the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies,
Part No. 4469714 Rev A) and using the reagents provided in the Ion
Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies, Part
No. 4466456) and the Ion Chip Kit (Ion Torrent Systems/Life
Technologies, Part No. 4462923).
[0434] The resulting sets of sequencing reads using reference and
modified polymerases were analyzed to measure the number of 50Q17
reads, 100Q17 reads, and 200Q17 reads. Using the standard software
supplied with the PGM.TM. sequencing system, the total number of
100Q17 or 200Q17 reads obtained in sequencing reactions using
reference and modified polymerases were measured and compared. The
exemplary modified polymerase including the mutations E220K, N234R
and D423K provided significantly increased numbers of 50Q17 reads,
100Q17 reads, and 200Q17 reads relative to the reference polymerase
(data not shown).
Example 6
Comparing Performance of Exemplary Modified and Reference
Polymerases in an Ion-Based Nucleic Acid Sequencing System
[0435] Exemplary modified polymerases comprising a mutant Bst
polymerase having the amino acid sequence of SEQ ID NO: 2 and
further including three of the following exemplary amino acid
substitutions: N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H,
D144M, D144K, L212A, E220K, N234R, N234K, V241K, V251K, D264Q,
D264S, D264K, Y272R, H273R, L280R, H281A, E294S, E294F, E294G,
E294K, V299K, V299H, V299F, D303R, I331Q, E325R, L335T, E336P,
I354W, I354F, I370A, Q409R, G416K, V418M, V418I, G420K, D423S,
D423K, D423N, D423R, D423T, D423G, D423I, D423K, G425R, Q428W,
N429R, N429K, E446Q, F448K, N457T, A462T, H473R, Y477F, D480R,
D480F, D480H, D480A, D480S, D480N, D480Q, N485W, N485Y, N487H,
N487W, N487F, N4871, V488R, E493Q, M495Q, H528A, V533I, H572R,
W577Y and D579F, wherein the numbering is relative of the amino
acid sequence of SEQ ID NO: 2, were purified essentially as
described in Example 1. Both the modified polymerases and a
reference polymerase having the amino acid sequence of SEQ ID NO: 2
(control reaction) were then evaluated for performance in an
ion-based sequencing reaction using the Ion Torrent PGM.TM.
Sequencing system, (Ion Torrent Systems, Part No. 4462917).
Briefly, genomic DNA was purified, adapter-ligated and size
selected as described in User Guide for the Ion Fragment Library
Kit (Ion Torrent Systems, Part No. 4466464; Publication Part No.
4467320 Rev B). The DNA fragments were then amplified onto Ion
Sphere.TM. particles (Ion Torrent Systems, Part No. 602-1075-01)
essentially according to the protocols provided in the User Guide
for the Ion Xpress.TM. Template Kit v 2.0 (Ion Torrent Systems,
Part No. 4469004A) and using the reagents provided in the Ion
Template Preparation Kit (Ion Torrent Systems/Life Technologies,
Part No. 4466461), the Ion Template Reagents Kit (Ion Torrent
Systems/Life Technologies, Part No. 4466462) and the Ion Template
Solutions Kit (Ion Torrent Systems/Life Technologies, Part No.
4466463). The amplified DNA was then loaded into a PGM.TM. 314
sequencing chip. The chip was loaded into an Ion Torrent PGM.TM.
Sequencing system (Ion Torrent Systems/Life Technologies, Part No.
4462917) and sequenced essentially according to the protocols
provided in User Guide for the Ion Sequencing Kit v2.0 (Ion Torrent
Systems/Life Technologies, Part No. 4469714 Rev A) and using the
reagents provided in the Ion Sequencing Kit v2.0 (Ion Torrent
Systems/Life Technologies, Part No. 4466456) and the Ion Chip Kit
(Ion Torrent Systems/Life Technologies, Part No. 4462923).
[0436] The resulting sets of sequencing reads using reference and
modified polymerases were analyzed to measure the raw read accuracy
of the resulting sequencing reads (as reported by the Ion Torrent
standard software provided with the Ion Torrent Sequencing System),
the number of 50Q17 reads, 100Q17 reads, and 200Q17 reads. Using
the standard software supplied with the PGM.TM. sequencing system,
the total number of 100Q17 or 200Q17 reads obtained in sequencing
reactions using reference and modified polymerases were measured
and compared.
[0437] FIGS. 4-7 depict the increase in accuracy obtained using an
exemplary modified polymerase (A5) comprising the amino acid
sequence of SEQ ID NO: 2 and further including amino acid
substitutions: E220K, N234R, and D423K, wherein the numbering is
relative to SEQ ID NO: 2, compared to the accuracy obtained using a
reference polymerase comprising the amino acid sequence of SEQ ID
NO: 2 (i.e., an exemplary Bst polymerase), and further including a
different set of amino acid substitutions (LR2). As shown in FIGS.
4-7, the exemplary modified polymerase including the mutations
provided (A5) significantly increased accuracy (as measured by
error rate and raw read accuracy) relative to the reference
polymerase (LR2). The amino acid sequence of the modified
polymerase shown as A5 in FIGS. 4-7 is provided below, as SEQ ID
NO: 19.
TABLE-US-00020 (SEQ ID NO: 19) 10 20 30 40 50 60 MAKMAFTLAD
RVTEEMLADK AALVVEVVEE NYHDAPIVGI AVVNERGRFF LRPETALADP 70 80 90 100
110 120 QFVAWLGDET KKKSMFDSKR AAVALKWKGI ELCGVSFDLL LAAYLLDPAQ
GVDDVAAAAK 130 140 150 160 170 180 MKQYEAVRPD EAVYGKGAKR AVPDEPVLAE
HLVRKAAAIW ELERPFLDEL RRNEQDRLLV 190 200 210 220 230 240 ELEQPLSSIL
AEMEFAGVKV DTKRLEQMGK ELAEQLGTVK QRIYELAGQE FNIRSPKQLG 250 260 270
280 290 300 VILFEKLQLP VLKKTKTGYS TSADVLEKLA PYHEIVENIL HYRQLGKLQS
TYIEGLLKVV 310 320 330 340 350 360 RPDTKKVHTI FNQALTQTGR LSSTEPNLQN
IPIRLEEGRK IRQAFVPSES DWLIFAADYS 370 380 390 400 410 420 QIELRVLAHI
AEDDNLMEAF RRDLDIHTKT AMDIFQVSED EVTPNMRRQA KAVNFGIVYG 430 440 450
460 470 480 ISKYGLAQNL NISRKEAAEF IERYFQSFPG VKRYMENIVQ EAKQKGYVTT
LLHRRRYLPD 490 500 510 520 530 540 ITSRNFNVRS FAERMAMNTP IQGSAADIIK
KAMIDLNARL KEERLQAHLL LQVHDELILE 550 560 570 580 APKEEMERLC
RLVPEVMEQA VTLRVPLKVD YRYGSTWYDA K
[0438] The corresponding nucleic acid sequence encoding the
modified polymerase (A5) (i.e., SEQ ID NO: 19) is provided below as
SEQ ID NO: 23. It will be readily apparent to one of ordinary skill
in the art, that any one or more of the reference or modified
polymerases disclosed, or suggested, by the disclosure can be
readily converted (e.g., reverse translated) to the corresponding
nucleic acid sequence encoding the reference or modified
polymerase. It will also be apparent to the skilled artisan that
the nucleic acid sequence for each polypeptide is variable due to
the degenerate nature of codons. For example, there are six codons
that code for leucine (CTT, CTC, CTA, CTG, TTA and TTG). Thus, the
base at position 1 of this codon can be a C or T, position 2 of
this codon is always a T, and the base at position 3 can be T, C, A
or G. Accordingly, any reference or modified polymerase disclosed
or suggested by the disclosure can be translated to any one or more
of the degenerate codon nucleic acid sequences.
TABLE-US-00021 (SEQ ID NO: 23)
ATGGCTAAAATGGCTTTTACTCTTGCTGATCGTGTTACTGAAGAAATGCTTGCTGATAAA
GCTGCTCTTGTTGTTGAAGTTGTTGAAGAAAATTATCATGATGCTCCTATTGTTGGTATT
GCTGTTGTTAATGAACGTGGTCGTTTTTTTCTTCGTCCTGAAACTGCTCTTGCTGATCCT
CAATTTGTTGCTTGGCTTGGTGATGAAACTAAAAAAAAATCTATGTTTGATTCTAAACGT
GCTGCTGTTGCTCTTAAATGGAAAGGTATTGAACTTTGTGGTGTTTCTTTTGATCTTCTT
CTTGCTGCTTATCTTCTTGATCCTGCTCAAGGTGTTGATGATGTTGCTGCTGCTGCTAAA
ATGAAACAATATGAAGCTGTTCGTCCTGATGAAGCTGTTTATGGTAAAGGTGCTAAACGT
GCTGTTCCTGATGAACCTGTTCTTGCTGAACATCTTGTTCGTAAAGCTGCTGCTATTTGG
GAACTTGAACGTCCTTTTCTTGATGAACTTCGTCGTAATGAACAAGATCGTCTTCTTGTT
GAACTTGAACAACCTCTTTCTTCTATTCTTGCTGAAATGGAATTTGCTGGTGTTAAAGTT
GATACTAAACGTCTTGAACAAATGGGTAAAGAACTTGCTGAACAACTTGGTACTGTTAAA
CAACGTATTTATGAACTTGCTGGTCAAGAATTTAATATTCGTTCTCCTAAACAACTTGGT
GTTATTCTTTTTGAAAAACTTCAACTTCCTGTTCTTAAAAAAACTAAAACTGGTTATTCT
ACTTCTGCTGATGTTCTTGAAAAACTTGCTCCTTATCATGAAATTGTTGAAAATATTCTT
CATTATCGTCAACTTGGTAAACTTCAATCTACTTATATTGAAGGTCTTCTTAAAGTTGTT
CGTCCTGATACTAAAAAAGTTCATACTATTTTTAATCAAGCTCTTACTCAAACTGGTCGT
CTTTCTTCTACTGAACCTAATCTTCAAAATATTCCTATTCGTCTTGAAGAAGGTCGTAAA
ATTCGTCAAGCTTTTGTTCCTTCTGAATCTGATTGGCTTATTTTTGCTGCTGATTATTCT
CAAATTGAACTTCGTGTTCTTGCTCATATTGCTGAAGATGATAATCTTATGGAAGCTTTT
CGTCGTGATCTTGATATTCATACTAAAACTGCTATGGATATTTTTCAAGTTTCTGAAGAT
GAAGTTACTCCTAATATGCGTCGTCAAGCTAAAGCTGTTAATTTTGGTATTGTTTATGGT
ATTTCTAAATATGGTCTTGCTCAAAATCTTAATATTTCTCGTAAAGAAGCTGCTGAATTT
ATTGAACGTTATTTTCAATCTTTTCCTGGTGTTAAACGTTATATGGAAAATATTGTTCAA
GAAGCTAAACAAAAAGGTTATGTTACTACTCTTCTTCATCGTCGTCGTTATCTTCCTGAT
ATTACTTCTCGTAATTTTAATGTTCGTTCTTTTGCTGAACGTATGGCTATGAATACTCCT
ATTCAAGGTTCTGCTGCTGATATTATTAAAAAAGCTATGATTGATCTTAATGCTCGTCTT
AAAGAAGAACGTCTTCAAGCTCATCTTCTTCTTCAAGTTCATGATGAACTTATTCTTGAA
GCTCCTAAAGAAGAAATGGAACGTCTTTGTCGTCTTGTTCCTGAAGTTATGGAACAAGCT
GTTACTCTTCGTGTTCCTCTTAAAGTTGATTATCGTTATGGTTCTACTTGGTATGATGCT
AAA
Example 7
Transfer of Mutations from One Modified Polymerase to Another
Polymerase
[0439] Various exemplary mutations were introduced via
site-directed mutagenesis into exemplary reference polymerases
having the amino acid sequences of SEQ ID NO: 2, 20, 21 and 23 (See
Table 1). After sequence verification, the modified polymerases
containing amino acid mutations (e.g., a Taq DNA polymerase having
amino acid mutation D732R, wherein the numbering corresponds to SEQ
ID NO. 20; and a Klenow fragment DNA polymerase having amino acid
mutation D505R, wherein the numbering corresponds to SEQ ID NO. 23)
were transformed into bacterial cells for expression. Colonies
containing expression construct were inoculated into BRM media,
grown to OD=0.600 and induced by adding IPTG to a final
concentration of 1 mM. The cells were then grown for a further 3
hours at 37.degree. C.
[0440] The induced cells were then centrifuged for 10 minutes at
6000 rpm, supernatant was discarded, and the cells were resuspended
in resuspension buffer (100 mM Tris, pH 7.5, 100 mM NaCl). The
resuspended cells were sonicated at a setting of 60 (amplitude) for
one minute, and then placed on ice for 1 minute. The sonication was
repeated in this manner for a total of 5 times. Samples were
incubated at 65.degree. C. for 10 minutes and centrifuged at 9000
rpm. The supernatant was recovered and further purified over a
Heparin column. Purified polymerase was assayed to measure the
dissociation rate constant as described in Example 2.
[0441] Heparin DNA Affinity Column
[0442] The following results were observed during purification of
the modified polymerases on a Heparin column. All mutants exhibited
tighter binding to a heparin column. Taq D732R came off the column
at a conductivity of 43mS/cm where the wild type comes off at 39
mS/cm. Klenow D505R came off the column at a conductivity of 47
mS/cm where wild type Klenow comes off at 32 mS/cm.
[0443] Template Affinity/Dissociation Assay:
[0444] The dissociation rate of each modified and reference
polymerase from a DNA template (oligo 221) in the presence of
excess competitor DNA (hairpin oligo 173) was measured. Decreasing
fluorescence is monitored over time on a spectrophotometer as the
polymerase dissociates from the fluorescein-labeled template. The
dissociation rate is calculated by fitting the data to a one-phase
exponential decay equation.
[0445] Representative results of an assay where the dissociation
rate constant (also referred to as the "dissociation time
constant") of various modified polymerases, as well as reference
polymerases having the amino acid sequence of SEQ ID NO: 16 or SEQ
ID NO: 18, was measured at time intervals (depicted in FIG. 8). The
polymerases included in the assay are represented in FIG. 8 as
follows: Bst 1.0=Reference polymerase having the amino acid
sequence of SEQ ID NO: 16; BST D775R=modified polymerase having the
amino acid sequence of SEQ ID NO: 16 and further including the
mutation D775R; Klenow WT=reference polymerase having the amino
acid sequence of SEQ ID NO: 18; Klenow D505R=modified polymerase
having the amino acid sequence of SEQ ID NO: 18 and further
including the mutation D505R. As indicated in FIG. 8, the modified
polymerases exhibited significantly higher dissociation time
constants as compared with the corresponding reference
polymerase.
Example 8
Evaluation of DNA binding affinities of Bst Polymerase, Klenow
Fragment DNA Polymerase and Taq DNA Polymerase Mutants
[0446] Various exemplary mutations were introduced via
site-directed mutagenesis into exemplary reference polymerases to
generate modified polymerases. In this example, reference
polymerase SEQ ID NO: 2 was modified to contain a further amino
acid mutation (D480R). Reference polymerase SEQ ID NO: 15 was also
modified to contain a further amino acid mutation (D732R).
Additionally, reference polymerase SEQ ID NO: 18 was modified to
contain amino acid mutation (D505R). The modified polymerases were
sequence verified, and expressed essentially according to the
procesure of Example 1. The modified polymerases were then assayed
to measure dissociation rate constant essentially according to the
procedure of Example 2.
[0447] Representative results of an assay where the dissociation
rate constant (also referred to as the "dissociation time
constant") of the modified polymerases, as well as the reference
polymerases was measured at specific time intervals (depicted in
FIGS. 9-11). The polymerases included in the assay represented in
FIG. 9 as follows: Bst 1.0=Reference polymerase having the amino
acid sequence of SEQ ID NO: 16; LR1=modified polymerase having the
amino acid sequence of SEQ ID NO: 16 and further including the
mutation D775R. FIG. 9 also provides the rate constants (K) for
each polymerase. The ratio of these values
(K.sub.Bst1.0/K.sub.BstLR1) is 4.7, which means that Bst 1.0
polymerase dissociates 4.7 fold faster than the LR1 mutant. Thus,
the LR1 mutant decreases dissociation from a nucleic acid template
by a factor of about 4.7.
[0448] The polymerases included in the assay represented in FIG. 10
are as follows: WT=reference polymerase having the amino acid
sequence of SEQ ID NO: 18 (Klenow); LR1=modified polymerase having
the amino acid sequence of SEQ ID NO: 18 and further including the
mutation D505R. FIG. 10 also provides the rate constants (K) for
each polymerase. The ratio of these values (K.sub.WT/K.sub.LR1) is
13, which means that the Klenow polymerase dissociates 13 fold
faster than the LR1 mutant. Thus, the LR1 mutant decreases
dissociation from a nucleic acid template by a factor of about
13.
[0449] The polymerases included in the assay represented in FIG. 11
are as follows: WT=reference polymerase having the amino acid
sequence of SEQ ID NO: 15 (wild-type Taq DNA polymerase);
LR1=modified polymerase having the amino acid sequence of SEQ ID
NO: 18 and further including the mutation D505R. FIG. 11 also
provides the rate constants (K) for each polymerase. In this
instance, wild-type Taq DNA polymerase dissociated at a fast rate
from the template in the experiment, that rate constants were
unable to be recorded. However, as noted in FIG. 11, the LR1-Taq
DNA polymerase mutant was detected using the same experimental
conditions and can therefore be concluded to dissociate at a much
slower rate from the nucleic acid template than the corresponding
wild-type Taq DNA polymerase.
Example 9
Further Evaluation of DNA Binding Affinities Of Taq DNA Polymerase
Mutants
[0450] Various exemplary mutations were introduced via
site-directed mutagenesis into an exemplary reference polymerase
(wild-type Taq DNA polymerase--SEQ ID NO: 15) to generate a series
of modified polymerases. In this example, reference polymerase, SEQ
ID NO: 20 was modified to contain a single amino acid mutation
selected from D732R, E745Q or E471K. Each modified polymerase was
sequence verified, and expressed essentially according to Example
1. The modified polymerases were then assayed to measure
dissociation rate constant essentially according to Example 2.
[0451] Representative results of an assay where the dissociation
rate constant (also referred to as the "dissociation time
constant") of the modified polymerases, as well as the reference
polymerase was measured at specific time intervals (depicted in
FIG. 12). The polymerases included in the assay represented in FIG.
12 are as follows wt Taq=Reference polymerase having the amino acid
sequence of SEQ ID NO: 15; D732R=modified polymerase having the
amino acid sequence of SEQ ID NO: 15 and further including the
mutation D732R; E745Q=modified polymerase having the amino acid
sequence of SEQ ID NO: 15 and further including the mutation E745Q;
E471K=modified polymerase having the amino acid sequence of SEQ ID
NO: 15 and further including the mutation E471K.
[0452] FIG. 12 also provides the rate constants (K) for each
polymerase. The ratio of wild-type Taq to the D732R mutant
(K.sub.wt taq/K.sub.D732R) is 14.1, which means that the wild-type
Taq DNA polymerase dissociates 14 fold faster than the Taq DNA
polymerase mutant. Thus, the Taq mutant decreases dissociation from
the nucleic acid template by a factor of about 14.
[0453] The ratio of wild-type Taq to the E745Q mutant (K.sub.wt
taq/K.sub.E745Q) is 4.7, which means that the wild-type Taq DNA
polymerase dissociates 4.7 fold faster than the Taq DNA polymerase
mutant. Thus, the Taq mutant decreases dissociation from the
nucleic acid template by a factor of about 4.7.
[0454] The ratio of wild-type Taq to the E471K mutant (K.sub.wt
taq/K.sub.E471K) is 5, which means that the wild-type Taq
polymerase dissociates 5 fold faster than the Taq mutant. Thus, the
Taq mutant decreases dissociation from the nucleic acid template by
a factor of about 5.
[0455] All three exemplary modified Taq DNA polymerases, as
prepared in this example, demonstrated decreased dissociation from
a nucleic acid template as compared to the reference polymerase
(wild-type Taq DNA polymerase).
Example 10
Evaluating Modified Polymerase Performance in Nucleic Acid
Sequencing
[0456] A modified polymerase comprising a mutant Bst polymerase
having the amino acid sequence of SEQ ID NO: 2 and further
including two amino acid substitutions D264K and E493Q (wherein the
numbering is relative to the amino acid sequence of SEQ ID NO: 2)
was purified essentially as described in Example 1. The modified
polymerase was then evaluated for performance in an ion-based
sequencing reaction using the Ion Torrent PGM.TM. sequencing system
(Ion Torrent Systems, Part No. 4462917). Briefly, genomic DNA was
purified, adapter-ligated and size selected as described in User
Guide for the Ion Fragment Library Kit (Ion Torrent Systems, Part
No. 4466464; Publication Part No. 4467320 Rev B). The DNA fragments
were then amplified onto Ion Sphere.TM. particles (Ion Torrent
Systems, Part No. 602-1075-01) essentially according to the
protocols provided in the User Guide for the Ion Xpress.TM.
Template Kit v 2.0 (Ion Torrent Systems, Part No. 4469004A) and
using the reagents provided in the Ion Template Preparation Kit
(Ion Torrent Systems/Life Technologies, Part No. 4466461), the Ion
Template Reagents Kit (Ion Torrent Systems/Life Technologies, Part
No. 4466462) and the Ion Template Solutions Kit (Ion Torrent
Systems/Life Technologies, Part No. 4466463). The amplified DNA was
then loaded into a PGM.TM. 318 sequencing chip. The chip was loaded
into an Ion Torrent PGM.TM. Sequencing system (Ion Torrent
Systems/Life Technologies, Part No. 4462917) and sequenced
essentially according to the protocols provided in User Guide for
the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies,
Part No. 4469714 Rev A) and using the reagents provided in the Ion
Sequencing Kit c2.0 (Ion Torrent Systems/Life Technologies, Part
No. 4466456) and the Ion Chip Kit (Ion Torrent Systems/Life
Technologies, Part No. 4462923).
[0457] The resulting sets of sequencing reads using the modified
polymerase were analyzed to measure the number of AQ17 bases, AQ 20
bases, AQ17 mean, AQ20 mean, number of library reads, and AQ7
alignments. Using the standard software supplied with the PGM.TM.
sequencing system, the total number of AQ17 or AQ20 reads obtained
in the sequencing reactions using the modified polymerase were
measured and compared. The data for four independent sequencing
runs performed as outlined in this example, is shown in FIG. 13. As
can be seen, each of the four sequencing runs generated over 1 Gb
(gigabyte) of data at AQ17 (average=1.09 Gb).
Example 11
Evaluating Modified Polymerase Performance in Nucleic Acid
Sequencing
[0458] Two batches of modified polymerase comprising a mutant Bst
polymerase having the amino acid sequence of SEQ ID NO: 2 and
further including two amino acid substitutions D264K and E493Q
(wherein the numbering is relative to the amino acid sequence of
SEQ ID NO: 2) were purified essentially as described in Example 1.
Each batch (Old LR2 or New LR2) of modified polymerase was then
evaluated for performance in an ion-based sequencing reaction using
the Ion Torrent PGM.TM. sequencing system (Ion Torrent Systems,
Part No. 4462917). Briefly, genomic DNA was purified,
adapter-ligated and size selected as described in User Guide for
the Ion Fragment Library Kit (Ion Torrent Systems, Part No.
4466464; Publication Part No. 4467320 Rev B). The DNA fragments
were then amplified onto Ion Sphere.TM. particles (Ion Torrent
Systems, Part No. 602-1075-01) essentially according to the
protocols provided in the User Guide for the Ion Xpress.TM.
Template Kit v 2.0 (Ion Torrent Systems, Part No. 4469004A) and
using the reagents provided in the Ion Template Preparation Kit
(Ion Torrent Systems/Life Technologies, Part No. 4466461), the Ion
Template Reagents Kit (Ion Torrent Systems/Life Technologies, Part
No. 4466462) and the Ion Template Solutions Kit (Ion Torrent
Systems/Life Technologies, Part No. 4466463). The amplified DNA was
then loaded into a PGM.TM. 318 sequencing chip. The chip was loaded
into an Ion Torrent PGM.TM. Sequencing system (Ion Torrent
Systems/Life Technologies, Part No. 4462917) and sequenced
essentially according to the protocols provided in User Guide for
the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies,
Part No. 4469714 Rev A) and using the reagents provided in the Ion
Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies, Part
No. 4466456) and the Ion Chip Kit (Ion Torrent Systems/Life
Technologies, Part No. 4462923).
[0459] The resulting sets of sequencing reads using either the old
LR2 batch or new LR2 batch of modified polymerase were analyzed to
measure the number of AQ17 bases, AQ 20 bases, AQ17 mean, and AQ20
mean. Using the standard software supplied with the PGM.TM.
sequencing system, the total number of AQ17 or AQ20 reads obtained
in the sequencing reactions using the modified polymerase were
measured and compared. The data for seven independent sequencing
runs performed as outlined in this example, is shown in FIG. 14. As
can be seen, each of the seven sequencing runs generated over 1 Gb
(gigabyte) of data at AQ17; while five of the sequencing runs
generated over 1 Gb of data at AQ20.
Example 12
Evaluating Modified Polymerase Performance in Nucleic Acid
Sequencing
[0460] A modified polymerase comprising a mutant Bst polymerase
having the amino acid sequence of SEQ ID NO: 20 was purified
essentially as described in Example 1. The modified polymerase was
then evaluated for performance in an ion-based sequencing reaction
using the Ion Torrent PGM.TM. sequencing system (Ion Torrent
Systems, Part No. 4462917). Briefly, genomic DNA was purified,
adapter-ligated and size selected as described in User Guide for
the Ion Fragment Library Kit (Ion Torrent Systems, Part No.
4466464; Publication Part No. 4467320 Rev B). The DNA fragments
were then amplified onto Ion Sphere.TM. particles (Ion Torrent
Systems, Part No. 602-1075-01) essentially according to the
protocols provided in the User Guide for the Ion Xpress.TM.
Template Kit v2.0 (Ion Torrent Systems, Part No. 4469004A) and
using the reagents provided in the Ion Template Preparation Kit
(Ion Torrent Systems/Life Technologies, Part No. 4466461), the Ion
Template Reagents Kit (Ion Torrent Systems/Life Technologies, Part
No. 4466462) and the Ion Template Solutions Kit (Ion Torrent
Systems/Life Technologies, Part No. 4466463). The amplified DNA was
then loaded into a PGM.TM. 316 sequencing chip. The chip was loaded
into an Ion Torrent PGM.TM. Sequencing system (Ion Torrent
Systems/Life Technologies, Part No. 4462917) and sequenced
essentially according to the protocols provided in User Guide for
the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies,
Part No. 4469714 Rev A) and using the reagents provided in the Ion
Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies, Part
No. 4466456) and the Ion Chip Kit (Ion Torrent Systems/Life
Technologies, Part No. 4462923).
[0461] The resulting sequencing read using the modified polymerase
were analyzed to measure the number of mapped Q17 bases, the number
of mapped Q20 bases, mean coverage depth at Q17, mean coverage
depth at Q20, longest Q17 and Q20 alignments, and Q17 and Q20
alignments. The data for the sequencing run performed as outlined
in this example is shown in FIG. 15. As can be seen, the sequencing
run generated over 1 Gb (gigabyte) of data at Q17 (1.02 Gb); a Q17
accuracy rate of 482 base pairs and a Q20 accuracy rate of 471 base
pairs.
Example 13
Evaluating Modified Polymerase Performance in Emulsion PCR
[0462] A modified polymerase comprising a mutant Taq DNA polymerase
having the amino acid sequence of SEQ ID NO: 15 and further
including amino acid mutation D732R was purified essentially as
described in Example 1 (SEQ ID NO: 24).
TABLE-US-00022 (SEQ ID NO: 24) 1 MRGMLPLFEP KGRVLLVDGH HLAYRTFHAL
KGLTTSRGEP VQAVYGFAKS LLKALKEDGD 61 AVIVVFDAKA PSFRHEAYGG
YKAGRAPTPE DFPRQLALIK ELVDLLGLAR LEVPGYEADD 121 VLASLAKKAE
KEGYEVRILT ADKDLYQLLS DRIHVLHPEG YLITPAWLWE KYGLRPDQWA 181
DYRALTGDES DNLPGVKGIG EKTARKLLEE WGSLEALLKN LDRLKPAIRE KILAHMDDLK
241 LSWDLAKVRT DLPLEVDFAK RREPDRERLR AFLERLEFGS LLHEFGLLES
PKALEEAPWP 301 PPEGAFVGFV LSRKEPMWAD LLALAAARGG RVHRAPEPYK
ALRDLKEARG LLAKDLSVLA 361 LREGLGLPPG DDPMLLAYLL DPSNTTPEGV
ARRYGGEWTE EAGERAALSE RLFANLWGRL 421 EGEERLLWLY REVERPLSAV
LAHMEATGVR LDVAYLRALS LEVAEEIARL EAEVFRLAGH 481 PFNLNSRDQL
ERVLFDELGL PAIGKTEKTG KRSTSAAVLE ALREAHPIVE KILQYRELTK 541
LKSTYIDPLP DLIHPRTGRL HTRFNQTATA TGRLSSSDPN LQNIPVRTPL GQRIRRAFIA
601 EEGWLLVALD YSQIELRVLA HLSGDENLIR VFQEGRDIHT ETASWMFGVP
REAVDPLMRR 661 AAKTINFGVL YGMSAHRLSQ ELAIPYEEAQ AFIERYFQSF
PKVRAWIEKT LEEGRRRGYV 721 ETLFGRRRYV PRLEARVKSV REAAERMAFN
MPVQGTAADL MKLAMVKLFP RLEEMGARML 781 LQVHDELVLE APKERAEAVA
RLAKEVMEGV YPLAVPLEVE VGIGEDWLSA KE
[0463] This modified polymerase had previously shown a 14-fold
decrease in the rate of template dissociation as compared to
wild-type Taq DNA polymerase (see Example 9). The modified Taq DNA
polymerase was then evaluated for performance in an emulsion PCR
reaction to generate nucleic acid libraries. The nucleic acid
libraries were prepared using a 400 by insert and higher salt
conditions than previously evaluated. The libraries obtained using
the modified Taq DNA polymerase from the emulsion PCR (emPCR) were
applied downstream in an ion-based sequencing reaction using the
Ion Torrent PGM.TM. sequencing system (Ion Torrent Systems, Part
No. 4462917).
[0464] Briefly, genomic DNA was purified, adapter-ligated and size
selected as described in User Guide for the Ion Fragment Library
Kit (Ion Torrent Systems, Part No. 4466464; Publication Part No.
4467320 Rev B). In this example, DNA fragments of about 400 bp were
used as the nucleic acid template for generating nucleic acid
libraries. The DNA fragments were then amplified onto Ion
Sphere.TM. particles (Ion Torrent Systems, Part No. 602-1075-01)
essentially according to the protocols provided in the User Guide
for the Ion Xpress.TM. Template Kit v2.0 (Ion Torrent Systems, Part
No. 4469004A), except for substituting the kit DNA polymerase with
the modified Taq DNA polymerase and performing the emPCR process at
an elevated salt concentration (150 mM KCl). The amplified DNA was
then loaded into a PGM.TM. 316 sequencing chip. The chip was loaded
into an Ion Torrent PGM.TM. Sequencing system (Ion Torrent
Systems/Life Technologies, Part No. 4462917) and sequenced
essentially according to the protocols provided in User Guide for
the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies,
Part No. 4469714 Rev A) and using the reagents provided in the Ion
Sequencing Kit v2.0 (Ion Torrent Systems/Life Technologies, Part
No. 4466456) and the Ion Chip Kit (Ion Torrent Systems/Life
Technologies, Part No. 4462923).
[0465] The resulting sequencing read using the modified Taq DNA
polymerase during emPCR was analyzed to measure the number of AQ17
bases, AQ 20 bases, AQ17 mean, AQ20 mean, number of library reads,
and AQ7 alignments. The data for the sequencing run performed as
outlined in this example is shown in FIG. 16. As can be seen, the
sequencing run generated over 1 Gb (gigabyte) of data at Q17 (1.025
Gb); a Q17 accuracy rate of 443 base pairs and a Q20 accuracy rate
of 443 base pairs. The modified DNA polymerase was capable of
generating significant sequencing data, as a result of having
created substantial numbers of nucleic acid libraries during the
emPCR process.
Example 14
Evaluating Modified Polymerase Performance in Emulsion PCR
[0466] A modified polymerase comprising a mutant Taq DNA polymerase
having the amino acid sequence of SEQ ID NO: 24 was compared to
Wild Type Taq DNA polymerase for performance in emulsion PCR
reactions that generate nucleic acid libraries. The nucleic acid
libraries produced using the mutant Taq DNA polymerase were
prepared using a 400 by insert and higher salt conditions than were
used for Wild Type Taq DNA polymerase. The libraries obtained using
the modified or Wild Type Taq DNA polymerase from the emulsion PCR
(emPCR) were applied downstream in an ion-based sequencing reaction
using the Ion Torrent PGM.TM. sequencing system (Ion Torrent
Systems, Part No. 4462917).
[0467] Briefly, genomic DNA was purified, adapter-ligated and size
selected as described in User Guide for the Ion Fragment Library
Kit (Ion Torrent Systems, Part No. 4466464; Publication Part No.
4467320 Rev B). In this example, DNA fragments of about 400 bp were
used as the nucleic acid template for generating nucleic acid
libraries. The DNA fragments were then amplified onto Ion
Sphere.TM. particles (Ion Torrent Systems, Part No. 602-1075-01)
essentially according to the protocols provided in the User Guide
for the Ion Xpress.TM. Template Kit v2.0 (Ion Torrent Systems, Part
No. 4469004A), except for emulsions which substitute the kit DNA
polymerase with the modified Taq DNA polymerase and performing the
emPCR process at an elevated salt concentration (150 mM KCl). The
amplified DNA was then loaded into a PGM.TM. 316 sequencing chip.
The chip was loaded into an Ion Torrent PGM.TM. Sequencing system
(Ion Torrent Systems/Life Technologies, Part No. 4462917) and
sequenced essentially according to the protocols provided in User
Guide for the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life
Technologies, Part No. 4469714 Rev A) and using the reagents
provided in the Ion Sequencing Kit v2.0 (Ion Torrent Systems/Life
Technologies, Part No. 4466456) and the Ion Chip Kit (Ion Torrent
Systems/Life Technologies, Part No. 4462923).
[0468] The resulting sequencing read using the modified Taq DNA
polymerase (LR1Taq) or the Wild Type Taq DNA polymerase (Taq)
during emPCR were analyzed to measure the number of AQ17 bases, AQ
20 bases, AQ17 mean, Key Signal, Signal to Noise, and number of
library reads. The data for the sequencing run performed as
outlined in this example is shown in FIG. 17. As can be seen, the
sequencing runs using emulsion made with the modified Taq DNA
polymerase (LR1Taq) averaged 0.87 Gigabases of data at Q17 (0.874
Gb) compared to an average of 0.26 Gigabases of data at Q17 (0.263
Gb) for Wild Type Taq DNA polymerase. The modified DNA polymerase
was capable of generating significant sequencing data, as a result
of having created substantial numbers of nucleic acid libraries
during the emPCR process.
Sequence CWU 1
1
241581PRTBacillus stearothermophilus 1Met Ala Lys Met Ala Phe Thr
Leu Ala Asp Arg Val Thr Glu Glu Met1 5 10 15Leu Ala Asp Lys Ala Ala
Leu Val Val Glu Val Val Glu Glu Asn Tyr 20 25 30His Asp Ala Pro Ile
Val Gly Ile Ala Val Val Asn Glu His Gly Arg 35 40 45Phe Phe Leu Arg
Pro Glu Thr Ala Leu Ala Asp Pro Gln Phe Val Ala 50 55 60Trp Leu Gly
Asp Glu Thr Lys Lys Lys Ser Met Phe Asp Ser Lys Arg65 70 75 80Ala
Ala Val Ala Leu Lys Trp Lys Gly Ile Glu Leu Cys Gly Val Ser 85 90
95Phe Asp Leu Leu Leu Ala Ala Tyr Leu Leu Asp Pro Ala Gln Gly Val
100 105 110Asp Asp Val Ala Ala Ala Ala Lys Met Lys Gln Tyr Glu Ala
Val Arg 115 120 125Pro Asp Glu Ala Val Tyr Gly Lys Gly Ala Lys Arg
Ala Val Pro Asp 130 135 140Glu Pro Val Leu Ala Glu His Leu Val Arg
Lys Ala Ala Ala Ile Trp145 150 155 160Glu Leu Glu Arg Pro Phe Leu
Asp Glu Leu Arg Arg Asn Glu Gln Asp 165 170 175Arg Leu Leu Val Glu
Leu Glu Gln Pro Leu Ser Ser Ile Leu Ala Glu 180 185 190Met Glu Phe
Ala Gly Val Lys Val Asp Thr Lys Arg Leu Glu Gln Met 195 200 205Gly
Lys Glu Leu Ala Glu Gln Leu Gly Thr Val Glu Gln Arg Ile Tyr 210 215
220Glu Leu Ala Gly Gln Glu Phe Asn Ile Asn Ser Pro Lys Gln Leu
Gly225 230 235 240Val Ile Leu Phe Glu Lys Leu Gln Leu Pro Val Leu
Lys Lys Thr Lys 245 250 255Thr Gly Tyr Ser Thr Ser Ala Asp Val Leu
Glu Lys Leu Ala Pro Tyr 260 265 270His Glu Ile Val Glu Asn Ile Leu
His Tyr Arg Gln Leu Gly Lys Leu 275 280 285Gln Ser Thr Tyr Ile Glu
Gly Leu Leu Lys Val Val Arg Pro Asp Thr 290 295 300Lys Lys Val His
Thr Ile Phe Asn Gln Ala Leu Thr Gln Thr Gly Arg305 310 315 320Leu
Ser Ser Thr Glu Pro Asn Leu Gln Asn Ile Pro Ile Arg Leu Glu 325 330
335Glu Gly Arg Lys Ile Arg Gln Ala Phe Val Pro Ser Glu Ser Asp Trp
340 345 350Leu Ile Phe Ala Ala Asp Tyr Ser Gln Ile Glu Leu Arg Val
Leu Ala 355 360 365His Ile Ala Glu Asp Asp Asn Leu Met Glu Ala Phe
Arg Arg Asp Leu 370 375 380Asp Ile His Thr Lys Thr Ala Met Asp Ile
Phe Gln Val Ser Glu Asp385 390 395 400Glu Val Thr Pro Asn Met Arg
Arg Gln Ala Lys Ala Val Asn Phe Gly 405 410 415Ile Val Tyr Gly Ile
Ser Asp Tyr Gly Leu Ala Gln Asn Leu Asn Ile 420 425 430Ser Arg Lys
Glu Ala Ala Glu Phe Ile Glu Arg Tyr Phe Glu Ser Phe 435 440 445Pro
Gly Val Lys Arg Tyr Met Glu Asn Ile Val Gln Glu Ala Lys Gln 450 455
460Lys Gly Tyr Val Thr Thr Leu Leu His Arg Arg Arg Tyr Leu Pro
Asp465 470 475 480Ile Thr Ser Arg Asn Phe Asn Val Arg Ser Phe Ala
Glu Arg Met Ala 485 490 495Met Asn Thr Pro Ile Gln Gly Ser Ala Ala
Asp Ile Ile Lys Lys Ala 500 505 510Met Ile Asp Leu Asn Ala Arg Leu
Lys Glu Glu Arg Leu Gln Ala His 515 520 525Leu Leu Leu Gln Val His
Asp Glu Leu Ile Leu Glu Ala Pro Lys Glu 530 535 540Glu Met Glu Arg
Leu Cys Arg Leu Val Pro Glu Val Met Glu Gln Ala545 550 555 560Val
Thr Leu Arg Val Pro Leu Lys Val Asp Tyr His Tyr Gly Ser Thr 565 570
575Trp Tyr Asp Ala Lys 5802581PRTBacillus stearothermophilus 2Met
Ala Lys Met Ala Phe Thr Leu Ala Asp Arg Val Thr Glu Glu Met1 5 10
15Leu Ala Asp Lys Ala Ala Leu Val Val Glu Val Val Glu Glu Asn Tyr
20 25 30His Asp Ala Pro Ile Val Gly Ile Ala Val Val Asn Glu Arg Gly
Arg 35 40 45Phe Phe Leu Arg Pro Glu Thr Ala Leu Ala Asp Pro Gln Phe
Val Ala 50 55 60Trp Leu Gly Asp Glu Thr Lys Lys Lys Ser Met Phe Asp
Ser Lys Arg65 70 75 80Ala Ala Val Ala Leu Lys Trp Lys Gly Ile Glu
Leu Cys Gly Val Ser 85 90 95Phe Asp Leu Leu Leu Ala Ala Tyr Leu Leu
Asp Pro Ala Gln Gly Val 100 105 110Asp Asp Val Ala Ala Ala Ala Lys
Met Lys Gln Tyr Glu Ala Val Arg 115 120 125Pro Asp Glu Ala Val Tyr
Gly Lys Gly Ala Lys Arg Ala Val Pro Asp 130 135 140Glu Pro Val Leu
Ala Glu His Leu Val Arg Lys Ala Ala Ala Ile Trp145 150 155 160Glu
Leu Glu Arg Pro Phe Leu Asp Glu Leu Arg Arg Asn Glu Gln Asp 165 170
175Arg Leu Leu Val Glu Leu Glu Gln Pro Leu Ser Ser Ile Leu Ala Glu
180 185 190Met Glu Phe Ala Gly Val Lys Val Asp Thr Lys Arg Leu Glu
Gln Met 195 200 205Gly Lys Glu Leu Ala Glu Gln Leu Gly Thr Val Glu
Gln Arg Ile Tyr 210 215 220Glu Leu Ala Gly Gln Glu Phe Asn Ile Asn
Ser Pro Lys Gln Leu Gly225 230 235 240Val Ile Leu Phe Glu Lys Leu
Gln Leu Pro Val Leu Lys Lys Thr Lys 245 250 255Thr Gly Tyr Ser Thr
Ser Ala Asp Val Leu Glu Lys Leu Ala Pro Tyr 260 265 270His Glu Ile
Val Glu Asn Ile Leu His Tyr Arg Gln Leu Gly Lys Leu 275 280 285Gln
Ser Thr Tyr Ile Glu Gly Leu Leu Lys Val Val Arg Pro Asp Thr 290 295
300Lys Lys Val His Thr Ile Phe Asn Gln Ala Leu Thr Gln Thr Gly
Arg305 310 315 320Leu Ser Ser Thr Glu Pro Asn Leu Gln Asn Ile Pro
Ile Arg Leu Glu 325 330 335Glu Gly Arg Lys Ile Arg Gln Ala Phe Val
Pro Ser Glu Ser Asp Trp 340 345 350Leu Ile Phe Ala Ala Asp Tyr Ser
Gln Ile Glu Leu Arg Val Leu Ala 355 360 365His Ile Ala Glu Asp Asp
Asn Leu Met Glu Ala Phe Arg Arg Asp Leu 370 375 380Asp Ile His Thr
Lys Thr Ala Met Asp Ile Phe Gln Val Ser Glu Asp385 390 395 400Glu
Val Thr Pro Asn Met Arg Arg Gln Ala Lys Ala Val Asn Phe Gly 405 410
415Ile Val Tyr Gly Ile Ser Asp Tyr Gly Leu Ala Gln Asn Leu Asn Ile
420 425 430Ser Arg Lys Glu Ala Ala Glu Phe Ile Glu Arg Tyr Phe Gln
Ser Phe 435 440 445Pro Gly Val Lys Arg Tyr Met Glu Asn Ile Val Gln
Glu Ala Lys Gln 450 455 460Lys Gly Tyr Val Thr Thr Leu Leu His Arg
Arg Arg Tyr Leu Pro Asp465 470 475 480Ile Thr Ser Arg Asn Phe Asn
Val Arg Ser Phe Ala Glu Arg Met Ala 485 490 495Met Asn Thr Pro Ile
Gln Gly Ser Ala Ala Asp Ile Ile Lys Lys Ala 500 505 510Met Ile Asp
Leu Asn Ala Arg Leu Lys Glu Glu Arg Leu Gln Ala His 515 520 525Leu
Leu Leu Gln Val His Asp Glu Leu Ile Leu Glu Ala Pro Lys Glu 530 535
540Glu Met Glu Arg Leu Cys Arg Leu Val Pro Glu Val Met Glu Gln
Ala545 550 555 560Val Thr Leu Arg Val Pro Leu Lys Val Asp Tyr Arg
Tyr Gly Ser Thr 565 570 575Trp Tyr Asp Ala Lys 5803581PRTBacillus
stearothermophilus 3Met Ala Lys Met Ala Phe Thr Leu Ala Asp Arg Val
Thr Glu Glu Met1 5 10 15Leu Ala Asp Lys Ala Ala Leu Val Val Glu Val
Val Glu Glu Asn Tyr 20 25 30His Asp Ala Pro Ile Val Gly Ile Ala Val
Val Asn Glu Arg Gly Arg 35 40 45Phe Phe Leu Arg Pro Glu Thr Ala Leu
Ala Asp Pro Gln Phe Val Ala 50 55 60Trp Leu Gly Asp Glu Thr Lys Lys
Lys Ser Met Phe Asp Ser Lys Arg65 70 75 80Ala Ala Val Ala Leu Lys
Trp Lys Gly Ile Glu Leu Cys Gly Val Ser 85 90 95Phe Asp Leu Leu Leu
Ala Ala Tyr Leu Leu Asp Pro Ala Gln Gly Val 100 105 110Asp Asp Val
Ala Ala Ala Ala Lys Met Lys Gln Tyr Glu Ala Val Arg 115 120 125Pro
Asp Glu Ala Val Tyr Gly Lys Gly Ala Lys Arg Ala Val Pro Asp 130 135
140Glu Pro Val Leu Ala Glu His Leu Val Arg Lys Ala Ala Ala Ile
Trp145 150 155 160Glu Leu Glu Arg Pro Phe Leu Asp Glu Leu Arg Arg
Asn Glu Gln Asp 165 170 175Arg Leu Leu Val Glu Leu Glu Gln Pro Leu
Ser Ser Ile Leu Ala Glu 180 185 190Met Glu Phe Ala Gly Val Lys Val
Asp Thr Lys Arg Leu Glu Gln Met 195 200 205Gly Lys Glu Leu Ala Glu
Gln Leu Gly Thr Val Glu Gln Arg Ile Tyr 210 215 220Glu Leu Ala Gly
Gln Glu Phe Asn Ile Asn Ser Pro Lys Gln Leu Gly225 230 235 240Val
Ile Leu Phe Glu Lys Leu Gln Leu Pro Val Leu Lys Lys Thr Lys 245 250
255Thr Gly Tyr Ser Thr Ser Ala Asp Val Leu Glu Lys Leu Ala Pro Tyr
260 265 270His Glu Ile Val Glu Asn Ile Leu His Tyr Arg Gln Leu Gly
Lys Leu 275 280 285Gln Ser Thr Tyr Ile Glu Gly Leu Leu Lys Val Val
Arg Pro Asp Thr 290 295 300Lys Lys Val His Thr Ile Phe Asn Gln Ala
Leu Thr Gln Thr Gly Arg305 310 315 320Leu Ser Ser Thr Glu Pro Asn
Leu Gln Asn Ile Pro Ile Arg Leu Glu 325 330 335Glu Gly Arg Lys Ile
Arg Gln Ala Phe Val Pro Ser Glu Ser Asp Trp 340 345 350Leu Ile Phe
Ala Ala Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala 355 360 365His
Ile Ala Glu Asp Asp Asn Leu Met Glu Ala Phe Arg Arg Asp Leu 370 375
380Asp Ile His Thr Lys Thr Ala Met Asp Ile Phe Gln Val Ser Glu
Asp385 390 395 400Glu Val Thr Pro Asn Met Arg Arg Gln Ala Lys Ala
Val Asn Phe Gly 405 410 415Ile Val Tyr Gly Ile Ser Asp Tyr Gly Leu
Ala Gln Asn Leu Asn Ile 420 425 430Ser Arg Lys Glu Ala Ala Glu Phe
Ile Glu Arg Tyr Phe Gln Ser Phe 435 440 445Pro Gly Val Lys Arg Tyr
Met Glu Asn Ile Val Gln Glu Ala Lys Gln 450 455 460Lys Gly Tyr Val
Thr Thr Leu Leu Arg Arg Arg Arg Tyr Leu Pro Asp465 470 475 480Ile
Thr Ser Arg Asn Phe Asn Val Arg Ser Phe Ala Glu Arg Met Ala 485 490
495Met Asn Thr Pro Ile Gln Gly Ser Ala Ala Asp Ile Ile Lys Lys Ala
500 505 510Met Ile Asp Leu Asn Ala Arg Leu Lys Glu Glu Arg Leu Gln
Ala Ala 515 520 525Leu Leu Leu Gln Val His Asp Glu Leu Ile Leu Glu
Ala Pro Lys Glu 530 535 540Glu Met Glu Arg Leu Cys Arg Leu Val Pro
Glu Val Met Glu Gln Ala545 550 555 560Val Thr Leu Arg Val Pro Leu
Lys Val Asp Tyr Arg Tyr Gly Ser Thr 565 570 575Trp Tyr Asp Ala Lys
5804581PRTBacillus stearothermophilus 4Met Ala Lys Met Ala Phe Thr
Leu Ala Asp Arg Val Thr Glu Glu Met1 5 10 15Leu Ala Asp Lys Ala Ala
Leu Val Val Glu Val Val Glu Glu Asn Tyr 20 25 30His Asp Ala Pro Ile
Val Gly Ile Ala Val Val Asn Glu Arg Gly Arg 35 40 45Phe Phe Leu Arg
Pro Glu Thr Ala Leu Ala Asp Pro Gln Phe Val Ala 50 55 60Trp Leu Gly
Asp Glu Thr Lys Lys Lys Ser Met Phe Asp Ser Lys Arg65 70 75 80Ala
Ala Val Ala Leu Lys Trp Lys Gly Ile Glu Leu Cys Gly Val Ser 85 90
95Phe Asp Leu Leu Leu Ala Ala Tyr Leu Leu Asp Pro Ala Gln Gly Val
100 105 110Asp Asp Val Ala Ala Ala Ala Lys Met Lys Gln Tyr Glu Ala
Val Arg 115 120 125Pro Asp Glu Ala Val Tyr Gly Lys Gly Ala Lys Arg
Ala Val Pro Asp 130 135 140Glu Pro Val Leu Ala Glu His Leu Val Arg
Lys Ala Ala Ala Ile Trp145 150 155 160Glu Leu Glu Arg Pro Phe Leu
Asp Glu Leu Arg Arg Asn Glu Gln Asp 165 170 175Arg Leu Leu Val Glu
Leu Glu Gln Pro Leu Ser Ser Ile Leu Ala Glu 180 185 190Met Glu Phe
Ala Gly Val Lys Val Asp Thr Lys Arg Leu Glu Gln Met 195 200 205Gly
Lys Glu Leu Ala Glu Gln Leu Gly Thr Val Glu Gln Arg Ile Tyr 210 215
220Glu Leu Ala Gly Gln Glu Phe Asn Ile Asn Ser Pro Lys Gln Leu
Gly225 230 235 240Val Ile Leu Phe Glu Lys Leu Gln Leu Pro Val Leu
Lys Lys Thr Lys 245 250 255Thr Gly Tyr Ser Thr Ser Ala Asp Val Leu
Glu Lys Leu Ala Pro Tyr 260 265 270Arg Glu Ile Val Glu Asn Ile Leu
Ala Tyr Arg Gln Leu Gly Lys Leu 275 280 285Gln Ser Thr Tyr Ile Glu
Gly Leu Leu Lys Val Val Arg Pro Asp Thr 290 295 300Lys Lys Val His
Thr Ile Phe Asn Gln Ala Leu Thr Gln Thr Gly Arg305 310 315 320Leu
Ser Ser Thr Glu Pro Asn Leu Gln Asn Ile Pro Ile Arg Leu Glu 325 330
335Glu Gly Arg Lys Ile Arg Gln Ala Phe Val Pro Ser Glu Ser Asp Trp
340 345 350Leu Ile Phe Ala Ala Asp Tyr Ser Gln Ile Glu Leu Arg Val
Leu Ala 355 360 365His Ile Ala Glu Asp Asp Asn Leu Met Glu Ala Phe
Arg Arg Asp Leu 370 375 380Asp Ile His Thr Lys Thr Ala Met Asp Ile
Phe Gln Val Ser Glu Asp385 390 395 400Glu Val Thr Pro Asn Met Arg
Arg Gln Ala Lys Ala Val Asn Phe Gly 405 410 415Ile Val Tyr Gly Ile
Ser Asp Tyr Gly Leu Ala Gln Asn Leu Asn Ile 420 425 430Ser Arg Lys
Glu Ala Ala Glu Phe Ile Glu Arg Tyr Phe Gln Ser Phe 435 440 445Pro
Gly Val Lys Arg Tyr Met Glu Asn Ile Val Gln Glu Ala Lys Gln 450 455
460Lys Gly Tyr Val Thr Thr Leu Leu Arg Arg Arg Arg Phe Leu Pro
Asp465 470 475 480Ile Thr Ser Arg Asn Phe Asn Val Arg Ser Phe Ala
Glu Arg Met Ala 485 490 495Met Asn Thr Pro Ile Gln Gly Ser Ala Ala
Asp Ile Ile Lys Lys Ala 500 505 510Met Ile Asp Leu Asn Ala Arg Leu
Lys Glu Glu Arg Leu Gln Ala Ala 515 520 525Leu Leu Leu Gln Val His
Asp Glu Leu Ile Leu Glu Ala Pro Lys Glu 530 535 540Glu Met Glu Arg
Leu Cys Arg Leu Val Pro Glu Val Met Glu Gln Ala545 550 555 560Val
Thr Leu Arg Val Pro Leu Lys Val Asp Tyr Arg Tyr Gly Ser Thr 565 570
575Trp Tyr Asp Ala Lys 58056PRTArtificial Sequenceconsensus
sequence for motif A family A polymerase 5Asp Xaa Ser Xaa Xaa Glu1
569PRTArtificial Sequenceconsensus sequence for motif B family A
polymerase 6Lys Xaa Xaa Xaa Xaa Xaa Xaa Tyr Gly1 574PRTArtificial
Sequenceconsensus sequence for motif C family A polymerase 7Val His
Asp Glu188PRTArtificial Sequenceconsensus sequence for motif A
family B polymerase 8Asp Xaa Xaa Ser Leu Tyr Pro Ser1
599PRTArtificial Sequenceconsensus sequence for motif B family B
polymerase 9Lys Xaa Xaa Xaa Asn Ser Xaa Tyr Gly1 5106PRTArtificial
Sequenceconsensus sequence for motif C family B polymerase 10Tyr
Gly Asp Thr Asp Ser1 5117PRTArtificial Sequenceconsensus sequence
for motif A 11Asp Xaa Xaa Xaa Xaa Phe Tyr1 5128PRTArtificial
Sequenceconsensus sequence for motif B 12Phe Xaa Gly Xaa Xaa Xaa
Ser Ala1
5134PRTArtificial Sequenceconsensus sequence for motif C 13Tyr Xaa
Asp Asp1149PRTArtificial Sequenceconsensus sequence for motif D
14Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys1 515832PRTThermus aquaticus
15Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu1
5 10 15Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
Gly 20 25 30Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly
Phe Ala 35 40 45Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala
Val Ile Val 50 55 60Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu
Ala Tyr Gly Gly65 70 75 80Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu
Asp Phe Pro Arg Gln Leu 85 90 95Ala Leu Ile Lys Glu Leu Val Asp Leu
Leu Gly Leu Ala Arg Leu Glu 100 105 110Val Pro Gly Tyr Glu Ala Asp
Asp Val Leu Ala Ser Leu Ala Lys Lys 115 120 125Ala Glu Lys Glu Gly
Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp 130 135 140Leu Tyr Gln
Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly145 150 155
160Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser
Asp Asn 180 185 190Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala
Arg Lys Leu Leu 195 200 205Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu
Lys Asn Leu Asp Arg Leu 210 215 220Lys Pro Ala Ile Arg Glu Lys Ile
Leu Ala His Met Asp Asp Leu Lys225 230 235 240Leu Ser Trp Asp Leu
Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val 245 250 255Asp Phe Ala
Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe 260 265 270Leu
Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu 275 280
285Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp
Ala Asp305 310 315 320Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg
Val His Arg Ala Pro 325 330 335Glu Pro Tyr Lys Ala Leu Arg Asp Leu
Lys Glu Ala Arg Gly Leu Leu 340 345 350Ala Lys Asp Leu Ser Val Leu
Ala Leu Arg Glu Gly Leu Gly Leu Pro 355 360 365Pro Gly Asp Asp Pro
Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn 370 375 380Thr Thr Pro
Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu385 390 395
400Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu
405 410 415Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr
Arg Glu 420 425 430Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met
Glu Ala Thr Gly 435 440 445Val Arg Leu Asp Val Ala Tyr Leu Arg Ala
Leu Ser Leu Glu Val Ala 450 455 460Glu Glu Ile Ala Arg Leu Glu Ala
Glu Val Phe Arg Leu Ala Gly His465 470 475 480Pro Phe Asn Leu Asn
Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp 485 490 495Glu Leu Gly
Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg 500 505 510Ser
Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile 515 520
525Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly
Arg Leu545 550 555 560His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr
Gly Arg Leu Ser Ser 565 570 575Ser Asp Pro Asn Leu Gln Asn Ile Pro
Val Arg Thr Pro Leu Gly Gln 580 585 590Arg Ile Arg Arg Ala Phe Ile
Ala Glu Glu Gly Trp Leu Leu Val Ala 595 600 605Leu Asp Tyr Ser Gln
Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly 610 615 620Asp Glu Asn
Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr625 630 635
640Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu
Tyr Gly 660 665 670Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile
Pro Tyr Glu Glu 675 680 685Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln
Ser Phe Pro Lys Val Arg 690 695 700Ala Trp Ile Glu Lys Thr Leu Glu
Glu Gly Arg Arg Arg Gly Tyr Val705 710 715 720Glu Thr Leu Phe Gly
Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg 725 730 735Val Lys Ser
Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro 740 745 750Val
Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu 755 760
765Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala
Val Ala785 790 795 800Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr
Pro Leu Ala Val Pro 805 810 815Leu Glu Val Glu Val Gly Ile Gly Glu
Asp Trp Leu Ser Ala Lys Glu 820 825 83016876PRTBacillus
stearothermophilus 16Met Lys Lys Lys Leu Val Leu Ile Asp Gly Ser
Ser Val Ala Tyr Arg1 5 10 15Ala Phe Phe Ala Leu Pro Leu Leu His Asn
Asp Lys Gly Ile His Thr 20 25 30Asn Ala Val Tyr Gly Phe Thr Met Met
Leu Asn Lys Ile Leu Ala Glu 35 40 45Glu Glu Pro Thr His Met Leu Val
Ala Phe Asp Ala Gly Lys Thr Thr 50 55 60Phe Arg His Glu Ala Phe Gln
Glu Tyr Lys Gly Gly Arg Gln Gln Thr65 70 75 80Pro Pro Glu Leu Ser
Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Arg 85 90 95Ala Tyr Arg Ile
Pro Ala Tyr Glu Leu Glu Asn Tyr Glu Ala Asp Asp 100 105 110Ile Ile
Gly Thr Leu Ala Ala Arg Ala Glu Gln Glu Gly Phe Glu Val 115 120
125Lys Val Ile Ser Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Pro His
130 135 140Val Thr Val Asp Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu
Pro Tyr145 150 155 160Thr Pro Glu Thr Val Arg Glu Lys Tyr Gly Leu
Thr Pro Glu Gln Ile 165 170 175Val Asp Leu Lys Gly Leu Met Gly Asp
Lys Ser Asp Asn Ile Pro Gly 180 185 190Val Pro Gly Ile Gly Glu Lys
Thr Ala Val Lys Leu Leu Arg Gln Phe 195 200 205Gly Thr Val Glu Asn
Val Leu Ala Ser Ile Asp Glu Ile Lys Gly Glu 210 215 220Lys Leu Lys
Glu Thr Leu Arg Gln His Arg Glu Met Ala Leu Leu Ser225 230 235
240Lys Lys Leu Ala Ala Ile Arg Arg Asp Ala Pro Val Glu Leu Ser Leu
245 250 255Asp Asp Ile Ala Tyr Gln Gly Glu Asp Arg Glu Lys Val Val
Ala Leu 260 265 270Phe Lys Glu Leu Gly Phe Gln Ser Phe Leu Glu Lys
Met Glu Ser Pro 275 280 285Ser Ser Glu Glu Glu Lys Pro Leu Ala Lys
Met Ala Phe Thr Leu Ala 290 295 300Asp Arg Val Thr Glu Glu Met Leu
Ala Asp Lys Ala Ala Leu Val Val305 310 315 320Glu Val Val Glu Glu
Asn Tyr His Asp Ala Pro Ile Val Gly Ile Ala 325 330 335Val Val Asn
Glu His Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu 340 345 350Ala
Asp Pro Gln Phe Val Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys 355 360
365Ser Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly
370 375 380Ile Glu Leu Cys Gly Val Ser Phe Asp Leu Leu Leu Ala Ala
Tyr Leu385 390 395 400Leu Asp Pro Ala Gln Gly Val Asp Asp Val Ala
Ala Ala Ala Lys Met 405 410 415Lys Gln Tyr Glu Ala Val Arg Pro Asp
Glu Ala Val Tyr Gly Lys Gly 420 425 430Ala Lys Arg Ala Val Pro Asp
Glu Pro Val Leu Ala Glu His Leu Val 435 440 445Arg Lys Ala Ala Ala
Ile Trp Glu Leu Glu Arg Pro Phe Leu Asp Glu 450 455 460Leu Arg Arg
Asn Glu Gln Asp Arg Leu Leu Val Glu Leu Glu Gln Pro465 470 475
480Leu Ser Ser Ile Leu Ala Glu Met Glu Phe Ala Gly Val Lys Val Asp
485 490 495Thr Lys Arg Leu Glu Gln Met Gly Lys Glu Leu Ala Glu Gln
Leu Gly 500 505 510Thr Val Glu Gln Arg Ile Tyr Glu Leu Ala Gly Gln
Glu Phe Asn Ile 515 520 525Asn Ser Pro Lys Gln Leu Gly Val Ile Leu
Phe Glu Lys Leu Gln Leu 530 535 540Pro Val Leu Lys Lys Thr Lys Thr
Gly Tyr Ser Thr Ser Ala Asp Val545 550 555 560Leu Glu Lys Leu Ala
Pro Tyr His Glu Ile Val Glu Asn Ile Leu His 565 570 575Tyr Arg Gln
Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu 580 585 590Lys
Val Val Arg Pro Asp Thr Lys Lys Val His Thr Ile Phe Asn Gln 595 600
605Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Thr Glu Pro Asn Leu Gln
610 615 620Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln
Ala Phe625 630 635 640Val Pro Ser Glu Ser Asp Trp Leu Ile Phe Ala
Ala Asp Tyr Ser Gln 645 650 655Ile Glu Leu Arg Val Leu Ala His Ile
Ala Glu Asp Asp Asn Leu Met 660 665 670Glu Ala Phe Arg Arg Asp Leu
Asp Ile His Thr Lys Thr Ala Met Asp 675 680 685Ile Phe Gln Val Ser
Glu Asp Glu Val Thr Pro Asn Met Arg Arg Gln 690 695 700Ala Lys Ala
Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly705 710 715
720Leu Ala Gln Asn Leu Asn Ile Ser Arg Lys Glu Ala Ala Glu Phe Ile
725 730 735Glu Arg Tyr Phe Glu Ser Phe Pro Gly Val Lys Arg Tyr Met
Glu Asn 740 745 750Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr
Thr Leu Leu His 755 760 765Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser
Arg Asn Phe Asn Val Arg 770 775 780Ser Phe Ala Glu Arg Met Ala Met
Asn Thr Pro Ile Gln Gly Ser Ala785 790 795 800Ala Asp Ile Ile Lys
Lys Ala Met Ile Asp Leu Asn Ala Arg Leu Lys 805 810 815Glu Glu Arg
Leu Gln Ala His Leu Leu Leu Gln Val His Asp Glu Leu 820 825 830Ile
Leu Glu Ala Pro Lys Glu Glu Met Glu Arg Leu Cys Arg Leu Val 835 840
845Pro Glu Val Met Glu Gln Ala Val Thr Leu Arg Val Pro Leu Lys Val
850 855 860Asp Tyr His Tyr Gly Ser Thr Trp Tyr Asp Ala Lys865 870
875171746DNABacillus stearothermophilus 17atggcaaaaa tggcatttac
cctggcagat cgtgttaccg aagaaatgct ggcagataaa 60gcagcactgg ttgttgaagt
tgtggaagaa aactatcatg atgcaccgat tgttggtatt 120gccgttgtta
atgaacgcgg tcgttttttt ctgcgtccgg aaaccgcact ggcagatccg
180cagtttgttg catggctggg tgatgaaacc aaaaagaaaa gcatgttcga
cagcaaacgt 240gcagcagttg cactgaaatg gaaaggtatt gaactgtgcg
gtgtgtcatt tgatctgctg 300ctggcagcat atctgctgga tccggcacag
ggtgttgatg atgttgcagc agcagcaaaa 360atgaaacagt atgaagcagt
tcgtccggat gaagcagttt atggtaaagg tgcaaaacgt 420gcagttccgg
atgaaccggt tctggcagaa catctggttc gtaaagcagc agcaatttgg
480gaactggaac gtccgtttct ggatgaactg cgtcgtaatg aacaggatcg
tctgctggtt 540gaactggaac agccgctgag cagcattctg gcagaaatgg
aatttgccgg tgttaaagtt 600gataccaaac gtctggaaca aatgggtaaa
gaactggccg aacaactggg caccgttgaa 660cagcgtattt atgaactggc
aggccaagaa tttaacatta atagcccgaa acagctgggc 720gttatcctgt
ttgaaaaact gcagctgccg gttctgaaaa aaaccaaaac cggttatagc
780accagcgcag atgttctgga aaaactggca ccgtatcatg aaattgtgga
aaacattctg 840cactatcgtc agctgggtaa actgcagagc acctatattg
aaggtctgct gaaagttgtg 900cgtccggata ccaaaaaagt gcataccatt
tttaaccagg cactgaccca gaccggtcgt 960ctgagcagca ccgaaccgaa
tctgcagaat attccgattc gtctggaaga aggtcgtaaa 1020attcgtcagg
catttgttcc gagcgaaagc gattggctga tttttgcagc agattatagc
1080cagattgaac tgcgtgttct ggcacatatt gccgaagatg ataatctgat
ggaagcattt 1140cgtcgcgatc tggatattca taccaaaacc gccatggata
tttttcaggt tagcgaagat 1200gaagtgaccc cgaatatgcg tcgtcaggca
aaagcagtta attttggtat tgtgtatggc 1260atcagcgatt atggtctggc
acagaatctg aatattagcc gtaaagaagc agccgaattt 1320atcgaacgtt
actttcagag ctttccgggt gttaaacgct atatggaaaa cattgtccaa
1380gaagccaaac agaaaggtta tgttaccacc ctgctgcatc gtcgtcgtta
tctgccgcgt 1440attaccagcc gtaactttaa tgttcgtagc tttgcagaac
gcatggcaat gaataccccg 1500attcagggta gcgcagcaga tattatcaaa
aaagccatga tcgatctgaa cgcacgtctg 1560aaagaagaac gtctgcaggc
acatttactg ctgcaggttc atgatgaact gattctggaa 1620gcaccgaaag
aagaaatgga acgtctttgt cgtctggttc cggaagttat ggaacaggca
1680gttaccctgc gtgttccgct gaaagttgat tatcgttatg gtagcacctg
gtatgatgcc 1740aaataa 174618606PRTEscherichia coli 18Met Val Ile
Ser Tyr Asp Asn Tyr Val Thr Ile Leu Asp Glu Glu Thr1 5 10 15Leu Lys
Ala Trp Ile Ala Lys Leu Glu Lys Ala Pro Val Phe Ala Phe 20 25 30Asp
Thr Glu Thr Asp Ser Leu Asp Asn Ile Ser Ala Asn Leu Val Gly 35 40
45Leu Ser Phe Ala Ile Glu Pro Gly Val Ala Ala Tyr Ile Pro Val Ala
50 55 60His Asp Tyr Leu Asp Ala Pro Asp Gln Ile Ser Arg Glu Arg Ala
Leu65 70 75 80Glu Leu Leu Lys Pro Leu Leu Glu Asp Glu Lys Ala Leu
Lys Val Gly 85 90 95Gln Asn Leu Lys Tyr Asp Arg Gly Ile Leu Ala Asn
Tyr Gly Ile Glu 100 105 110Leu Arg Gly Ile Ala Phe Asp Thr Met Leu
Glu Ser Tyr Ile Leu Asn 115 120 125Ser Val Ala Gly Arg His Asp Met
Asp Ser Leu Ala Glu Arg Trp Leu 130 135 140Lys His Lys Thr Ile Thr
Phe Glu Glu Ile Ala Gly Lys Gly Lys Asn145 150 155 160Gln Leu Thr
Phe Asn Gln Ile Ala Leu Glu Glu Ala Gly Arg Tyr Ala 165 170 175Ala
Glu Asp Ala Asp Val Thr Leu Gln Leu His Leu Lys Met Trp Pro 180 185
190Asp Leu Gln Lys His Lys Gly Pro Leu Asn Val Phe Glu Asn Ile Glu
195 200 205Met Pro Leu Val Pro Val Leu Ser Arg Ile Glu Arg Asn Gly
Val Lys 210 215 220Ile Asp Pro Lys Val Leu His Asn His Ser Glu Glu
Leu Thr Leu Arg225 230 235 240Leu Ala Glu Leu Glu Lys Lys Ala His
Glu Ile Ala Gly Glu Glu Phe 245 250 255Asn Leu Ser Ser Thr Lys Gln
Leu Gln Thr Ile Leu Phe Glu Lys Gln 260 265 270Gly Ile Lys Pro Leu
Lys Lys Thr Pro Gly Gly Ala Pro Ser Thr Ser 275 280 285Glu Glu Val
Leu Glu Glu Leu Ala Leu Asp Tyr Pro Leu Pro Lys Val 290 295 300Ile
Leu Glu Tyr Arg Gly Leu Ala Lys Leu Lys Ser Thr Tyr Thr Asp305 310
315 320Lys Leu Pro Leu Met Ile Asn Pro Lys Thr Gly Arg Val His Thr
Ser 325 330 335Tyr His Gln Ala Val Thr Ala Thr Gly Arg Leu Ser Ser
Thr Asp Pro 340 345 350Asn Leu Gln Asn Ile Pro Val Arg Asn Glu Glu
Gly Arg Arg Ile Arg 355 360 365Gln Ala Phe Ile Ala Pro Glu Asp Tyr
Val Ile Val Ser Ala Asp Tyr 370 375 380Ser Gln Ile Glu Leu Arg Ile
Met Ala His Leu Ser Arg Asp Lys Gly385 390 395 400Leu Leu Thr Ala
Phe Ala Glu Gly Lys Asp Ile His Arg Ala Thr Ala 405 410 415Ala Glu
Val Phe Gly Leu Pro Leu Glu Thr Val Thr Ser Glu Gln Arg 420
425 430Arg Ser Ala Lys Ala Ile Asn Phe Gly Leu Ile Tyr Gly Met Ser
Ala 435 440 445Phe Gly Leu Ala Arg Gln Leu Asn Ile Pro Arg Lys Glu
Ala Gln Lys 450 455 460Tyr Met Asp Leu Tyr Phe Glu Arg Tyr Pro Gly
Val Leu Glu Tyr Met465 470 475 480Glu Arg Thr Arg Ala Gln Ala Lys
Glu Gln Gly Tyr Val Glu Thr Leu 485 490 495Asp Gly Arg Arg Leu Tyr
Leu Pro Asp Ile Lys Ser Ser Asn Gly Ala 500 505 510Arg Arg Ala Ala
Ala Glu Arg Ala Ala Ile Asn Ala Pro Met Gln Gly 515 520 525Thr Ala
Ala Asp Ile Ile Lys Arg Ala Met Ile Ala Val Asp Ala Trp 530 535
540Leu Gln Ala Glu Gln Pro Arg Val Arg Met Ile Met Gln Val His
Asp545 550 555 560Glu Leu Val Phe Glu Val His Lys Asp Asp Val Asp
Ala Val Ala Lys 565 570 575Gln Ile His Gln Leu Met Glu Asn Cys Thr
Arg Leu Asp Val Pro Leu 580 585 590Leu Val Glu Val Gly Ser Gly Glu
Asn Trp Asp Gln Ala His 595 600 60519581PRTBacillus
stearothermophilus 19Met Ala Lys Met Ala Phe Thr Leu Ala Asp Arg
Val Thr Glu Glu Met1 5 10 15Leu Ala Asp Lys Ala Ala Leu Val Val Glu
Val Val Glu Glu Asn Tyr 20 25 30His Asp Ala Pro Ile Val Gly Ile Ala
Val Val Asn Glu Arg Gly Arg 35 40 45Phe Phe Leu Arg Pro Glu Thr Ala
Leu Ala Asp Pro Gln Phe Val Ala 50 55 60Trp Leu Gly Asp Glu Thr Lys
Lys Lys Ser Met Phe Asp Ser Lys Arg65 70 75 80Ala Ala Val Ala Leu
Lys Trp Lys Gly Ile Glu Leu Cys Gly Val Ser 85 90 95Phe Asp Leu Leu
Leu Ala Ala Tyr Leu Leu Asp Pro Ala Gln Gly Val 100 105 110Asp Asp
Val Ala Ala Ala Ala Lys Met Lys Gln Tyr Glu Ala Val Arg 115 120
125Pro Asp Glu Ala Val Tyr Gly Lys Gly Ala Lys Arg Ala Val Pro Asp
130 135 140Glu Pro Val Leu Ala Glu His Leu Val Arg Lys Ala Ala Ala
Ile Trp145 150 155 160Glu Leu Glu Arg Pro Phe Leu Asp Glu Leu Arg
Arg Asn Glu Gln Asp 165 170 175Arg Leu Leu Val Glu Leu Glu Gln Pro
Leu Ser Ser Ile Leu Ala Glu 180 185 190Met Glu Phe Ala Gly Val Lys
Val Asp Thr Lys Arg Leu Glu Gln Met 195 200 205Gly Lys Glu Leu Ala
Glu Gln Leu Gly Thr Val Lys Gln Arg Ile Tyr 210 215 220Glu Leu Ala
Gly Gln Glu Phe Asn Ile Arg Ser Pro Lys Gln Leu Gly225 230 235
240Val Ile Leu Phe Glu Lys Leu Gln Leu Pro Val Leu Lys Lys Thr Lys
245 250 255Thr Gly Tyr Ser Thr Ser Ala Asp Val Leu Glu Lys Leu Ala
Pro Tyr 260 265 270His Glu Ile Val Glu Asn Ile Leu His Tyr Arg Gln
Leu Gly Lys Leu 275 280 285Gln Ser Thr Tyr Ile Glu Gly Leu Leu Lys
Val Val Arg Pro Asp Thr 290 295 300Lys Lys Val His Thr Ile Phe Asn
Gln Ala Leu Thr Gln Thr Gly Arg305 310 315 320Leu Ser Ser Thr Glu
Pro Asn Leu Gln Asn Ile Pro Ile Arg Leu Glu 325 330 335Glu Gly Arg
Lys Ile Arg Gln Ala Phe Val Pro Ser Glu Ser Asp Trp 340 345 350Leu
Ile Phe Ala Ala Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala 355 360
365His Ile Ala Glu Asp Asp Asn Leu Met Glu Ala Phe Arg Arg Asp Leu
370 375 380Asp Ile His Thr Lys Thr Ala Met Asp Ile Phe Gln Val Ser
Glu Asp385 390 395 400Glu Val Thr Pro Asn Met Arg Arg Gln Ala Lys
Ala Val Asn Phe Gly 405 410 415Ile Val Tyr Gly Ile Ser Lys Tyr Gly
Leu Ala Gln Asn Leu Asn Ile 420 425 430Ser Arg Lys Glu Ala Ala Glu
Phe Ile Glu Arg Tyr Phe Gln Ser Phe 435 440 445Pro Gly Val Lys Arg
Tyr Met Glu Asn Ile Val Gln Glu Ala Lys Gln 450 455 460Lys Gly Tyr
Val Thr Thr Leu Leu His Arg Arg Arg Tyr Leu Pro Asp465 470 475
480Ile Thr Ser Arg Asn Phe Asn Val Arg Ser Phe Ala Glu Arg Met Ala
485 490 495Met Asn Thr Pro Ile Gln Gly Ser Ala Ala Asp Ile Ile Lys
Lys Ala 500 505 510Met Ile Asp Leu Asn Ala Arg Leu Lys Glu Glu Arg
Leu Gln Ala His 515 520 525Leu Leu Leu Gln Val His Asp Glu Leu Ile
Leu Glu Ala Pro Lys Glu 530 535 540Glu Met Glu Arg Leu Cys Arg Leu
Val Pro Glu Val Met Glu Gln Ala545 550 555 560Val Thr Leu Arg Val
Pro Leu Lys Val Asp Tyr Arg Tyr Gly Ser Thr 565 570 575Trp Tyr Asp
Ala Lys 58020581PRTBacillus stearothermophilus 20Met Ala Lys Met
Ala Phe Thr Leu Ala Asp Arg Val Thr Glu Glu Met1 5 10 15Leu Ala Asp
Lys Ala Ala Leu Val Val Glu Val Val Glu Glu Asn Tyr 20 25 30His Asp
Ala Pro Ile Val Gly Ile Ala Val Val Asn Glu Arg Gly Arg 35 40 45Phe
Phe Leu Arg Pro Glu Thr Ala Leu Ala Asp Pro Gln Phe Val Ala 50 55
60Trp Leu Gly Asp Glu Thr Lys Lys Lys Ser Met Phe Asp Ser Lys Arg65
70 75 80Ala Ala Val Ala Leu Lys Trp Lys Gly Ile Glu Leu Cys Gly Val
Ser 85 90 95Phe Asp Leu Leu Leu Ala Ala Tyr Leu Leu Asp Pro Ala Gln
Gly Val 100 105 110Asp Asp Val Ala Ala Ala Ala Lys Met Lys Gln Tyr
Glu Ala Val Arg 115 120 125Pro Asp Glu Ala Val Tyr Gly Lys Gly Ala
Lys Arg Ala Val Pro Asp 130 135 140Glu Pro Val Leu Ala Glu His Leu
Val Arg Lys Ala Ala Ala Ile Trp145 150 155 160Glu Leu Glu Arg Pro
Phe Leu Asp Glu Leu Arg Arg Asn Glu Gln Asp 165 170 175Arg Leu Leu
Val Glu Leu Glu Gln Pro Leu Ser Ser Ile Leu Ala Glu 180 185 190Met
Glu Phe Ala Gly Val Lys Val Asp Thr Lys Arg Leu Glu Gln Met 195 200
205Gly Lys Glu Leu Ala Glu Gln Leu Gly Thr Val Lys Gln Arg Ile Tyr
210 215 220Glu Leu Ala Gly Gln Glu Phe Asn Ile Arg Ser Pro Lys Gln
Leu Gly225 230 235 240Val Ile Leu Phe Glu Lys Leu Gln Leu Pro Val
Leu Lys Lys Thr Lys 245 250 255Thr Gly Tyr Ser Thr Ser Ala Asp Val
Leu Glu Lys Leu Ala Pro Tyr 260 265 270His Glu Ile Val Glu Asn Ile
Leu His Tyr Arg Gln Leu Gly Lys Leu 275 280 285Gln Ser Thr Tyr Ile
Glu Gly Leu Leu Lys Val Val Arg Pro Asp Thr 290 295 300Lys Lys Val
His Thr Ile Phe Asn Gln Ala Leu Thr Gln Thr Gly Arg305 310 315
320Leu Ser Ser Thr Glu Pro Asn Leu Gln Asn Ile Pro Ile Arg Leu Glu
325 330 335Glu Gly Arg Lys Ile Arg Gln Ala Phe Val Pro Ser Glu Ser
Asp Trp 340 345 350Leu Ile Phe Ala Ala Asp Tyr Ser Gln Ile Glu Leu
Arg Val Leu Ala 355 360 365His Ile Ala Glu Asp Asp Asn Leu Met Glu
Ala Phe Arg Arg Asp Leu 370 375 380Asp Ile His Thr Lys Thr Ala Met
Asp Ile Phe Gln Val Ser Glu Asp385 390 395 400Glu Val Thr Pro Asn
Met Arg Arg Gln Ala Lys Ala Val Asn Phe Gly 405 410 415Ile Val Tyr
Gly Ile Ser Lys Tyr Gly Leu Ala Gln Asn Leu Asn Ile 420 425 430Ser
Arg Lys Glu Ala Ala Glu Phe Ile Glu Arg Tyr Phe Gln Ser Phe 435 440
445Pro Gly Val Lys Arg Tyr Met Glu Asn Ile Val Gln Glu Ala Lys Gln
450 455 460Lys Gly Tyr Val Thr Thr Leu Leu Arg Arg Arg Arg Tyr Leu
Pro Asp465 470 475 480Ile Thr Ser Arg Asn Phe Asn Val Arg Ser Phe
Ala Glu Arg Met Ala 485 490 495Met Asn Thr Pro Ile Gln Gly Ser Ala
Ala Asp Ile Ile Lys Lys Ala 500 505 510Met Ile Asp Leu Asn Ala Arg
Leu Lys Glu Glu Arg Leu Gln Ala Ala 515 520 525Leu Leu Leu Gln Val
His Asp Glu Leu Ile Leu Glu Ala Pro Lys Glu 530 535 540Glu Met Glu
Arg Leu Cys Arg Leu Val Pro Glu Val Met Glu Gln Ala545 550 555
560Val Thr Leu Arg Val Pro Leu Lys Val Asp Tyr Arg Tyr Gly Ser Thr
565 570 575Trp Tyr Asp Ala Lys 5802136DNAArtificial SequenceDNA
oligonucleotide 21tttttttgca ggtgacaggt ttttcctgtc accngc
362244DNAArtificial SequenceDNA oligonucleotide 22tttttttccc
tttcctttcg ggtgacaggt ttttcctgtc accc 44231743DNABacillus
stearothermophilus 23atggctaaaa tggcttttac tcttgctgat cgtgttactg
aagaaatgct tgctgataaa 60gctgctcttg ttgttgaagt tgttgaagaa aattatcatg
atgctcctat tgttggtatt 120gctgttgtta atgaacgtgg tcgttttttt
cttcgtcctg aaactgctct tgctgatcct 180caatttgttg cttggcttgg
tgatgaaact aaaaaaaaat ctatgtttga ttctaaacgt 240gctgctgttg
ctcttaaatg gaaaggtatt gaactttgtg gtgtttcttt tgatcttctt
300cttgctgctt atcttcttga tcctgctcaa ggtgttgatg atgttgctgc
tgctgctaaa 360atgaaacaat atgaagctgt tcgtcctgat gaagctgttt
atggtaaagg tgctaaacgt 420gctgttcctg atgaacctgt tcttgctgaa
catcttgttc gtaaagctgc tgctatttgg 480gaacttgaac gtccttttct
tgatgaactt cgtcgtaatg aacaagatcg tcttcttgtt 540gaacttgaac
aacctctttc ttctattctt gctgaaatgg aatttgctgg tgttaaagtt
600gatactaaac gtcttgaaca aatgggtaaa gaacttgctg aacaacttgg
tactgttaaa 660caacgtattt atgaacttgc tggtcaagaa tttaatattc
gttctcctaa acaacttggt 720gttattcttt ttgaaaaact tcaacttcct
gttcttaaaa aaactaaaac tggttattct 780acttctgctg atgttcttga
aaaacttgct ccttatcatg aaattgttga aaatattctt 840cattatcgtc
aacttggtaa acttcaatct acttatattg aaggtcttct taaagttgtt
900cgtcctgata ctaaaaaagt tcatactatt tttaatcaag ctcttactca
aactggtcgt 960ctttcttcta ctgaacctaa tcttcaaaat attcctattc
gtcttgaaga aggtcgtaaa 1020attcgtcaag cttttgttcc ttctgaatct
gattggctta tttttgctgc tgattattct 1080caaattgaac ttcgtgttct
tgctcatatt gctgaagatg ataatcttat ggaagctttt 1140cgtcgtgatc
ttgatattca tactaaaact gctatggata tttttcaagt ttctgaagat
1200gaagttactc ctaatatgcg tcgtcaagct aaagctgtta attttggtat
tgtttatggt 1260atttctaaat atggtcttgc tcaaaatctt aatatttctc
gtaaagaagc tgctgaattt 1320attgaacgtt attttcaatc ttttcctggt
gttaaacgtt atatggaaaa tattgttcaa 1380gaagctaaac aaaaaggtta
tgttactact cttcttcatc gtcgtcgtta tcttcctgat 1440attacttctc
gtaattttaa tgttcgttct tttgctgaac gtatggctat gaatactcct
1500attcaaggtt ctgctgctga tattattaaa aaagctatga ttgatcttaa
tgctcgtctt 1560aaagaagaac gtcttcaagc tcatcttctt cttcaagttc
atgatgaact tattcttgaa 1620gctcctaaag aagaaatgga acgtctttgt
cgtcttgttc ctgaagttat ggaacaagct 1680gttactcttc gtgttcctct
taaagttgat tatcgttatg gttctacttg gtatgatgct 1740aaa
174324832PRTThermus aquaticus 24Met Arg Gly Met Leu Pro Leu Phe Glu
Pro Lys Gly Arg Val Leu Leu1 5 10 15Val Asp Gly His His Leu Ala Tyr
Arg Thr Phe His Ala Leu Lys Gly 20 25 30Leu Thr Thr Ser Arg Gly Glu
Pro Val Gln Ala Val Tyr Gly Phe Ala 35 40 45Lys Ser Leu Leu Lys Ala
Leu Lys Glu Asp Gly Asp Ala Val Ile Val 50 55 60Val Phe Asp Ala Lys
Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly65 70 75 80Tyr Lys Ala
Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu 85 90 95Ala Leu
Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu 100 105
110Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp
Lys Asp 130 135 140Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu
His Pro Glu Gly145 150 155 160Tyr Leu Ile Thr Pro Ala Trp Leu Trp
Glu Lys Tyr Gly Leu Arg Pro 165 170 175Asp Gln Trp Ala Asp Tyr Arg
Ala Leu Thr Gly Asp Glu Ser Asp Asn 180 185 190Leu Pro Gly Val Lys
Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu 195 200 205Glu Glu Trp
Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu 210 215 220Lys
Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys225 230
235 240Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
Val 245 250 255Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu
Arg Ala Phe 260 265 270Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His
Glu Phe Gly Leu Leu 275 280 285Glu Ser Pro Lys Ala Leu Glu Glu Ala
Pro Trp Pro Pro Pro Glu Gly 290 295 300Ala Phe Val Gly Phe Val Leu
Ser Arg Lys Glu Pro Met Trp Ala Asp305 310 315 320Leu Leu Ala Leu
Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro 325 330 335Glu Pro
Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu 340 345
350Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro
Ser Asn 370 375 380Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly
Glu Trp Thr Glu385 390 395 400Glu Ala Gly Glu Arg Ala Ala Leu Ser
Glu Arg Leu Phe Ala Asn Leu 405 410 415Trp Gly Arg Leu Glu Gly Glu
Glu Arg Leu Leu Trp Leu Tyr Arg Glu 420 425 430Val Glu Arg Pro Leu
Ser Ala Val Leu Ala His Met Glu Ala Thr Gly 435 440 445Val Arg Leu
Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala 450 455 460Glu
Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His465 470
475 480Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
Asp 485 490 495Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr
Gly Lys Arg 500 505 510Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg
Glu Ala His Pro Ile 515 520 525Val Glu Lys Ile Leu Gln Tyr Arg Glu
Leu Thr Lys Leu Lys Ser Thr 530 535 540Tyr Ile Asp Pro Leu Pro Asp
Leu Ile His Pro Arg Thr Gly Arg Leu545 550 555 560His Thr Arg Phe
Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser 565 570 575Ser Asp
Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln 580 585
590Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu
Ser Gly 610 615 620Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg
Asp Ile His Thr625 630 635 640Glu Thr Ala Ser Trp Met Phe Gly Val
Pro Arg Glu Ala Val Asp Pro 645 650 655Leu Met Arg Arg Ala Ala Lys
Thr Ile Asn Phe Gly Val Leu Tyr Gly 660 665 670Met Ser Ala His Arg
Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu 675 680 685Ala Gln Ala
Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg 690 695 700Ala
Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val705 710
715 720Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Arg Leu Glu Ala
Arg 725 730 735Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe
Asn Met Pro 740 745 750Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu
Ala Met Val Lys Leu 755 760 765Phe Pro Arg Leu Glu Glu Met Gly Ala
Arg Met Leu Leu Gln Val His 770 775
780Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
Ala785 790 795 800Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro
Leu Ala Val Pro 805 810 815Leu Glu Val Glu Val Gly Ile Gly Glu Asp
Trp Leu Ser Ala Lys Glu 820 825 830
* * * * *